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Abstract 
 
Thymidine kinase 1 (TK1) is a deoxynucleoside kinase that catalyzes the transfer of γ-
phosphate from ATP to the 5`-OH of thymidine (dThd) to form thymidine 
monophosphate. In humans and other mammalians TK1 is a key enzyme in the salvage 
of dTTP for DNA synthesis. 
Deoxynucleoside kinases have several useful applications, but one of the more important 
ones is the activation of antiviral and anticancer drugs such as the nucleoside analogs 
AZT (3`-azido-2`-3`-dideoxythymidine) and AraC (1-β-D-arabinofuranosylcytosine) which 
are used for HIV and cancer treatment, respectively.  
In humans there are four different deoxynucleoside kinases with overlapping specificities 
towards the deoxynucleosides, dThd, deoxyadenosine (dAdo), deoxyguanosine (dGuo) 
and deoxycytidine (dCyd). In C. elegans, however, there only seems to be a single 
deoxynucleoside kinase-like gene with high sequence similarity to human TK1 (HuTK1). 
That discovery led to the interesting question regarding the substrate specificity of the C. 
elegans kinase: Can C. elegans TK1 (CeTK1) phosphorylate other substrates than HuTK1 
can since it is apparently the only deoxynucleoside kinase in the cell? 
In the present characterization of CeTK1 the enzyme is compared with HuTK1 with 
regard to substrate specificity, native size, activation by ATP, stability and kinetic 
parameters for dThd. CeTK1 is truncated in the C-terminal (CeTK1-C∆57) in order to see 
how the truncation affects stability and activity, and the effects are compared to the 
effect of a 41 amino acid C-terminal truncation that has previously been performed in 
HuTK1 (HuTK1-∆41). The truncations in the two enzymes are performed at the same 
position after a conserved sequence. Furthermore, a number of mutations have been 
performed in the active site of both HuTK1-∆41 (M28I, M28A, L124A, T163S and T163A) 
and CeTK1 (M42I, L143A, S182T and S182A) in order to elucidate the effect of specific 
amino acids on substrate specificity and activity of the enzymes. 
The sequence of CeTK1 is similar to that of human TK1, but besides accepting dThd as a 
substrate CeTK1 also phosphorylates dGuo. In contrast to HuTK1, the CeTK1 exclusively 
exists as a dimer with a molecular mass of ~60 kDa even if incubated with ATP. 
Incubation with ATP induces a transition into a more active enzyme with a higher kcat but 
unchanged Km. C-terminal deletion of the enzyme results in lower catalytic efficiency and 
stability. All the mutants showed activity with both dThd and the nucleoside analog AZT, 
but most of them had lower activities than the enzymes on which the mutation had been 
performed. Some mutations gave broader substrate specificities, however. Especially 
interesting is the gain of dCyd activity with CeTK1-M42I and –L143A since dCyd is a 
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substrate that cannot be phosphorylated by WT CeTK1 or any other known TK1. And also 
very interesting is the highly increased specificity of HuTK1-C∆41-T163S towards the 
nucleoside analog AZT compared to the natural substrate dThd. 
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Abstract in Danish 
 
Thymidinkinase 1 (TK1) er en deoxynukleosidkinase, der katalyserer overførslen af γ-
phosphat fra ATP til 5`-OH på thymidin (dThd) under dannelsen af thymidinmono-
phosphat. I mennesker og andre pattedyr er TK1 et nøgleenzym i salvage pathway, hvor 
nedbrudte deoxynukleotider rephosphoryleres til dTTP til DNA-syntese.  
Deoxynukleosidkinaser har mange anvendelsesmuligheder, men en af de vigtigste er, at 
de kan aktivere antivirale og anticancer-lægemidler som nukelosidanalogene AZT (3`-
azido-2`-3`-dideoxythymidin) og AraC (1-β-D-arabinofuranosylcytosin), der anvendes til 
behandling af henholdsvis HIV og cancer.  
I menneskeceller er der fire forskellige deoxynukleosidkinaser med overlappende 
substratspecificiteter for deoxynukleosiderne dThd, deoxyadenosin (dAdo), deoxy-
guanosin (dGuo) og deoxycytidin (dCyd). I C. elegans ser der dog tilsyneladende kun ud 
til at være et enkelt deoxynukleosidkinase-lignende gen, der har høj sekvenslighed med 
human TK1 (HuTK1). Denne opdagelse førte til et interessant spørgsmål angående C. 
elegans-kinasens substratspecificitet: Kan C. elegans TK1 (CeTK1) phosphorylere andre 
substrater, end HuTK1 kan, da den tilsyneladende er den eneste deoxynukleosidkinase i 
cellen? 
I denne karakterisering af CeTK1 sammenlignes enzymet med HuTK1 med hensyn til 
substratspecificitet, nativ molekylvægt, aktivering af ATP, stabilitet og kinetiske 
parametre med dThd. CeTK1 er desuden trunkeret i C-terminalen (CeTK1-C∆57) med det 
formål at se, hvordan dette påvirker enzymets stabilitet og aktivitet, og effekten 
sammenlignes med effekten af en C-terminal trunkering, der tidligere er foretaget i 
HuTK1 (HuTK1-∆41). Trunkeringen er i begge enzymer foretaget samme sted efter en 
konserveret sekvens. Endvidere er der lavet et antal mutationer i det aktive site på både 
HuTK1-∆41 (M28I, M28A, L124A, T163S og T163A) og CeTK1 (M42I, L143A, S182T og 
S182A) med det formål at belyse de enkelte aminosyrers effekt på enzymernes 
substratspecificitet og aktivitet. 
CeTK1 og HuTK1 har høj sekvenslighed, men ud over at acceptere substratet dThd, kan 
CeTK1 også phosphorylere dGuo. I modsætning til HuTK1 er CeTK1 udelukkende en 
dimer med en molekylvægt på ~60 kDa, selv når det bliver inkuberet med ATP. ATP-
inkubering af CeTK1 inducerer en overgang til et mere aktivt enzym med højere kcat men 
uændret Km. C-terminal trunkering resulterer i et enzym med lavere stabilitet og 
katalytisk ydeevne. Alle mutanterne udviste aktivitet med både dThd og 
nukleosidanalogen AZT, men de fleste havde lavere aktiviteter end de tilsvarende 
enzymer, som mutationerne var foretaget på. Nogle mutationer resulterede dog i bredere 
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substratspecificiteter. Nogle af de mest interessante er CeTK1-M42I og –L143A, der 
udviser aktivitet med dCyd. Dette substrat kan ikke phosphoryleres af WT CeTK1 eller 
andre kendte TK1’er. Ydermere har HuTK1-C∆41-T163S forøget aktivitet med nukleosid-
analogen AZT i forhold til det naturlige substrat dThd. 
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Introduction 
 
The DNA precursors, deoxynucleotides, can be synthesized by two different pathways. In 
de novo pathway the deoxynucleotides are synthesized from small inorganic molecules 
such as CO2, H2O and NH3, and in the simpler salvage pathway they are synthesized from 
deoxynucleosides taken up from the extracellular compartment.  These deoxynucleosides 
originate from dead cells and ingested food. The most important step in the latter 
pathway is the phosphorylation of deoxynucleosides (dN’s) to deoxynucleoside 
monophosphates (dNMP’s) catalyzed by deoxynucleoside kinases. Deoxynucleoside 
kinases catalyze the transfer of γ-phosphoryl group from ATP to the dN’s under the 
formation of dNMP’s. The dNMP’s are subsequently phosphorylated to dNDP’s and dNTP’s 
by mono- and diphosphate deoxynucleoside kinases.  
 
Deoxynucleoside kinases are also responsible for the initial phosphorylation of nucleoside 
analogs like azidothymidine (AZT, 3`-azido-3`-deoxythymidine), acyclovir (ACV, 9-[(2-
hydroxyethoxy)methyl]guanine) and ganciclovir (GCV, 9-[(1,3-Dihydroxy-2-propoxy) 
methyl]guanine) which are being used in the treatment of viral diseases and cancer. By 
phosphorylation of the non-toxic nucleoside analogs to monophosphates by 
deoxynucleoside kinases the analogs can subsequently be phosphorylated to di- and  
triphosphates by other cellular kinases. The triphosphorylated nucleoside analogs are 
eventually incorporated into DNA where they can inhibit the DNA polymerase, cause 
chain termination and initiate apoptosis [Consoli et al., 1998; Beltinger et al., 1999]. 
Hence, the deoxynucleoside kinases are of great medical importance for traditional 
chemotherapy of viral diseases and cancer. They are also important for suicide gene 
therapy of tumours with nucleoside analogs. 
In gene therapy based treatment with deoxynucleoside kinases the kinase gene is 
introduced into the target cells where it is expressed. Subsequent treatment with 
nucleoside analogs that are specifically phosphorylated by the introduced kinase will then 
cause the analogs to stop DNA replication and/or induce apoptosis only in the cells 
harbouring the foreign deoxynucleoside kinase. This has been attempted in the treatment 
of  melanoma and glioblastoma with a thymidine kinase from Herpes Simplex Virus Type1 
(HSV1TK) in combination with GCV [Klatzmann et al., 1998a; Klatzmann et al., 1998b; 
Ram et al., 1997]. 
 
Mammalian cells have four different deoxynucleoside kinases with overlapping substrate 
specificities, but none of them can phosphorylate all of the naturally occurring 
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deoxynucleosides. Thymidine kinase 1 (TK1) has the most limited substrate specificity 
and only phosphorylates thymidine (dThd) whereas thymidine kinase 2 (TK2) also 
phosphorylates deoxycytidine (dCyd). Deoxycytidine kinase (dCK) and deoxyguanosine 
kinase (dGK) can both phosphorylate dCyd, deoxyguanosine (dGuo) and deoxyadenosine 
(dAdo), but dCK has the highest specificity for dCyd and dGK has the highest specificity 
for dGuo [Arnér & Eriksson, 1995; Eriksson et al., 2002]. In 1989, a deoxynucleoside 
kinase was discovered from the fruit fly, Drosophila melanogaster, which could 
phosphorylate all of the naturally occurring deoxynucleosides with high efficiency 
[Munch-Petersen et al., 1998a; Munch-Petersen et al., 1998b]. Later, a similar type of 
multisubstrate deoxynucleoside kinase was also discovered in the butterfly Bombyx mori 
and the mosquito Anopheles gambiae [Knecht et al., 2002; Knecht et al., 2003]. By 
performing a BLAST search with different deoxynucleoside kinases on the genome of C. 
elegans only one matching sequence is found. Since the genome is fully sequenced this 
suggests that the nematode, just like the insects, only has one deoxynucleoside kinase. 
However, as judged from the amino acid sequence the kinase in C. elegans (CeTK1) is a 
TK1-type kinase. Based on structural comparisons TK1-type kinases have recently been 
proposed to have an entirely different evolutionary origin than the ones observed in 
insects [Welin et al., 2004; Piskur et al, 2004]. The amino acid sequence resembles that 
of human thymidine kinase 1 (HuTK1), and to some extent they also share substrate 
specificity. Both HuTK1 and CeTK1 phosphorylate the substrate dThd, but in addition 
CeTK1 displayed a lower activity with dGuo [Skovgaard, 2004]. 
 
The three dimensional structure of HuTK1 has recently been solved [Welin et al., 2004; 
Birringer et al., 2005], and in the present work the structure of CeTK1 is modelled based 
on this structure. Besides, functionally important amino acids in HuTK1 are compared to 
those in CeTK1 by amino acid alignment in order to identify similarities and differences in 
function and regulation. 
In the experimental part of this work CeTK1 is characterized with respect to subunit and 
native molecular mass, stability, substrate specificity and kinetic parameters with 
different substrates. Furthermore, CeTK1 is  incubated with ATP in order to determine 
whether CeTK1 is subject to an ATP-induced activation similar to what have been 
observed for HuTK1 [Munch-Petersen et al., 1993].  
By deletion of the 41 C-terminal amino acids of HuTK1 (HuTK1-C∆41) the stability and 
activity of the enzyme has been shown to increase [Zhu et al., in press]. A similar C-
terminal deletion has been performed in CeTK1 resulting in an enzyme that lacks the 57 
C-terminal amino acid residues (CeTK1-C∆57). The truncated enzyme is analyzed with 
regard to stability, substrate specificity, kinetic parameters and ATP-activation. 
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Furthermore, a number of mutations have been performed in the active site of CeTK1 
and HuTK1-C∆41 in order to determine the effect of selected amino acids on substrate 
specificity. All the mutations are performed on amino acids in the region surrounding the 
substrate base. In CeTK1 the mutations are M42I, L143A, S182T and S182A, and in 
HuTK1-C∆41 they are M28I, M28A, L124A, T163S and T163A. All the mutant enzymes 
are purified and analyzed with respect to substrate specificity and kinetic parameters for 
all accepted substrates. 
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1 Caenorhabditis elegans 
 
In this thesis the enzymatic properties of a thymidine kinase from C. elegans is 
presented. Therefore, a brief introduction is given to this organism. Unless stated 
otherwise the information below is based on:”The Nematode Caenorhabditis Elegans” 
[Wood, 1988]. 
 
Caenorhabditis elegans is a small soil nematode which is found all over the world. It 
belongs to the class Secernentea, the order Rhabiditida and the family Rhabditidae. It 
feeds on bacteria (in laboratories is normally fed with E. coli), and it has been used as 
animal model organism since 1963 thanks to the work of Sidney Brenner. Adults are 
about 1 mm in length and have a reproductive cycle of about 3 days when grown at 
room temperature. 
 
 
 
Figure 1.1: Above: an adult hermaphrodite and below: an adult male [Sulston and Horvitz, 1977]. 
 
Two different sexes can be found; hermaphrodite and male, with the hermaphrodite 
being the more abundant of the two (figure 1.1). Hermaphrodites are producing both egg 
and sperm cells, and are capable of self-fertilization and of fertilization by a male, but 
one hermaphrodite is not able to fertilize another. Self-fertilization allows a single 
heterozygous worm to produce homozygous progeny. This is a very important feature 
that makes C. elegans a convenient organism for genetic studies. 
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The hermaphrodite gonad first produces germ cells which differentiate as sperm (circa 
250 sperm cells are produced) and then produce eggs. A hermaphrodite that has not 
been fertilized by a male normally lays about 300 eggs in a life span. The eggs hatch as 
larvae, and the nematodes develop through four larval stages, L1-L4, separated by 
moults. When they are grown the adult larvae will live for approx. 17 days, but they are 
only fertile for about four days after the last moult. 
The L1 larva hatches from the egg approx. 14 hours after fertilization when it is only 250 
µm long. Over the next 50 hours it develops into an adult larva through the four stages 
(figure 1.2.A). When food supply is scarce at early larval development C. elegans can 
choose an alternative development where it enters a specialized L3 larval stage called the 
dauer larva (figure 1.2.B). The dauer larva does not eat and will not dry out, and it is 
able to live for up to three to four months without further development. It will only 
continue its development into the L4 larval stage if a food source becomes available. 
 
 
Figure 1.2: A: Representation of the life cycle of C. elegans. The numbers on the outside of the 
circle indicate hours after fertilization, and the numbers on the inside indicate hours after hatching. 
The times for the different larval stages are also shown on the inside. B: Depiction of the different 
larval stages in the C. elegans life cycle including the alternative life cycle of the dauer larva. 
 
C. elegans is a simple and very well-studied organism with a genome size of 97 million 
nucleotide pairs, about 18000 genes and very few different cell types 
[http://www.wormbase.org]. A unique feature of this worm is that its development is 
stereotypical which means that cells divide and specialize after a highly characteristic 
pattern so that every worm has the same number and type of cells arranged in exactly 
the same manner [Watson et al., 2004]. The adult hermaphrodite has 959 somatic cells, 
and the adult male has 1031. The whole genome sequence was finished in 1998 by the 
C. elegans Genome Sequencing Consortium, being the first animal genome obtained 
[Hodgkin et al., 1998]. The full sequence is available at http://www.wormbase.org. 
A B
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The C. elegans cells contain a diploid nucleus with five pairs of autosomal chromosomes 
and one pair of sex chromosomes. The hermaphrodite gender carries the sex 
chromosomes XX and the male carries XO, and the autosomal chromosome pairs are 
named I, II, III IV and V.  
When analyzing the C. elegans genome it is interesting to note that there only seems to 
be one deoxynucleoside kinase-like gene. This gene is encoding the protein CeTK1, and it 
was annotated in the NCBI database in 2001 by the C. elegans Genome Sequencing 
Consortium. It is positioned on chromosome IV, and the complete mRNA is 1026 bases 
long with a sequence exactly matching that of the genome. The gene has 5 exons and 
encodes a protein of 269 amino acids (M.W.: 29.7 kDa and pI: 6.0). This protein, along 
with the human ortholouge, is the subjects of this master thesis. 
 
 14
2 Nucleotide and deoxynucleotide biosynthesis 
 
Two different pathways are responsible for biosynthesis of the DNA precursors, 
deoxynucleotides. In de novo pathway both deoxynucleotides and nucleotides (RNA 
precursors) are synthesized from simple inorganic molecules like CO2, H2O, and NH3 in a 
long, complex and energy-demanding pathway involving many different enzymes and co-
factors. In the more simple salvage pathway deoxynucleotides are synthesized from 
degraded DNA from dead cells or from digested foods. Deoxynucleoside kinases are the 
key enzymes in the latter. 
 
De novo pathway 
The initial steps in this pathway lead to the formation of nucleoside monophosphates 
(NMP’s). For the purine nucleosides the base is assembled step by step on 5-
phosphoribosyl-1-pyrophosphate (PRPP), and for the pyrimidine nucleosides the base is 
assembled first and then transferred to PRPP. In the formation of nucleotides the 
nucleoside monophosphates (NMP’s) are phosphorylated in two steps to nucleoside 
triphosphates (NTP’s); the precursors for RNA formation. In the formation of 
deoxynucleotides the NMP’s are first phosphorylated to nucleoside diphosphates (NDP’s) 
and subsequently reduced by ribonucleotide reductase to deoxynucleoside diphosphates 
(dNDP’s). Further phosphorylation produces deoxynucleoside triphosphates (dNTP’s) that 
can be incorporated into DNA (figure 2.1) [Matthews and van Holde, 1996]. 
 
The key enzyme in de novo synthesis of deoxynucleotides is ribonucleotide reductase. It 
was discovered in bacteria already in 1966 [Larsson & Reichard, 1966a; Larsson & 
Reichard, 1966b] and later identified in mammalian cells [Thelander et al., 1980]. The 
enzyme consists of two subunits, and besides from the active site where the NDP’s are 
bound the enzyme also contains two different regulatory sites [reviewed by Reichard, 
1987]. One regulatory site is responsible for activity regulation and has the role of 
turning the enzyme activity on and off. The other is a specificity regulatory site and is 
only functional when the enzyme activity is turned on. The activity regulatory site is 
regulated by ATP and dATP. Bound dATP is inhibiting reduction of all four substrates; 
ADP, GDP, CDP, and UDP. Both UDP and CDP are sources for dTTP in the de novo 
pathway (figure 2.1). If dATP is replaced by ATP the enzyme becomes active. When in 
the active conformation the substrate specificity is determined by the 
nucleotides/deoxynucleotides: ATP, dATP, dGTP or dTTP bound to the specificity 
regulatory site.  When ATP or dATP is bound reduction of the substrates CDP and UDP is 
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favoured. When dTTP is bound the reduction of UDP and CDP is inhibited, and that of 
GDP is activated. And finally, when the site is occupied by dGTP reduction of CDP, UDP 
and GDP is inhibited, and that of ADP is activated [Reichard, 1987; Nelson and Cox, 
2000].  
 
 
Figure 2.1: Synthesis of deoxynucleotides by de novo pathway starting from the reduction of 
nucleoside diphosphates. A: formation of dATP, dGTP and dCTP. B: formation of dTTP. 
 
This regulatory system is designed with the purpose of keeping a constantly balanced 
pool of deoxynucleotides for DNA synthesis. An imbalance in the pool can be fatal to the 
cell. For instance, in patients with an immunodeficiency caused by a malfunctioning 
adenosine deaminase there is a significant imbalance in the deoxynucleotide pool due to 
an increase in dATP. Accumulated levels of dATP will cause the levels of dGTP, dCTP and 
dATP to decease, leading to a block of DNA synthesis. Lack of DNA synthesis prevents 
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the white blood cells from proliferating and leads to immunodeficiency [Giblett et al., 
1972; Yoshioka et al., 1987]. 
 
Salvage pathway 
The salvage pathway to deoxynucleotide synthesis is less complex and energy-
demanding than the de novo pathway.  
In heterotrophic organisms the main source of nucleotides and deoxynucleotides is 
nucleic acids ingested with foods. The nucleic acids are degraded to oligonucleotides in 
the small intestine by ribonucleases and deoxyribonucleases; two endonucleases 
produced in pancreas. The oligonucleotides are then degraded to (d)NMP’s by 
phosphodiesterases, and subsequent dephosphorylation leads to the production of 
(deoxy)nucleosides. Due to the neutral charge of (deoxy)nucleosides they are able to 
pass through the epithelial layer in the small intestine and into the blood stream. They 
can now be rephosphorylated in the cells by enzymes in salvage pathway and be reused 
for synthesis of new nucleic acids [Matthews and van Holde, 1996; Zubay, 1998].  
 
The first phosphorylation step of deoxynucleosides is catalyzed by deoxynucleoside 
kinases. It is a group of highly specific enzymes of which some are located in the 
mitochondrial matrix and some in the cytosol. The deoxynucleoside kinases are the key 
enzymes in salvage pathway [reviewed by Arnér & Eriksson, 1995 and Eriksson et al., 
2000], and the cytosolic kinase phosphorylating thymidine is the focus of this work. 
Different organisms carry different deoxynucleoside kinases with varying substrate 
specificities, and the four human deoxynucleoside kinases will be described in further 
detail in chapter 4. After being phosphorylated to the monophosphate level the dNMP’s 
are phosphorylated again by the less specific nucleoside monophosphate kinases. 
Humans have four different monophosphate kinases of which three can phosphorylate 
both dNMP’s and NMP’s. One phosphorylates AMP and dAMP, another GMP and dGMP, a 
third CMP, dCMP and UMP, and the last only dTMP.  
The final phosphorylation is catalyzed by nucleoside diphosphate kinase which has even 
broader substrate specificity than the monophosphate kinases. There is only one 
nucleoside diphosphate kinase, and it is non-specific regarding both substrate sugar and 
substrate base. It can catalyze the transfer of phosphate from any (d)NTP to any (d)NTP, 
although the phosphate donor is often ATP due to a relatively higher concentration of 
this nucleotide. The nucleotides and deoxynucleotides are then ready to participate in 
RNA and DNA synthesis, respectively [Nelson and Cox, 2000; Zubay, 1998]. 
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The activity of the nucleoside diphosphate kinase is 10-100 times higher than that of the 
nucleoside monophosphate kinases. And the monophosphate kinases again have higher 
activity than the deoxynucleoside kinases. This results in a relatively higher concentration 
of dNTP’s than dNDP’s and dNDP concentrations higher than dNMP’s. The slower catalytic 
rate and the narrow substrate specificity make the deoxynucleoside kinases the key 
enzymes in the salvage of deoxynucleotides [Zubay, 1998]. 
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3 Applications of deoxynucleoside kinases 
 
The applications of deoxynucleoside kinases are vast. The most obvious application is the 
production of dNTP’s for PCR and other DNA reactions, but also production of some 
nucleoside monophosphates has industrial relevance. The purine nucleoside mono-
phosphates GMP and IMP, occurring in many foodstuffs such as meat, seafood and 
mushrooms, are widely used as ingredients to enhance the flavour of culinary products 
like snacks and seasonings [Soldo et al., 2003]. In order to phosphorylate GMP and IMP 
a deoxynucleoside kinase that phosphorylates nucleosides and not only deoxynucleosides 
must be constructed. The most important application of deoxynucleoside kinases, 
though, is their role in suicide gene therapy. 
 
The purpose of suicide gene therapy is to kill unwanted cells in the body, such as cancer 
cells, cells infected by HIV or mal-behaving transplanted cells. In general the diseased 
cells are transfected with a so-called suicide gene encoding a protein which is capable of 
converting a non-toxic drug into a toxic one. The patient is subsequently treated with this 
non-toxic drug, resulting in all the cells containing this suicide gene entering apoptosis. 
All healthy cells in the body are thus not affected by the treatment. Suicide gene therapy 
with deoxynucleoside kinases is an extended development of traditional chemotherapy. 
Nucleoside analogs have been applied in traditional chemotherapy for decades. 
 
Deoxynucleoside kinases in traditional chemotherapy 
Nucleoside analogs are drugs similar in molecular structure to the body’s own 
deoxynucleosides. They can be mono-phosphorylated by the body’s own deoxynucleoside 
kinases, and subsequently di- and tri-phosphorylated and incorporated into DNA in the 
same fashion as for the natural deoxynucleosides. When a nucleoside analog is 
incorporated into DNA they have different ways of blocking further DNA synthesis. Some 
will inhibit the DNA polymerase and others are missing a free 3`-OH group on the sugar 
moiety preventing the formation of the phosphodiester-bridge (the molecular structure of 
the natural deoxynucleosides and selected nucleoside analogs are displayed in appendix 
F). Prohibited elongation of the DNA chain will provoke the cell to induce apoptosis 
[Beltinger et al., 1999]. Since the nucleoside analogs are phosphorylated by the naturally 
existing deoxynucleoside kinases, the treatment leads to apoptosis in all dividing cell 
groups in the body, and since cancer cells are rapidly dividing they are strongly affected.  
Some analogs, such as 2-chloro-2`-deoxyadenosine (2-CdA, Cladribine), can also induce 
apoptosis in both dividing and non-dividing T cells [Carson et al., 1983]. This selective 
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toxicity against T-cells renders cladribine a useful antileukaemic agent (Leustatin®). Many 
details in the mechanism still remain to be deduced, but it has been shown that 2-CdA 
disrupts the integrity of mitochondria leading to the release of the pro-apoptotic proteins 
cytochrome-c and apoptosis inducing factor from the mitochondrial intermembrane space 
to the cytosol [Genini et al., 2000]. The 5`-triphosphate of 2-CdA is known to activate an 
apoptose-activating factor (Apaf-1), enabling it to form a complex with cytochrome-c 
called the apoptosome [Leoni et al., 1998]. The apoptosome is able to initiate the 
caspase cascade, leading to apoptosis. A structurally similar nucleoside analog, 9-beta-D-
arabinofuranosyl-2-fluoroadenine (F-ara-A, Fludarabine), is provided in its mono-
phosphate form as a common anti-cancer medicine (Fludara(R)) against chronic 
lymphocytic leukaemia. It is provided in monophosphate form due to the higher solubility 
of monophosphates in water, and the drug is quickly dephosphorylated by serum 
phosphatases. The nucleoside is taken up and rephosphorylated within the cell where the 
triphosphate form leads to apoptosis [Consoli et al., 1998; Hochster et al., 2000]. By 
applying deoxynucleoside kinases in enzymatic production of Fludara ® the drug could 
be produced in a faster and less energy demanding manner with less by-products than 
from a chemical production. General, chemical synthesis of drugs often demands 
environmentally harsh chemicals and high temperatures and results in several by-
products, whereas enzymatic synthesis is very efficient and takes place at lower 
temperatures (mostly around 37 °C) and with the production of few, if any, by-products. 
 
Deoxynucleoside kinases in suicide gene therapy 
Since cancer cells are rapidly dividing they will obviously be affected by the traditional 
chemotherapeutic drugs, but the disadvantage is that constantly dividing cells like hair, 
skin and intestinal cells are also strongly affected by many of the drugs, leading to hair 
loss and problems with skin and digestion [Hofman et al., 2004].  
By using foreign or modified human deoxynucleoside kinases as suicide genes nucleoside 
analogs that are not phosphorylated by the natural human deoxynucleoside kinases can 
be applied, and thus only the diseased cells that have received the suicide gene will be 
affected by drug treatment. One such suicide gene that has been researched intensely is 
the thymidine kinase gene from Herpes simplex virus type 1 (HSV1TK) [Heyman et al., 
1989: Ram et al., 1997; Klatzmann et al., 1998a; Klatzmann et al., 1998b; Freeman et 
al., 1993; Moolten and Wells, 1990]. Besides from phosphorylating thymidine the HSV1TK 
protein also phosphorylates a number of purine analogs like 9-(2-hydroxyethoxymethyl)-
guanine (acyclovir, ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (ganciclovir, 
GCV) which both have an acyclic sugar, rendering them unable to make the 
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phosphodiester bond to other nucleotides. HSV1TK also phosphorylates a wide range of 
pyrimidine analogs like (E)-5-(2-bromovinyl)-2`-deoxyuridine (BVDU) and 1-β-D-arabino-
furanosylthymine (AraT) [Degreve et al., 1999].  
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Figure 3.1: Chemical structure of the purine and pyrimidine nucleoside analogs: 9-(2-hydroxy-
ethoxymethyl)guanine (acyclovir, ACV), 9-(1,3-dihydroxy-2-propoxymethyl)guanine (ganciclovir, 
GCV), (E)-5-(2-bromovinyl)-2`-deoxyuridine (BVDU), and 1-β-D-arabinofuranosylthymine (AraT) 
 
In attempts to cure cancers like melanoma (skin cancer) and glioblastoma (brain cancer) 
cells producing a retroviral vector carrying the HSV1TK gene have been injected into the 
tumor [Klatzmann et al., 1998a; Klatzmann et al., 1998b; Ram et al., 1997]. The 
retroviral vector is transduced from the host cells to the cancer cells wherein HSV1TK 
protein is produced. Subsequent treatment with GCV will cause the transduced cells to 
enter apoptosis. The exact mechanism leading from chain termination to apoptosis is not 
known, but it has been shown that GCV treatment induces accumulation of p53 and 
increases expression of death receptors on the cell surface. It is likely that p53 is 
mediating the translocation of the receptor CD95 to the surface which may lead to 
increased interaction between CD95 and the constitutively expressed CD95-L. The 
following recruitment of the death domain protein FADD and caspase-8 triggers the 
caspase cascade and leads to apoptosis [Beltinger et al., 1999]. The advantage of using 
the retroviral vector system is that the vectors can only be transduced to dividing cells. 
All the surrounding healthy tissue will mainly be in the G0 phase of the cell cycle and 
therefore be unaffected by the treatment. Injecting retroviral vector producing cells in 
place of simply injecting the retroviral vectors into the tumor will result in a constant 
supply of vectors over a longer period of time. Diseased cells that are leaving the G0 
phase after the injection will thus still be subjected to a high level of retroviral vector 
carrying HSV1TK, and the chances of killing all the diseased cells are greatly increased 
[Culver et al., 1992].  
Deoxynucleoside kinases like HSV1TK could also function as a sort of safeguard suicide 
gene that could be activated by nucleoside analogs to kill mal-behaving transplanted 
cells. In 2002, attempts to cure X-linked severe combined immune deficiency in 11 
infants by transplantation of autologous CD34+ transduced hematopoetic stem cells were 
GCV    ACV BVDU AraT 
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successful in 9 patients. The stem cells were transduced with a retroviral vector carrying 
CD34+, and unfortunately two of the infants developed leukaemia-like cancer with a 
rapidly dividing T cell clone carrying the integrated retroviral genome near the Lmo2 
oncogene [reviewed by Herzog & Arruda, 2003]. If the CD34+ had been co-transduced 
with for example HSV1TK the genetically modified transplanted cells could be eliminated 
by administering the nucleoside analog GCV. 
 
An interesting phenomenon called the “bystander effect” has been observed when 
treating with i.e. retroviral vector producing-cells [Reviewed by Pope at al., 1997]. Cancer 
cells that are not transduced with the retroviral vector have been seen to induce 
apoptosis simply by having a transduced neighbour cell. This bystander effect is of great 
importance due to difficulties with efficiently transducing all cancer cells in a tumour in 
vivo [Ram et al., 1997; Klatzmann et al., 1998a], and it has been widely researched 
[Freeman et al., 1993; Mesnil et al., 1996; Beltinger et al., 1999; Degreve et al., 1999]. 
In spite of the intense research the exact mechanism of the phenomenon is still unclear. 
Several theories exist. One proposed method is the transfer of triphosphorylated 
nucleoside analogs between cells via gap junctions [Mesnil et al., 1996]. Another is 
transfer of cell content from a transduced dying cancer cell to its neighbour by apoptose 
vesicles [Freeman et al., 1993]. When applying the retroviral vector method it is of great 
importance to choose a nucleoside analog that has a high potential for bystander effect. 
Not all analogs are transferred with equal efficiency between cells. For instance, purines 
like GCV and ACV are transferred to a greater extent than pyrimidines like BVDU and 
AraT [Degreve et al., 1999]. Research on a multisubstrate deoxynucleoside kinase 
(DmdNK) that is potentially useful for suicide gene therapy has shown that also different 
cell lines display different potential for bystander effect [Zheng et al., 2000; Zheng et al., 
2001]. Two human cancer cell lines were transduced with a retrovirus encoding the 
DmdNK cDNA and subsequently subjected to the nucleoside analog BVDU. Bystander 
effect was observed in the thymidine kinase-deficient osteosarcoma cell line but not in 
the MIA PaCa-2 pancreatic adenocarcinoma cell line [Zheng et al., 2001]. 
 
In order to create new and improved systems consisting of suicide genes and matching 
nucleoside analogs it is essential to obtain knowledge about new deoxynucleoside kinases 
and their substrate specificities. In order to change existing deoxynucleoside kinases to 
our liking it is likewise important to understand the structural differences giving rise to 
different substrate affinities. In the following chapters different deoxynucleoside kinases 
from different organisms are presented, and the structure of HuTK1 is described 
thoroughly followed by a sequence comparison between HuTK1 and CeTK1. 
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4 Deoxynucleoside kinases and dNTP pools 
 
In dividing human cells four different deoxynucleoside kinases can be found; 
deoxycytidine kinase – dCK, deoxyguanosine kinase – dGK, mitochondrial thymidine 
kinase – TK2 and cytosolic thymidine kinase – TK1. TK1 is cell cycle-regulated and absent 
in resting cells, while the three others are present during the entire cell cycle [Sherley & 
Kelly, 1988b; Kaufman & Kelly, 1991]. The four kinases have overlapping substrate 
specificities and are named after their preferred substrate, and they are all subjected to 
feedback inhibition by deoxynucleoside triphosphates – the end product of the 
deoxynucleoside phosphorylations [Arnér & Eriksson, 1995]. Over a time span of 
relatively few years they have all been cloned and expressed [TK1: Bradshaw & 
Deininger, 1984; dCK: Chottiner et al., 1991; dGK: Wang et al., 1996 and Johansson & 
Karlsson, 1996; TK2: Johansson & Karlsson, 1997 and Wang et al., 1999]. By comparing 
the amino acid sequences it is evident that dCK, dGK and TK2 are related since they 
share a great deal of conserved motifs. In TK1 those motifs are absent with the 
exception of a glycine rich loop in the N-terminal. Until recently, structural comparison 
has only been possible by sequence alignments since three dimensional structures have 
only been available for dCK and dGK [dCK: Sabini et al., 2003; dGK: Johansson et al., 
2001]. But from the recently solved structure of TK1 being fundamentally different from 
the others it is clear that this protein is of an entirely different evolutionary origin than 
the other human deoxynucleoside kinases [Piskur et al., 2004; Welin et al., 2004; 
Sandrini & Piskur, 2005]. dCK, dGK and TK2 belong to a class referred to as the dNK-type 
kinases, a class that also includes DmdNK and HSV1TK, and TK1 belongs to a class 
referred to as TK1-type kinases. 
 
Human deoxycytidine kinase 
Deoxycytidine kinase is a cytosolic and nuclear deoxynucleoside kinase. The dCK gene is 
mapped to chromosome 4 band q13.3-q21.1 [Song et al., 1993; Stegmann et al., 1993]. 
It extends over more than 34 kilobases, and the coding region is composed of 7 exons 
ranging in size from 90 to 1544 base pairs [Song et al., 1993]. 
The dCK protein has a subunit size of 30 kDa, and the active form of the enzyme is a 
homodimer (with a molecular mass of 60 kDa) [Bohman & Eriksson, 1988]. dCK 
phosphorylates the natural substrates dCyd, dAdo and dGuo with a preference for dCyd, 
and it phosphorylates the deoxycytidine analog arabinosylcytosine (AraC, 1-β-D-
arabinofuranosylcytosine) with similar affinity as for the two natural purines [Bohman & 
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Eriksson, 1988; Eriksson et al., 1991a]. The exact kinetic parameters vary a great deal 
between different publications [Bohman & Eriksson, 1988; Datta et al., 1989; Eriksson et 
al., 1991a; Eriksson et al., 1991b; Chottiner et al., 1991], but from a review by Eriksson 
and co-workers [Eriksson et al., 2002] the kcat/Km values for dCyd, dAdo, dGuo and AraC 
are 2x105 M-1s-1, 8x104 M-1s-1, 6x104 M-1s-1 and 5x104 M-1s-1, respectively. From the same 
article it is evident that dCK shows activity with several other nucleoside analogs. The 
enzyme does not follow classical Michaelis-Menten kinetics, but shows Hill coefficients 
below unity demonstrating negative cooperativity [Eriksson et al., 1991a]. dCK accepts 
both ATP and UTP as phosphate donors, but has a clear preference for UTP with a 50 
times higher substrate efficiency [Krawiec et al., 1995]. The reaction mechanism is 
Random Bi-Bi with ATP, while with UTP it is ordered at low nucleoside concentrations 
with the phosphate donor binding before the acceptor [Hughes et al., 1997]. 
Previously, dCK was believed to be a solely cytosolic enzyme, but Johansson and co-
workers [Johansson et al., 1997] demonstrated the presence of a nuclear localization 
signal sequence in the N-terminal region of the protein, and they localized the protein in 
the nucleus of several human cell lines by tagging it with green fluorescent protein. 
Another research group [Hatzis et al., 1998] found dCK to be localized in the nucleus at 
some conditions and in the cytosol at others. By tracking the protein with polyclonal 
antibodies in several cell lines they showed that native dCK was mainly localized in the 
cytoplasm, and only by over-expressing dCK in transfected cells would it be localized in 
the nucleus. They suggest the existence of a cytoplasmic retention mechanism – perhaps 
a protein blocking the nuclear localization signal. When dCK is over-expressed the 
majority of dCK’s will contain an accessible nuclear localization sequence due to limited 
amounts of the cytoplasmic retention partner. Thus, dCK will be transported to the 
nucleus only when over-expressed, and otherwise it is localized in the cytosol.  
 
Human deoxyguanosine kinase 
The deoxyguanosine kinase gene is located at chromosome 2 band p13 [Johansson et 
al., 1996], and it has been cloned and expressed [Johansson & Karlsson, 1996; Wang et 
al., 1996]. The gene was found to contain a mitochondrial import signal sequence 
[Johansson & Karlsson, 1996], and different studies confirm the localization of the protein 
to mitochondria. One study shows mitochondrial localization in dGK transfected cells by 
tagging the protein with green fluorescent protein [Johansson et al., 1997], and another 
shows the same with native proteins tagged with both immunofluorescence and 
antibodies [Jüllig & Eriksson, 2000].  
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The human dGK gene encodes a 30 kDa protein which is similar to the size determined 
for cloned dGK expressed in bacteria, but the purified bovine dGK has a lower molecular 
weight of only 28 kDa [Wang et al., 1996; Park & Ives, 1988; Wang et al., 1993]. Since 
the genes for human and bovine dGK encode proteins of the same length the difference 
in size is most likely due to proteolytic cleavage during the mitochondrial import process. 
Human dGK is very similar in amino acid sequence to dCK with exception of the N-
terminal region which can be explained by the different localization of the proteins, and 
thus different localization signal sequences. 
The active enzyme is a homodimer, and it phosphorylates the purines dGuo, dAdo and 
deoxyinosine (dIno) and to some extent also the pyrimidine dCyd [Wang et al., 1993; 
Sjöberg et al., 1998; Johansson & Karlsson, 1996]. The kcat/Km values for dGuo dAdo and 
dCyd are 6x10-4 M-1s-1, 4x10-3 M-1s-1, and 1x10-3 M-1 s-1, respectively [Eriksson et al., 
2002]. dGK also phosphorylates a number of purine and pyrimidine analogs but with 
higher affinities for the purines [Sjöberg et al., 1998]. It accepts several nucleoside 
triphosphates as phosphate donors, but it has the highest efficiency with ATP and UTP 
[Eriksson et al., 2002].  
 
Human thymidine kinase 2 
Thymidine kinase 2 is also named mitochondrial thymidine kinase due to its mitochondrial 
location, but besides from sharing thymidine as a substrate it has very little in common 
with thymidine kinase 1. The TK2 gene is mapped to chromosome 16 band q22 
[Johansson & Karlsson, 1997], and it has been cloned by several research groups. The 
two first attempts to clone the gene resulted in incomplete TK2 cDNA lacking the 
mitochondrial translocation signal [Johansson & Karlsson, 1997; Wang et al., 1999], and 
not until recently has the full length TK2 been cloned, sequenced and expressed [Wang 
et al., 2003]. The gene spans a length of 45 kb and contains a total of 10 exons varying 
in size from 32 to 1304 bp [Wang et al., 2003]. 
The subunit size and oligomerization of TK2 is varying in different publications. In earlier 
studies the subunit size was believed to be 49 kDa [Ellims & Van der Weyden, 1980], and 
later studies showed evidence of 29 kDa [Munch-Petersen et al., 1991; Wang et al., 
2003]. The latter value corresponds with the size deduced from the coding sequence 
(~30 kDa) [Wang et al., 2003]. The active protein has been shown to be everything from 
dimers and hexamers of 98 kDa and 340 kDa, respectively [Ellims & Van Der Weyden, 
1980], to monomers of 30-40 kDa [Munch-Petersen et al., 1991; Jansson et al., 1992; 
Wang et al., 2003] and dimers of 70 kDa [Lee & Cheng, 1976; Munch-Petersen, 1984] 
Since the closely related proteins dCK and dGK are both dimers [Bohman & Eriksson, 
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1988; Wang et al., 1993] the most likely oligomerization form of TK2 is a dimer with a 
subunit size of approx. 30 kDa. 
TK2 phosphorylates the natural pyrimidines, dThd, dCyd and deoxyuridine (dUrd), and 
several pyrimidine analogs, and it shows a clear preference for dThd [Munch-Petersen et 
al., 1991]. It follows Michaelis-Menten kinetics with the substrates dCyd and dUrd 
displaying Km values of 36 µM and 6 µM, respectively. With dThd TK2 exhibits negative 
cooperativity with a Hill coefficient of 0.5, and at low substrate concentrations (below 8-
10 µM) the apparent Km is 0.3 µM, but at higher concentrations (above 8-10 µM) the 
apparent Km is 16 µM. As phosphate donor TK2 accepts ATP and CTP, and the enzyme is 
inhibited by dTTP and dCTP [Munch-Petersen et al., 1991; Wang et al., 1999]. Even 
though the synonym for TK2 is mitochondrial thymidine kinase it has also been shown to 
be present in the cytosol [Söderlund & Arnér, 1995]. 
 
Human thymidine kinase 1 
Thymidine kinase 1, also called cytosolic thymidine kinase, is the most widely researched 
of the deoxynucleoside kinases. 
In 1971 the gene for TK1 was located to chromosome 17 [Miller et al., 1971], but later 
the location was narrowed down to be q25.2-q25.3, a region containing genes related to 
breast cancer and leukaemia [Petty et al., 1996]. The gene spans 12.9 kb and consists of 
7 exons varying in size from 32 to 851 bp. The large size of the gene is mainly due to the 
presence of some very large introns [Flemington et al., 1987]. 
 
As mentioned in the introduction to this chapter TK1 is very different in sequence 
compared to the three other human deoxynucleoside kinases. But it is not only different 
in sequence, it is also different with regard to regulation [Bradshaw & Deininger, 1984; 
Sherley & Kelly, 1988a]. Whereas dCK, dGK and TK2 are all constitutively expressed 
during the entire cell cycle TK1 is cell cycle regulated and is mainly expressed during S-
phase [Sherley & Kelly, 1988b; Kauffman & Kelly, 1991]. Due to the relatively broad 
substrate specificity dCK, dGK and TK2 are sufficient to phosphorylate all four natural 
purine and pyrimidine deoxynucleosides. They are therefore believed to supply non-
dividing cells with deoxynucleotides for DNA repair [Johansson & Karlsson, 1997]. TK1 
has a narrow substrate specificity limited to the two pyrimidines dThd and dUrd. 
 
In the G1 phase of the cell cycle there is a very low presence of TK1 protein, but by 
entering S phase the amount increases 30 times after which the level decreases again in 
the G2/M phase. The amount of TK1 mRNA is not varying correspondingly during the cell 
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cycle, proving that the regulation of TK1 is posttranslational [Sherley & Kelly, 1988b]. 
The regulation of TK1 during mitosis is complex, and is partly due to a change in the 
protein stability [Sherley & Kelly, 1988b] and partly due to a change in activity [Munch-
Petersen et al., 1993]. Upon cell division the TK1 is down-regulated by a decrease in 
protein half-life from 40 hours to 1 hour, and in the transition from G1 phase to S phase 
it is up-regulated by a 10 times increased efficiency in protein synthesis [Sherley & Kelly, 
1988b]. Later it has been discovered that the down-regulation in mitosis happens 
between metaphase and cell division, and is dependent on the amino acids in the C-
terminal region of the protein. By deleting the 10 C-terminal amino acids there is no 
effect on regulation, and the concentration of protein during cell cycle is equal to that of 
the wild type protein. But by deleting the 40 C-terminal amino acids the protein is 
stabilized, and the TK1 levels are high during the entire cell cycle [Kauffman & Kelly, 
1991]. 
Changes in enzyme activity are also an important factor in the cell cycle regulation of 
TK1. One such mechanism was discovered by Munch-Petersen and co-workers in 1993. 
They showed that TK1 exists in two oligomerization states. One is a tetramer of 96 kDa, 
and the other is a dimer of 48 kDa. In both forms the enzyme consists of identical 
subunits of 24 kDa [Munch-Petersen et al., 1993]. The oligomerization state is dependent 
on the presence of ATP. Without ATP the protein is a dimer, and with ATP it becomes a 
tetramer. The two forms have the same maximum velocity with dThd, but they have 
different Km values. The tetramer is 20 times more active than the dimer, and it is 
expected mainly to be the low activity dimer form of TK1 that is present during G0 and 
G1 phase of the cell cycle [Munch-Petersen et al., 1993; Munch-Petersen et al., 1995a]. 
The two different forms of TK1 do not only show different Km values (Km(tet)=0.5 µM and 
Km(dim)=15 µM), but also different reaction kinetics. The dimer displays negative 
cooperativity with dThd (n=0.74), while the tetramer displays classical Michaelis-Menten 
kinetics [Munch-Petersen et al., 1993]. TK1 phosphorylates thymidine nucleoside analogs 
like 5-halogenated deoxyuridines and AZT, and it is inhibited by dTTP [Munch-Petersen et 
al., 1995b; Arnér & Eriksson, 1995; Eriksson et al., 2002]. It accepts most (d)NTP’s as 
phosphate donors, but it has the highest efficiency with ATP and dATP [Eriksson et al., 
2002]. 
The ATP incubated TK1 (tetramer) has been shown to bind the substrates ATP and dThd 
in an ordered sequential manner, and ATP is believed to bind first [Munch-Petersen et al., 
1995a]. Due to the more complex kinetics of the dimeric enzyme the binding mechanism 
has not been determined. 
Several experiments indicate that the biphasic pattern observed for HuTK1 without ATP is 
due to the presence of two forms of the TK1 enzyme-displaying different Km and kcat 
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values [Munch-Petersen et al., 1993; Munch-Petersen et al., 1995a]. The dimer has lower 
kcat and higher Km values than the tetramer, and the equilibrium between the two forms 
depends on concentrations of substrates and enzyme. At high substrate concentrations 
the high activity form (tetramer) is believed to be dominant, and at low substrate 
concentrations the low activity form (dimer) is believed to be dominant. The following 
model for the reaction mechanism has been proposed for the enzyme that has not been 
pre-incubated with ATP:  
 
Figure 4.1: Model for the reaction mechanism of TK1 at saturating ATP concentrations and variable 
dThd concentrations. The suffices 2 and 4 refer to dimeric and tetrameric enzymes, respectively. 
TK1 is substrate-free enzyme, (TK1·ATP) is enzyme bound with ATP and (TK1·ATP·dThd) is 
enzyme bound with ATP and dThd [from Munch-Petersen et al., 1995a]. 
 
At low dThd concentration dimeric TK1 complexes with ATP and both substrates 
(reactions 1 and 2), and upon phosphoryl transfer the complex is dissolved (reaction 3). 
At low dThd concentration the rapid phosphoryl transfer reaction is preceding the slower 
dimer to tetramer transition (reaction 4 and 5). At higher dThd concentrations the 
concentrations of TK1 in complex with ATP or both substrates will build up, and the 
phosphoryl transfer will be rate-limiting. Hence, the tetramerization of the two dimeric 
complexes will take place with a rate depending on the concentration of each complex 
(reaction 4 and 5). When the enzyme is saturated with dThd it will mostly exist at the 
tetrameric form, and most of the product will be formed by reaction 7 [Munch-Petersen 
et al., 1995a]. 
 
Several individual amino acids involved in cell cycle regulation of TK1 have been 
identified, of which some are involved in mitotic break down of the protein and others in 
enzyme activity [Chang et al., 1998; Ke & Chang, 2004; Berenstein et al., 2000; 
Frederiksen et al., 2004]. 
The cellular break down of TK1 depends on a C-terminal sequence called the KEN box 
[Ke & Chang, 2004]. The KEN box sequence is recognized and bound by an enzyme 
(TK1)2
(TK1·ATP)2 (TK1·ATP·dThd)2
2
1 3
4 5
(TK1·ATP)4 (TK1·ATP·dThd)4
(TK1)4
6 7
Low dThd
High dThd 
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complex consisting of Cdh1 and APC (anaphase promoting complex). APC is an ubiquitin 
ligase which is activated by either Cdc20 or Cdh1. During M phase the APC/Cdc20 
complex ubiquitylates the proteins cyclin B and securin, and in the late part of M phase 
and in the transition to G0 and G1 phase the APC/Cdh1 complex ubiquitylates several 
proteins with the recognition sequence KEN. TK1 and other ubiquitylated proteins are 
then transported to the proteasome for proteolysis. The KEN box is fully conserved in 
TK1 of human, chicken and Chinese hamster [Pfleger & Kirschner, 2000; Ke & Chang, 
2004]. 
 
The cell cycle regulating protein kinases Cdk1 (synonymous to Cdc2) and Cdk2 is known 
to phosphorylate human TK1 on Ser13 [Chang at al., 1998]. Under normal circumstances 
Ser13 is phosphorylated in the M phase, but in an experiment where Cdk’s are inhibited 
the phosphorylation is absent. These results indicate that the Cdk1, which is normally 
present in M phase, is responsible for the mitotic phosphorylation of TK1 on Ser13. All 
substrates to Cdk1 contain the sequence Ser/Thr-Pro. The sequence is highly conserved 
in vertebrate TK1’s, confirming the above-mentioned relationship between the two 
proteins [Chang et al., 1998]. Since Cdk1 is expressed in M phase simultaneously with 
the decrease in TK1 protein levels this could lead to the belief that phosphorylation of 
Ser13 is involved in down regulation of the TK1 level. This is not the case, however. 
Ser13 is involved in regulation of enzyme activity since presence of a phosphate group on 
this amino acid lowers the enzymes affinity for dThd and prevents the previously 
described ATP-activating effect from tetramerization of the enzyme. Phosphorylation on 
Ser13 causes the ratio between tetrameric and dimeric TK1 to decrease and thus the 
overall activity of the enzyme decreases [Li et al., 2004]. It is possible that this activity 
down-regulation functions as a fine-tuning mechanism of TK1 activity before the M phase 
proteolysis. 
 
Val106 is also known to be important for TK1 activity regulation. In the first clone made 
by Bradshaw and Deininger in 1984, the amino acid in position 106 was a methionine and 
not a valine. For many years, researchers experienced discrepancies regarding activity 
and molecular weight between purified native TK1 and recombinant TK1 from the 
Bradshaw and Deininger clone [Sherley & Kelly, 1988a; Munch Petersen et al., 1991; 
Munch-Petersen et al., 1993; Jensen & Munch-Petersen, 1994]. From the work of Jensen 
and Munch-Petersen in 1994 it became clear that the recombinant TK1 from Bradshaw 
and Deininger was a permanent tetramer with high activity regardless of ATP-incubation. 
But it was not discovered until year 2000 that the difference between native and 
recombinant TK1 was due to a difference in amino acid 106 [Berenstein et al., 2000]. 
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The published sequence showed a methionine at site 106, whereas the Munch-Petersen 
group found a valine at this site. After sequencing a large number of samples from 
several leukaemic cell lines and from 21 different healthy individuals it became evident 
that Met106 must be an error, and that the true amino acid at this site is in fact a valine 
[Berenstein et al., 2000]. The effect of the difference was examined, and it was 
discocered that the two forms of human TK1, HuTK1-M106 and HuTK1-V106 have 
different oligomerization and activity properties. Recombinant HuTK1-V106 was proven to 
show the same activity and oligomerization pattern as purified human lymphocyte TK1, 
confirming that valine and not methionine is the natural amino acid in position 106 
[Berenstein et al., 2000]. Several mutations have been performed in this position, and it 
turns out to be the size and conformation of the amino acid rather than polarity that 
accounts for the differences in behaviour [Frederiksen et al., 2004]. 
 
Much effort has been invested in deducing the mechanisms of TK1 cell cycle regulation, 
and by first thought it may seem like it is a lot of work for very little information. There 
have been indications that a defect in TK1 regulation is present in leukaemic cancer cells, 
though [Kristensen et al., 1994]. In patients with chronic lymphatic leukaemia the TK1 
mRNA levels in the lymphocytes have been shown to be 100 times higher than in healthy 
lymphocytes without showing corresponding TK1 enzyme activity. These findings indicate 
a defect in the processing of the enzyme that could possibly influence the cancer 
development. It is also known that a tight regulation of the nucleotide pool is important 
since imbalances among other things can lead to increased mutation rates and severe 
skeletal myopathy [Song et al., 2003¸Saada et al., 2003]. Thus every little step that leads 
to a better understanding of the regulation mechanism is of great importance. 
 
Effect of unbalanced dNTP pools 
In order to enter the nucleus and be incorporated into DNA the cytoplasmic dNTP’s have 
to cross the nuclear membrane. The membrane is spanned by nuclear pore complexes 
allowing all ions and molecules with a molecular weight below 60 kDa to enter and exit 
freely. The nuclear and cytoplasmic dNTP pools are thus in equilibrium. The same simple 
exchange does not occur between the cytosol and mitochondrial matrix. 
For several years, it has been believed that dNTP’s for mitochondrial and nuclear DNA 
have belonged to two separate pools. It was not until recently that a deoxynucleotide 
carrier protein (DNC) was identified in the mitochondrial membrane [Dolce et al., 2001]. 
By in vitro experiments it has been shown that the protein transports all four dNDP’s, and 
to a lower extent NDP’s, dNTP’s and NTP’s, in exchange for the reverse transportation of 
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dNDP’s, ADP or ATP. [Dolce et al., 2001]. The transport of nucleosides has later been 
confirmed by in vivo experiments by tracking labelled dThd in several different human 
and mouse cells lines [Pontarin et al., 2003; Rampazzo at al., 2004]. The in vivo results 
also showed transport of unphosphorylated thymidine across the membrane. In spite of 
the nucleotide exchange between different cellular compartments both TK1 and TK2 are 
important for the cell. Due to the lack of de novo synthesis of nucleotides in mitochondria 
the salvage of dTTP by TK2 is of utmost importance since both the cytosolic TK1 and 
ribonucleotide reductase are only active in parts of the cell cycle and not active at all in 
G0 cells [Kauffman & Kelly, 1991; Chabes & Thelander, 2000]. In proliferating cells the 
majority of the thymidine is phosphorylated by TK1, and in quiescent cells it is 
phosphorylated by TK2 in mitochondria [Pontarin et al., 2003]. Lowered activity of any of 
the two will lead to imbalance in the nucleotide pool. TK2 deficiency is associated with 
mitochondrial DNA depletion syndrome (MDS) and can lead to severe skeletal myopathy 
[Saada et al., 2001; Saada et al., 2003] and reduced ability to repair nuclear DNA 
damages [Delsite et al., 2003]. The TK2 deficiency results from one of two types of point 
mutations in the TK2 gene leading to the expression of a functional enzyme, but with a 
significantly lowered activity [Saada et al., 2001]. Also, dGK is associated with 
mitochondrial DNA depletion. A single nucleotide deletion in the dGK gene has been 
found in patients with the hepathocerebral form of MDS, and no dGK protein can be 
detected in their liver cells. The majority of the affected individuals die from liver failure 
and neurological abnormalities within the first year of life [Mandel et al., 2001]. TK1 is 
important in regulating the size of the dTTP pool. dTTP is an effector of ribonucleotide 
reductase, and increase in the dTTP pool will down-regulate reduction of pyrimidine 
NDP’s and up-regulate reduction of purine NDP’s. Thus, TK1 is an indirect regulator of 
the cells dNTP pool by affecting the substrate specificity of ribonucleotide reductase 
[Berenstein, 2004]. Even though a functional TK1 is not necessary for cells in culture it 
has been shown in TK1 knockout mice (TK1-/-) that the enzyme is important in vivo 
[Dobrovolsky et al., 2003]. The knockout mice have a shortened life span compared to 
wild type (TK1+/+) and heterozygous (TK1+/-) mice, and they die from kidney failure 
before one year of age. Together with a number of other malfunctions in the knockout 
mice, like artery inflammation and lymphocyte abnormalities, this indicates that the 
pyrimidine nucleoside salvage pathway is vital in vivo.  
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5 Structure of Human thymidine kinase 1 
 
In 2004, Welin, Kosinska and co-workers finally solved the three-dimensional structure of 
Human TK1 [Welin et al., 2004]. The same structure was shortly thereafter presented by 
a Swiss research group [Birringer et al., 2005], and in both structures TK1 is lacking the 
C-terminal 40 or 41 amino acids. Several attempts have been made to crystallize TK1-
type kinases in full length, but most likely due to flexible parts the outcome was 
unsuccessful [Welin et al., 2004]. A recent study has revealed that partial removal of the 
C-terminal stabilizes HuTK1 pronouncedly. By removal of the last 41 amino acids the half 
life (the time after which 50 % activity is lost) of the enzyme at 20 °C increases from 
78±7 minutes for the HuTK1-WT to 335±24 minutes for HuTK1-C∆41, and by removing 
further 3 more amino acids the half life for HuTK1-C∆44 increases to 500±70 minutes 
[Zhu et al., in press]. These results confirm why it has not been possible to obtain a 
crystal structure of HuTK1 without truncation of the C-terminal. 
The latter of the two structure publications claims that the 40 amino acid C-terminal 
truncation causes TK1 to exist as a dimer in solution (in the presence of ATP), but it still 
crystallizes as a tetramer. In spite of the oligomerization change truncated dimeric 
enzyme should have unchanged activity with dThd [Birringer et al., 2005]. Compared to 
other findings this is puzzling. According to the first structure publication the removal of 
41 C-terminal amino acids does not affect the oligomerization properties nor the activity 
of TK1 [Welin et al., 2004]. These results have also been confirmed by the work of Zhu 
et al. (in press). When HuTK1 lacking the C-terminal 41 amino acids is incubated with 
ATP it is a tetramer with similar dThd activity as the tetrameric HuTK1-WT, but when 
incubated without ATP it is a dimer (like HuTK1-WT) with lower Km than dimeric HuTK1-
WT [Zhu et al., in press]. 
 
In order to further stabilize the enzyme for crystallization Welin and co-workers added 
the feedback inhibitor dTTP to the solution [Welin et al., 2004]. This was not done by the 
Swiss crystallization group, but in spite of that dTTP still showed up in the active site of 
the enzyme. Since E. coli was the expression host dTTP is believed to originate from the 
coli metabolism [Birringer et al., 2005]. Recently, it has also been attempted by Welin 
and co-workers to crystallize HuTK1 without dTTP, but the deoxynucleotide continually 
shows up in the active site in spite of attempts to remove it [Munch-Petersen, personal 
communication].  
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The tetramer and the two subunit domains 
As expected, the structure of HuTK1 is a tetramer, and each of the subunits consists of 
two domains, one α/β-domain and a smaller zinc-containing domain (figure 5.1). The 
active site is located between the two domains. 
 
Figure 5.1: A: Tetrameric orientation of the 
subunits in HuTK1. One interface is formed by 
antiparallel α1 helices and the other by 
antiparallel β6 from the β-sheet. Next to β6 α4 
and α3 are located. B: Subunit structure of 
HuTK1 with dTTP in the substrate binding site. 
The upper part is the lasso domain, and the 
lower is the α/β-domain.  Mg2+ is shown in 
yellow and Zn2+ is shown in grey [Welin et al., 
2004]. 
 
The monomers in the active enzyme are organized in a plane circular structure creating a 
central channel in the tetramer (figure 5.1.A). Neighbouring subunits are oriented upside 
down relative to each other, and the channel is mainly occupied by polar and charged 
residues [Welin et al., 2004]. 
 
The α/β-domain consists of a central β-sheet with 6 parallel β-strands in the order β3-β2-
β4-β5-β1-β6 surrounded by α-helices (figure 5.1.B). On one side there are one long α-
helix and a flexible loop, which have also been interpreted as a 310-helix and a short a-
helix. On the other side there are three shorter α-helices and a few 310-helices and short 
β-strands [Welin et al., 2004; Birringer et al., 2005]. At first glance the α/β-domain looks 
similar to the structure of other nucleoside kinases [HSV1TK: Wild et al., 1995; dCK: 
Sabini et al., 2003; dGK & DmdNK: Johansson et al., 2001], but by superimposing some 
of the structures it becomes clear that only α1, the P-loop and four of the central β-
sheets are coinciding, and the rest are substantially different [Birringer et al., 2005]. The 
A 
B 
 33
structures involved in the superimposition performed by Birringer and co-workers appears 
to be one of adenylate kinase [Abele & Schulz, 1995], and most likely also HSV1TK, 
DmdNK and dGK [Wild et al., 1995; Eriksson et al., 2002]. The α/β-domain is more 
closely related to that of the ATP-binding domain in enzymes of the RecA-F1ATPase 
family and can be found in helicases and repair proteins [Sawaya et al., 1999; Welin et 
al., 2004] (figure 5.2). Most of the proteins in the RecA family are slightly larger than the 
α/β-domain of HuTK1, and the most similar structure to this domain is a protein called 
CobA [Welin et al., 2004]. It is an adenosyltransferase that transfers the adenosyl group 
from ATP to corrinoid substrates like hydroxocobalamin and cobinamide (figure 5.2.A) 
[Bauer et al., 2001].  
 
 
Figure 5.2. A: CobA from Salmonella typhimurium. B: Helicase domain from the replicative 
helicase-primase from Bacteriophage T7. The organisation of the central β-sheet relative to the 
surrounding helices is very similar to that observed for the α/β-domain of HuTK1. [A: Bauer et al., 
2001; B: Sawaya et al., 1999]. 
 
The small zinc-containing domain in HuTK1 spans from residue number 150 to the C-
terminal, but the structure is only known until residue 191 (figure 5.3). The small domain 
covers the substrate-binding site and consists of two perpendicular β-ribbons connected 
by a large lasso-like loop. The β-ribbons are kept in position by four cysteine residues 
coordinating a zinc ion. Two of the cysteines; Cys153 and Cys156 are positioned before 
the lasso loop and the two others; Cys185 and Cys188 are positioned after the loop. The 
loop itself spans from Leu166 to Lys180 and is held in place by hydrogen bonds between 
main chain atoms in the loop and the two conserved residues Arg165 and Tyr181 at each 
end of the loop.  
 
So far no identical domains to the lasso domain have been found in other proteins, but a 
slightly similar zinc-binding motif can be found in adenylate kinase from the thermophile 
A B
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Bacillus stearothermophilus (figure 5.4) [Bae & Phillips, 2004]. In general the sequence 
Cys-X2-Cys-X16-Cys-X2-Cys/Asp is found in adenylate kinases from gram positive 
bacteria [Bae & Phillips, 2004].  
 
Figure 5.3 (left): The lasso 
domain of HuTK1. Four cysteine 
residues are coordinating a zinc 
ion (shown as a grey ball), and 
the lasso-like structure is kept in 
position by hydrogen bonds 
between main chain atoms in the 
loop and R165 and Y 181 [Welin 
et al., 2004].  
 
 
Figure 5.4 (right): Adenylate kinase 
from the gram positive Bacillus 
stearothermophilus. Four cysteine 
residues in the β-strands in the upper 
part of the figure (shown in blue) are 
coordinating the zinc ion (shown as an 
orange ball).  
The motif is similar to the one involved 
in zinc-binding in HuTK1 [Bae & 
Phillips, 2004]. 
 
There are two different types of subunit interactions in the tetramer. One interface is 
dominated by interactions between the two antiparallel β-sheets connected by water 
molecules (β6 interacting with β6 from the neighbouring subunit). Next to the β-strands 
α4 and α3 are located. And the other interface consists of two long antiparallel α-helices 
(α1 interacting with α1) interacting directly with each other (figure 5.1.A) [Welin et al., 
2004]. Val106, which has previously been mentioned as an amino acid important for 
tetramerization of the enzyme, is located in the N-terminal end of α3 not far from the 
first interface. It is not directly involved in the interface, though, but it is likely that the 
change to a larger or more bulky side chain such as methionine may cause α3 to shift 
slightly and thus interfere with interactions between the neighbouring subunit and some 
of the more C-terminal residues of α3. The position of Val106 shows us that an amino 
acid can influence on protein function and structure even if it is not located right in the 
centre of action. It is still not clear in which interface the enzyme breaks contact when 
shifting to the dimer form, but the position of Val106 near the first interface suggests 
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that the dimer HuTK1 consists of subunits that are connected by interactions between 
their α1-helices. 
 
The active site 
A general feature for the substrate binding site in deoxynucleoside kinases is that the 
nucleoside substrate is bound in the protein interior and the phosphate donor is bound 
near the protein surface with the triphosphates in close contact to the P-loop. In HuTK1 
the active site is located between the α/β-domain and the lasso domain, and the 
molecule in the active site is the feedback inhibitor dTTP. dTTP is bound in the 
deoxynucleoside site with the base and sugar buried in the interior of the protein 
between the two domains and the triphosphates positioned in the P-loop of the α/β-
domain. Thus it occupies both the deoxynucleoside site and the site for the phosphate 
groups of the phosphate donor [Welin et al., 2004].  
On the lasso domain side the thymine base stacks against the previously mentioned 
Arg165 and Tyr181 that also keep the lasso loop in position. The aromatic ring of Tyr is 
positioned parallel to the base. On the side of the α/β-domain the base stacks against 
Phe101 and Phe133, both orientated perpendicular to the base.   
 
 
 
Figure 5.5: Amino acids 
surrounding dTTP in the active 
site of HuTK1. The base is 
bound to main chain atoms of 
the lasso loop, and the methyl 
group is positioned in a 
hydrophobic pocket pointing 
towards Thr163. The 3`-OH of 
the ribose is hydrogen-bonded 
to the amino group of Gly176 
and to Asp58. The triphosphates 
are bound to several amino 
acids in the P-loop [Welin et al., 
2004]. 
 
 
The thymine base has hydrogen bonds to several backbone amino acids in the lasso 
loop; O2 with both amide N and carbonyl O of Val174, and N3 with carbonyl O of Val172 
(figure 5.5). There is also has a hydrogen bond between O4 of thymine with amide N of 
Phe128 in the α/β-domain. Binding of the base to backbone atoms is very unusual and is 
not observed in any deoxynucleoside kinases of the dNK-type [Eriksson et al., 2002]. 
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The methyl group of the base is located in a hydrophobic pocket and is pointing towards 
Thr163 and surrounded by Met28, Tyr181 and Leu124. The ribose moiety is stabilized by 
hydrogen bonds from 3`-OH to Asp58, Gly176 and maybe Arg60. The triphosphates are 
bound to several amino acids in the P-loop. The P-loop sequence (Gly26-Pro-Met-Phe-
Ser-Gly-Lys-Ser-Thr34) is highly conserved in all deoxynucleoside kinases, and it forms a 
big anion hole that binds the β-phosphate of the phosphate donor in order to facilitate 
the transfer of the γ-phosphoryl group to dThd [Welin et al., 2004; Birringer et al., 2005]. 
In other deoxynucleoside kinases the catalytic mechanism of the phosphoryl transfer 
involves a Glu that acts as a catalytic base accepting a proton from 5`-OH of the 
deoxynucleoside (figure 5.5). The deprotonated 5`-OH then makes a nucleophile attack 
on the γ-phosphate of the phosphate donor [Eriksson et al., 2002].  
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Expected catalytic mechanism of the phosphoryl transfer from ATP to dThd in HuTK1. 
The glutamic acid acts as a catalytic base in the reaction. 
 
In HuTK1 the proton acceptor is expected to be Glu98 since it is in a position similar to 
the Glu expected to act as catalytic bases in other deoxynucleoside kinases. Glu98 is 
positioned near the 5`-oxygen of the ribose, and in the structure containing dTTP it has 
hydrogen bonds to the neighbouring Asp58 [Eriksson et al., 2002; Welin et al., 2004]. 
Another amino acid expected to be involved in the phosphoryl transfer is Lys32 from the 
P-loop [Birringer et al., 2005]. A magnesium ion is stabilizing the transition state of the 
reaction, and Arg60 is in a position to do the same [Welin et al., 2004].  
In Vaccinia virus thymidine kinase (VvTK) Asp82 plays a role in Mg2+ binding, but does 
not participate directly with ATP. It is suspected to facilitate ATP hydrolysis by binding 
Mg2+, which helps position ATP correctly for the nucleophile attack [Black & Hruby, 
1992a]. Since Asp82 is located in a highly conserved sequence in TK1-type 
deoxynucleoside kinases the corresponding amino acid, Asp97, is expected to have the 
same role in HuTK1. Asp97 is located so it is pointing towards the β-phosphoryl of dTTP 
with the Mg2+ ion positioned in between [Welin et al., 2004]. Also, in VvTK mutation 
studies have shown that Gln114 plays an important role regarding dTTP feedback 
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inhibition. When Gln114 was mutated to His or Asp the protein maintained full activity 
with dThd, but the inhibition by dTTP was remarkably less than WT [Black & Hruby, 
1992b]. In HuTK1 the corresponding amino acid Gln129 is positioned over 7 Å from 
dTTP, and the nearest atom is O4 of the thymine base. Again, this underlines that amino 
acids can influence the enzymatic properties far from the site of action.  
 
Substrate specificity 
TK1-type deoxynucleoside kinases have far narrower substrate specificity than other 
deoxynucleoside kinases. This is consistent with the very small active site and the many 
contacts between the substrate and the amino acids in HuTK1. There is only little space 
around the methyl group of the thymine base compared to HSV1TK, which also accepts 
dThd as substrate. That explains why HuTK1 only phosphorylates a few 5-substituted 
analogs, and only analogs with small substituents like bromine, fluorine or ethyl. Analogs 
with larger substituents, like 2-chloroethyl or 2-bromovinyl, are not accepted since they 
would clash with Thr163 [Eriksson et al., 1991b]. 
There have been reports of TK1’s accepting large carboranylalkyl substituents on N3 of 
thymidine [Al-Madhoun et al., 2002]. N3 is pointing towards the cleft between the lasso 
domain (amino acids approx. 163-175) and the α/β-domain (amino acids approx. 123-
135), and when a small substrate like thymidine is in the nucleoside-binding site the cleft 
is closed, and there is little space. But it is likely that larger substituents can cause the 
cleft to open slightly, and thus let the carboranylalkyl group stick out of the substrate-
binding pocket towards the protein surface (the distance to the surface is approx. 6-10 Å) 
[Welin et al., 2004]. 
The space around the 2`-carbon in the ribose moiety is very narrow, explaining the 
rejection of ribonucleoside substrates. A 2`-OH group from a ribonucleoside would clash 
with Gly176 and Tyr181. There is a little more space around the 3`-OH of the ribose 
which is located near the protein surface with Asp58 and Ile175 on each side of the 
opening. This allows the substitution with bulkier groups like the fluorine or azido group 
of 3`-(fluoro/azido)-2`-deoxythymidine which are known substrates for HuTK1 [Welin et 
al., 2004; Birringer et al., 2005; Eriksson et al., 1991b]. 
In order to design new drugs for HuTK1 the areas to be explored are mainly around 3` 
and 4` positions of the deoxyribose and around N3 or the methyl group of the base. 
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6 Comparison of HuTK1 and CeTK1 
 
By performing a BLAST search on CeTK1, HuTK1 shows up as the sequence with the 
highest identity. From amino acid 25 to 225 in CeTK1 43 % of the residues are identical 
to those of HuTK1, and 63 % are similar amino acids with the same charge and chemical 
properties. When HuTK1 was crystallized a TK1-type kinase from Ureaplasma urealyticum 
(UuTK) was co-crystallized. The two enzymes have a sequence identity of 30 %, and the 
structures can be superimposed with an rms deviation of only 1.2 Å for 147 Cα atoms 
[Welin et al., 2004]. The rms deviation is a measure of how well a crystallographic model 
conforms to expected values of bond lengths and bond angles. The expected values are 
derived from measurements of the same parameters in high-resolution models of small 
molecules. The low rms deviation indicates that CeTK1 and many other TK1’s that have 
higher sequence identities most likely have the same three-dimensional structures. 
 
Structurally important amino acids 
From the alignment of several TK1’s from different organisms with ClustalX 1.83 (figure 
6.1) it is evident that there is a generally high identity between the sequences with the 
exception of the N- and C-terminal regions. Differences in those regions are believed to 
mainly affect stability and regulation of the proteins [Kauffman & Kelly, 1991; Chang et 
al., 1998]. 
 
There are several highly conserved motifs in TK1, but only a few have known functions. 
The most conserved sequence is clearly the P-loop containing the phosphate binding 
amino acids. All amino acids from Gly26 to Thr34 (HuTK1 numbering) are identical in 
HuTK1 and CeTK1, suggesting that the phosphate binding is the same in the two 
enzymes. The Mg2+ coordinating amino acid, Asp82, in VvTK (Asp97 in HuTK1), and the 
presumed catalytic base involved in the phosphoryl transfer, Glu98, are positioned in the 
second conserved sequence and are identical in all the aligned TK1s. They are even 
conserved in coli TK which differs greatly from the others, so it is a very reasonable 
assumption that the same Glu is the catalytic amino acid in CeTK1, and that the Mg2+ ion 
is coordinated by the same Asp. 
From the high conservation of amino acids surrounding the triphosphates and the ribose 
moiety it seems that any difference in substrate specificity between HuTK1 and CeTK1 
should arise from differences in amino acids surrounding the base.  
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H.sapiens         ---------MSCINLPTVLPGSPSKT-----RGQIQVILGPMFSGKSTELMRRVRRFQIA 46 
M.musculus        ---------MSYINLPTVLPSSPSKT-----RGQIQVILGPMFSGKSTELMRRVRRFQIA 
G.gallus          ---------MNCLTVPGVHPGSPGRP-----RGQIQVIFGPMFSGKSTELMRRVRRFQLA 
Vaccinia          ---------MN--------------------GGHIQLIIGPMFSGKSTELIRRVRRYQIA 
C.elegans         MDIEAAKNEMTCCSSNSSLSDFNTLPRCPNRVGSITVILGPMFSGKTTELLRLHDRQIIA 60 
B.cereus          ---------MYLINQN----------------GWIEVICGSMFSGKSEELIRRVRRTQFA 
E.coli            -------------------------------MAQLYFYYSAMNAGKSTALLQSSYNYQER 
U.urealyticum     ---------MAKVNAFSKK------------IGWIELITGPMFAGKTAELIRRLHRLEYA 39 
 
                                                  . : .  ..* :**:: *::   . 
                                                        
 
H.sapiens         QYKCLVIKYAKDTRYSSS-FCTHDRNT--MEALPA--CLLRDVAQEALG--VAVIGIDEG 99 
M.musculus        QYKCLVIKYAKDTRYSNS-FSTHDRNT--MDALPA--CMLRDVTQEALG--VAVIGIDEG 
G.gallus          QYRCLLVKYAKDTRYCTTGVSTHDRNT--MEARPA--CALQDVYQEALG--SAVIGIDEG 
Vaccinia          QYKCVTIKYSNDNRYGTG-LWTHDKNN--FEALEA--TKLCDVLESITD--FSVIGIDEG 
C.elegans         KRTCVLVKYAGDTRYDADLVATHSKMTGQGRTVKA--HRLSEVQSQIFNDEVQVVSIDEG 118 
B.cereus          KQHAIVFKPCIDNRYSEEDVVSHNGLK—VKAVPVSASKDIFEHITEE----MDVIAIDEV 
E.coli            GMRTVVYTAEIDDRFGAGKVSSRIGLSSPAKLFNQNSSLFDEIRAEHEQQAIHCVLVDEC 
U.urealyticum     DVKYLVFKPKIDTRSIRNIQSRTGTSLPS-VEVESAPEILNYIMSNSFNDETKVIGIDEV 98 
 
                      :  .   * *                         .  :  .        : :** 
                        
 
H.sapiens         QFFP—-DIVEFCEAMANAGKTVIVAALDGTFQRKPFGAILNLVPLAESVVKLTAVCMECF 157 
M.musculus        QFFP--DIVDFCEMMANEGKTVIVAALDGTFQRKAFGSILNLVPLAESVVKLTAVCMECF 
G.gallus          QFFP--DIVEFCEKMANTGKTVIVAALDGTFQRKAFGSILNLVPLAESVVKLNAVCMECY 
Vaccinia          QFFP--DIVEFCERMANEGKIVIVAALDGTFQRKPFNNILNLIPLSEMVVKLTAVCMKCF 
C.elegans         QFFE—-DLAETCEELAQRGKVVCVAALNGTFERKPFPQISLLLPYANEIKQVTAVCVECG 176 
B.cereus          QFFDG-DIVEVVQVLANRGYRVIVAGLDQDFRGLPFGQVPQLMAIAEHVTKLQAVCSACG 
E.coli            QFLTRQQVYELSEVVDQLDIPVLCYGLRTDFRGELFIGSQYLLAWSDKLVELKTICF-CG 
U.urealyticum     QFFDDR-ICEVANILAENGFVVIISGLDKNFKGEPFGPIAKLFTYADKITKLTAICNECG 157 
 
                  **:    : : .: : : .  *   .*   *. : *     *.. :: : ::.::*  * 
                    
 
H.sapiens         REAAYTKRLGT------EKEVEVIGGADKYHSVCRLCYFKKASGQPAGPDNKENCPVPGK 211 
M.musculus        REAAYTKRLGL------EKEVEVIGGADKYHSVCRLCYFKKSSAQTAGSDNK-NCLVLGQ 
G.gallus          REASYTKRLGA------EREVEVIGGADKYHSVCRACYFQKRP-QQLGSENKENVPMGVK 
Vaccinia          KEASFSKRLGE------ETEIEIIGGNDMYQSVCRKCYVGS------------------- 
C.elegans         SQANFSFRSTL------DKKVEVIGGSDTYTALCRECYVQKSEEKDAEEQMKTGCDKNEN 230 
B.cereus          SPASRTQRLIDGEPAAFDDPIILVGASESYEPRCRHCHAVP-----------------TK 
E.coli            RKASMVLRLDQAGRPYNEGEQVVIGGNERYVSVCRKHYKEALQVXSLTAIQERHRHD--- 
U.urealyticum     AEATHSLRKIDGKHADYNDDIVKIGCQEFYSAVCRHHHKVPNRPYLNSNSEEFIKFFKN- 216 
 
                   :*    *         : .   **  : * ::**  :                       
 
 
H.sapiens         --------------PGEAVAARKLFAPQQILQCSPAN-- 234 
M.musculus        --------------PGEALVVRKLFASQQVLQYNSAN-- 
G.gallus          --------------QLDMPASRKIFAS------------ 
Vaccinia          --------------------------------------- 
C.elegans         DITGIFLAKKEQRSDGSVSPPRKKIGLSKSMALEATART 269 
B.cereus          QR------------------------------------- 
E.coli            --------------------------------------- 
U.urealyticum     -----------------KKRNKNI--------------- 223   
 
Figure 6.1: Multiple sequence alignment of TK1 proteins from different organisms performed with 
ClustalX 1.83. The main conserved motifs are marked by a black square, and amino acids 
mentioned in the text are marked by grey boxes _. Secondary structure elements are marked for 
HuTK1 above the sequence and for UuTK below the sequence. 
 
The amino acids surrounding the ribose moiety in HuTK1, Asp58, Arg60, Glu98, Gln100 
and Gly176 are also conserved so similarly to HuTK1, CeTK1 can be expected to 
phosphorylate AZT and maybe other 3`-substituted nucleoside analogs. 
α1 β1 
α2 β2 β3 β4 
β5 α3 α4 β6 
α1 β1 
α2 β2 β3 β4 
α3 α4 β6 β5
α5 β rib β rib 
α5 β rib β rib 
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The amino acids that are hydrogen bonding to the base via backbone atoms, Val172, 
Val174 and Phe128, are all the same in CeTK1 and in several of the other TK1’s as well. 
They are not nearly as strongly conserved as the previously mentioned amino acids 
around the phosphates and ribose, but since they are interacting with the base via 
backbone atoms the characteristics of the side chain are likely to be less important. In 
general, the backbone structure is independent of the amino acid side chains. The two 
amino acids stacking the base from the lasso domain side, Arg165 and Tyr181, and the 
two stacking from the α/β-domain side, Phe101 and Phe133, are conserved in all the 
TK1's. Of the 5-methyl group surroundings Met28, Leu124, Thr163 and Tyr181, only 
Thr163 differs between the TK1s. In CeTK1, VvTK and UuTK the corresponding amino 
acid is a Ser. 
The two amino acids Arg165 and Tyr181 that make stacking interactions with the base 
are also important in order to keep the lasso loop in position [Welin et al., 2004]. Not 
unexpectedly, these amino acids are, as previously mentioned, highly conserved in all 
TK1’s. Four other amino acids that are expected to be important for maintaining the 
structure in the lasso domain are of course the four zinc-coordinating cysteine residues 
Cys153, Cys156, Cys185 and Cys188. With the exception of Cys188, which is a His in coli 
TK and UuTK, those cysteine residues are also conserved. But from the crystal structure 
of UuTK it is shown that the His residue has the same function as the corresponding Cys 
residue in HuTK1 [Welin et al., 2004].  
 
Amino acids involved in regulation 
As mentioned previously, the main differences between HuTK1 and CeTK1 are in the N- 
and C-terminal regions, suggesting different regulatory mechanisms for the two enzymes. 
The enzyme activity of HuTK1 is down-regulated during M phase by Cdk1 mediated 
phosphorylation of Ser13 [Berenstein et al., 2000]. In order to be recognized by Cdk1 the 
Ser has to be followed by a Pro, and neither that combination nor Thr-Pro, which is 
another consensus site for Cdk1 recognition, is to be found in the N-terminal of CeTK1 
[Chang et al., 1998]. The motif Ser249Pro is found in the C-terminal, however, and since it 
has been shown that C. elegans is harbouring a Cdk1-related kinase, and that the 
recognition sequence for Cdk’s in C. elegans is the same as in mammals regulation of 
CeTK1 activity by Cdk1 phosphorylation cannot be ruled out [Boxem et al., 1999; 
Wysocka et al., 2001]. 
Regulation by Cdk1 phosphorylation affects HuTK1’s ability to tetramerize into the high 
affinity state by preventing tetramerization upon phosphorylation of Ser13 [Li et al., 
2004]. It has been shown that tetramerization is affected by the amino acid in position 
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106 (HuTK1 numbering). When the amino acid is a Val HuTK1 tetramerizes in the 
presence of ATP, but if it is Met the tetramerization is prohibited [Berenstein et al., 
2000]. In CeTK1 the amino acid in the corresponding position is an Ala, but mutation 
studies have shown that HuTK1-A106 has the same properties as HuTK1-V106 with 
respect to the dimer-tetramer transition and kinetics [Frederiksen et al., 2004]. Thus it is 
likely that CeTK1 may show the same ATP dependent dimer-tetramer transition pattern 
as HuTK1. It cannot be ruled out, however, that CeTK1 has another oligomerization 
behaviour since other amino acids are likely to affect the enzyme as well. 
 
The C-terminal KEN box, responsible for ubiquitylation dependent proteolytic degradation 
of the HuTK1 in M phase [Ke & Chang, 2004], is not conserved in CeTK1. Further down 
the C-terminal in CeTK1, starting from Lys240, the similar sequence KEQ is present. The 
KEQ motif is located approx. 30 residues from the C-terminal which is about the same 
distance as the one with which the KEN box is located from the C-terminal of HuTK1.  
Regulation of HuTK1 by feedback inhibition can be affected by Gln114. If this residue is 
mutated to His or Asp the inhibition by dTTP is strongly reduced [Black & Hruby, 1992b]. 
In CeTK1 the corresponding amino acid is a Glu. Like His and Asp it is charged, but in 
atomic composition it is very similar to Gln. Since there have been no further amino acids 
involved in the mutation study it is not clear if Glu would affect the enzyme like Gln or 
like Asp and His, and the dTTP inhibition will have to be tested experimentally. 
 
Structure of CeTK1 and selected amino acid mutations 
Based on the structure of HuTK1 by Welin and co-workers the three-dimensional 
structure of CeTK1 has been modelled by the SWISS-MODEL Protein Modelling Server 
[Schwede et al., 2003; Guex & Peitsch, 1997; Peitsch, 1995]. The resulting structure is 
presented in figure 6.2.  
 
According to the model only few sections in the chain of CeTK1 deviate structurally from 
HuTK1. The red section in the front of the picture cannot be modelled since the structure 
of that part has not been determined for HuTK1. The other red chain in the back of the 
picture is located in an area that has an assigned structure in HuTK1, but the 
corresponding sequence from CeTK1 contains extra amino acids that cannot be 
accounted for in the HuTK1 structure. The main deviations are in the areas of β2 and β3 
(red section in the front) and between α2 and β4 (red section in the back). By looking at 
these sections in the sequence alignment in figure 6.1 it becomes evident that it is an 
area with a high discrepancy between the sequences. Mainly the CeTK1 sequence 
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contains a few extra amino acids, which explains the deviations in the three dimensional 
model. 
       
A closer look into the amino acids surrounding the substrate base in the active site 
reveals that the model of CeTK1 is nearly identical to the HuTK1 structure in this area 
(figure 6.3). As mentioned previously, the only difference around the substrate base is 
the position of Thr163 in HuTK1 which is replaced by Ser182 in CeTK1.  
 
 
    
Figure 6.3: Amino acids surrounding the substrate base in the modelled structure of CeTK1 and the 
same amino acids in the crystal structure of HuTK1. The structures are based on PDB files. Note 
that although the PDB file for HuTK1 is posted by the same author Met28 appears to be oriented 
differently in the present figure than in the figure presented in the article by Welin et al., 2004 
(figure 5.5). Structure images are produced by importing PDB files into PyMOL 0.98 for presentable 
visualization. 
 
Figure 6.2: Model of the three-dimensional 
structure of CeTK1 based on the structure 
of HuTK1 from Welin and co-workers 
[2004]. The model has been made with the 
SWISS-MODEL Protein Modelling Server and 
visualized in PyMOL 0.98. The dark blue 
chain depicts the structure of HuTK1, and 
the light blue chain depicts the modelled 
structure of CeTK1. The red sections depict 
where the predicted model deviates from 
HuTK1 or cannot be modelled due to lack of 
structure information for HuTK1 (the red 
segments belong to the CeTK1 chain). 
 
HuTK1-WT
T163
M28 
L124
F128
V172
V174
CeTK1-WT 
S182 
M42 
L143 
F147 
V191 
V193 
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It should be noted that the figures above are based on PDB files, and the Met28 in 
HuTK1 is oriented differently than in the figure presented in the article by Welin et al., 
2004 (figure 5.5). The orientation displayed in the current figure is consistent with the 
structure in the PDB file posted by Birringer et al., 2005, however. 
 
The amino acids mutated in this work are Ser182, Leu143 and Met42 in CeTK1 and 
Thr163, Leu124 and Met28 in HuTK1. The mutations have been modelled in PDB viewer 
and are displayed in figure 6.4 and 6.5. 
 
 
    
 
 
   
Figure 6.4: Amino acids surrounding the substrate base in the modelled structure of CeTK1. Amino 
acid substitutions have been modelled in PDB viewer. Structure images are produced by importing 
PDB files into PyMOL 0.98 for presentable visualization. 
 
Ser182 in CeTK1 has been the subject for two different mutations. It is mutated to a Thr 
in order to mimic the active site in HuTK1. Mutation from Ser to Thr seems to give 
slightly less space around the 5-methyl group of the thymine base. In order to provide 
more space around the 5-methyl group the same amino acid has been mutated to an Ala.  
 
CeTK1-S182T
T182 
M42
L143 
F147 
V191 
V193 
CeTK1-S182A
A182
M42 
L143 
F147
V191
V193 
CeTK1-L143A
S182 
M42
A143 
F147 
V191 
V193 
CeTK1-M42I
S182
I42 
L143 
F147
V191
V193 
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Also, Leu143 is in close proximity to the base located above the 6`-carbon atom on the 
α/β-domain side of the thymine ring. Mutating Leu143 to Ala will provide more space 
around the substrate base and perhaps leave room for larger substrates. In the same 
area, but on the side of the 6`-carbon, is Met42, a large hydrophobic amino acid with the 
sulphur atom pointing towards the 6`-carbon. By replacing the Met with the slightly 
shorter, but more branched, Ile a little extra space becomes available on the side of the 
HuTK1-T163S 
S163 
M28 
L124 
F128 
V172 
V174 
HuTK1-T163A
A163
M28 
L124
F128
V172
V174
HuTK1-M28I
T163
I28 
L124
F128
V172
V174
HuTK1-L124A 
T163 
M28 
A124 
F128 
V172 
V174 
HuTK1-T163A 
T163 
A28 
L124 
F128 
V172 
V174 
Figure 6.5: Amino acids surrounding the 
substrate base in the structure of HuTK1. 
Amino acid substitutions have been 
modelled in PDB viewer. Structure images 
are produced by importing PDB files into 
PyMOL 0.98 for presentable visualization. 
 45
thymine base. It may also alter the environment around the 3`-carbon of the ribose 
moiety by providing extra space since the tip of Met is located near the 2`- 3`-carbon 
atoms of ribose. This could affect the binding of nucleoside analogs like AZT although the 
azido group is facing away from Met28. 
 
Similar mutations with some modifications have been performed in HuTK1-C∆41, and 
based on models of the HuTK1-WT enzyme the mutations affect the thymine base 
surroundings as displayed in figure 6.5. 
The mutation of Thr163 to a Ser is an attempt to mimic the amino acids in CeTK1 in 
order to see if the substrate affinities of the two enzymes become more similar. The 
same amino acid has also been mutated to an Ala, like it was done for CeTK1, resulting 
in more space around the 5-methyl group of the base. Hence, the amino acids 
surrounding the thymine base are the same in CeTK1-S182A and HuTK1-C∆41-T163A.  
Another mutation performed in both enzymes is the change of Leu124 in HuTK1C∆41 to 
the much smaller Ala, providing more space above the 6`-carbon of he base. In CeTK1 
the total space around the thymine in the Leu mutant is larger than in the Leu mutant of 
HuTK1-C∆41 since the neighbouring amino acid Ser in CeTK1 is smaller than the 
corresponding Thr in HuTK1-C∆41. 
The final amino acid mutated in this work is Met28. It has been mutated to an Ile as with 
CeTK1, but also to an Ala, leaving an even larger space on the side of the 6`-carbon of 
thymine and at the 2`- and 3`-positions of the ribose. If the mutation of Met28 to Ile 
shows no effect on enzyme affinity and activity the mutation to Ala is expected to do so. 
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7 Enzyme Kinetics 
 
Due to complications regarding determination of kinetic values for some proteins in this 
work it was necessary to apply more complex enzyme kinetic procedures. Therefore, a 
theoretical background for these procedures is presented. Readers experienced in this 
field may wish to skip this chapter, however. 
 
Steady-state kinetics 
At a fixed enzyme concentration the rate of an enzyme-catalyzed reaction depends on 
the substrate concentration. As the substrate concentration increases so does the 
reaction velocity until a saturation of enzyme occurs. At saturation the velocity becomes 
constant in spite of increasing substrate concentrations. The relation between these 
parameters was first described in 1902 where both Henri and Brown suggested that an 
enzyme-substrate complex was an intermediate in this catalytic reaction, and Henri 
derived a mathematical equation that described the dependence of velocity on substrate 
concentration. In 1913, the equation was rediscovered by Michaelis and Menten, and a 
modified version was derived on the basis of a simple chemical equilibrium between 
enzyme, substrate and enzyme-substrate complex. The steady-state theory was 
introduced by Briggs and Haldane in 1925. Modern enzyme kinetics is based on the 
equation derived by Michaelis and Menten in 1913, and the steady-state theory by Briggs 
and Haldane.  
The Michaelis-Menten equation is derived on the basis of a simple two-step reaction 
mechanism: 
 
E + S         ES           E + P 
 
The enzyme (E) and substrate (S) can associate to form the enzyme-substrate complex 
(ES). The velocity of the reaction is determined by concentrations of E and S and the rate 
constant k1, whereas the velocity of dissociation back to E and S is determined by the 
concentration of ES complex and the rate constant k-1. The ES complex can also 
dissociate to E and product (P) with a rate depending on the rate constant k2. 
 
The system is simplified by studying the initial rate of reaction where the product 
concentration is negligible. By plotting initial reaction velocities (v) versus substrate 
concentrations ([S]) a hyperbolic plot is obtained (figure 7.1).  
k1 
k-1 
k2 
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Figure 7.1: The dependence of 
initial reaction velocity (v) on 
substrate concentration ([S]). Vmax 
is the maximal velocity where all 
enzyme molecules are saturated 
with substrate. Km is the substrate 
concentration where v is Vmax/2. 
 
 
At low [S] the initial velocity is linearly dependent on [S], but as [S] increases the 
increase in velocity becomes smaller.  Vmax is the maximum initial velocity at any given 
enzyme concentration where the enzyme is saturated with substrate.  
This hyperbolic dependence of initial velocity on substrate concentration is described by 
the Michaelis-Menten equation: 
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When enzyme and substrate are mixed the concentration of reaction intermediates 
quickly increases to a steady-state level. In the derivation of the Michaelis-Menten 
equation an assumption is made that the concentration of ES is constant. As long as the 
concentration of product is negligible the reaction from E + P to ES is also negligible and 
the steady-state conditions are maintained. Measurements of initial rates are performed 
at steady-state conditions, and analysis of initial rates of reaction is therefore often 
referred to as steady-state kinetics.  
 
The Michaelis constant, Km, is a combination of rate constants and therefore, its 
interpretation depends on the specific reaction mechanism in question. In the simple 
reaction above assuming only one form of ES, it equals (k2+k-1)/k1. As it is evident from 
figure 7.1 Km is also the substrate concentration at which the initial velocity is half of the 
maximal velocity. 
If the reaction mechanism has one rate-determining step the rate constant for this step 
determines the overall reaction rate. A general rate constant, kcat, is therefore used to 
describe the limiting rate constant of any enzyme-catalyzed reaction at saturation. Note 
that if there are several partially rate-determining steps, kcat becomes a combination of 
the rate constants of these steps 
Introducing kcat the MM equation can also be expressed: 
0 30
0
20
Vmax 
Vmax/2 
Km 
v 
[S]
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[Et] is the total enzyme concentration, and kcat is the number of substrate molecules 
converted to product on a single enzyme molecule in a given unit of time. It is often 
referred to as the enzymes turn-over number. At low substrate concentrations the 
equation reduces to: 
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From this equation it is evident that at substrate concentrations far below Km the velocity 
has a linear dependence on substrate concentration. The plot v versus [S] is linear with 
the slope kcat/Km, and thus kcat/Km is a pseudo-first order rate constant of the reaction if 
[S]<<Km. kcat/Km is often referred to as the specificity constant, and it has units of M-1s-1. 
It is ideal as a parameter of comparison between different enzymatic reactions since both 
kcat and Km are independent of reaction conditions others that pH and temperature. 
The upper limit of kcat/Km is determined by the rate with which substrate and enzyme 
molecules collide and diffuse together in an aqueous solution. This diffusion limit is 108-
109 M-1s-1, and enzymes with such high specificity constants are said to have achieved 
catalytic perfection. 
 
Allosteric enzymes 
Enzymes containing more than one active site will sometimes show cooperative binding 
of substrates. Unlike enzymes that exhibit classical Michaelis-Menten kinetics a non-
hyperbolic velocity curve is obtained for such enzymes.  
When the binding of a substrate molecule in one active site increases the affinity for 
binding a second substrate molecule the enzyme is said to exhibit positive cooperativity 
with the substrate. Positive cooperativity results in a sigmoid dependence of velocity on 
substrate concentration. In 1910, Archibald Hill introduced the Hill equation in order to 
describe the cooperative binding observed for the binding of oxygen to haemoglobin. The 
degree of cooperativity can be determined from the Hill coefficient, n. If n equals 1 the 
binding is not cooperative, but if n is greater than 1 the enzyme exhibits positive 
cooperativity with the substrate. This is the case for haemoglobin where binding of one 
molecule of O2 facilitates the binding of others. The theoretical maximum value of n 
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equals the total number of substrate binding sites, but it represents a hypothetical 
situation where all sites bind substrate simultaneously, and no protein molecules will be 
partially saturated. Velocity curves for cooperative enzymes can be fitted to the Hill 
equation: 
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This equation is a modified version of the Michaelis-Menten equation where K0.5 is the 
substrate concentration at which the enzyme exhibits half maximal velocity. It is evident 
from the equation that if n equals one the enzyme exhibits classical Michaelis-Menten 
kinetics, and K0.5 becomes equal to Km. 
 
The binding of a substrate molecule to one active site can also reduce the affinity for 
binding a second substrate molecule. This behaviour is termed negative cooperativity and 
results in a velocity curve that is neither hyperbolic nor sigmoid, but displays a creeping 
behaviour. At low substrate concentrations the velocity increases rapidly, but then slopes 
off markedly as the affinities of the vacant sites decrease. The degree of negative 
cooperativity can be determined by fitting the velocity curve to the Hill equation. 
Enzymes that exhibit negative cooperativity have Hill coefficients between zero and one. 
The Hill coefficient can also be determined directly from the ratio of substrate required 
for any two fractions of Vmax [Segel, 1993].  
 
  [ ] )S/([S] log
log3n
5.00.75
=  
 
For example, the ratio of [S] at 0.75Vmax to [S] at 0.5Vmax ([S]0.75/[S]0.5) is 3 for a normal 
hyperbolic velocity curve, but it is higher for a curve displaying negative cooperativity. 
The Hill coefficient can be determined from the logarithm of the [S]0.75/[S]0.5 ratio for a 
Michaelis-Menten curve (the numerator in the equation above) divided by the logarithm 
to the [S]0.75/[S]0.5 ratio of a curve displaying negative cooperativity (the denominator in 
the equation above). 
 
Progress curves and the integrated Michaelis-Menten equation  
Under some circumstances the determination of kinetic parameters by measuring initial 
velocities can be complicated by several issues. Problems with sustaining steady-state 
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conditions within enzyme/substrate concentrations that provide measurable data can 
arise, or it can be difficult to obtain velocities in the vicinity of Vmax due to limited 
solubility of substrate. In such cases kinetic parameters can be determined by studying 
the progress curve of an enzyme reaction. Such data can be analyzed by applying the 
integrated Michaelis-Menten equation.  
 
The reaction velocity can be described as increase in product or depletion of substrate 
over time (v=d[P]/dt=-d[S]/dt), and thus the Michealis-Menten equation can be written 
like: 
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By rearranging and integrating the equation becomes: 
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In order to get a linear form from which Km and Vmax can be deduced the equation is 
rearranged: 
max
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By plotting t/[P] versus (ln([S]0/[S]))/[P], Vmax and Km can be determined from the slope 
and the intercept on the Y-axis. 
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Figure 7.2: A: Progress curve showing increase in produce concentration [P] over time. The slope 
of the linear section of the curve is the initial velocity of the reaction. B: Plot of t/[P] versus 
(ln([S]0/[S]))/[P]. Intersection on Y-axis equals 1/Vmax and Km/Vmax equals the slope. 
 
The derivation assumes that the increase in velocity only results from increasing 
saturation of the enzyme and not from approach to equilibrium or from product inhibition 
[Segel, 1993]. Thus the method is only applicable to reactions in which there is no 
feedback inhibition from the product, and for reactions with very high equilibrium 
constants (all substrate is converted to product – which is the case for both HuTK1 and 
the drosophila dNK [Munch-Petersen, personal communication]). It is also important that 
both enzyme and substrate are stable enough to last the entire time course of the 
experiment, and there must be no significant non-enzymatic reaction taking place [Atkins 
and Nimmo, 1973]. 
B
1/Vmax
Km/Vm
A 
v0 
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8 Experimental procedures 
 
In this chapter the theory behind the experimental procedures employed in this work is 
described. Recipes and more detailed descriptions of the individual experiments can be 
found in appendix A.  
 
Overview of the experimental work 
The purpose of the experimental work presented in this report is to characterize the 
deoxynucleoside kinase CeTK1 and identify amino acid residues of importance for activity 
and specificity. The purpose is also to examine the effect of the 57 C-terminal amino 
acids, a truncation known to increase stability and thymidine kinase activity of HuTK1. In 
order to observe the effect of single amino acids on the enzymatic activity, and especially 
on substrate affinities, a number of point mutations were created in both HuTK1-C∆41 
and CeTK1.  
 
In experiments prior to this work the CeTK1 and HuTK1 genes have been cloned into the 
pGEX-2T vector and the C∆41 stop codon was created in HuTK1 gene [Skovgaard, 2004; 
Berenstein et al., 2000; Zhu et al., in press]. Hence, these procedures will not be 
described in the present report. The mutations, including the C-terminal truncation of 
CeTK1, are made with site-directed mutagenesis followed by a transformation of the 
plasmid into the E. coli strain XL10-Gold. The plasmids are purified, and the desired 
mutations are controlled by sequencing. They are then transformed into E. coli BL21, 
which is a strain suitable for protein expression.  
 
The inductions are started by addition of IPTG, and the optimal induction times are 
determined by measuring activity and protein content in time samples taken during the 
induction. When the optimal induction times have been determined, large-scale cultures 
are induced and harvested at appropriate times. The cells are lysed in the French press, 
and the proteins are purified by GSH affinity chromatography. The GST-tag is removed 
by thrombin cleavage. The purified proteins are characterized with respect to substrate 
specificity, and for the relevant substrates the kinetic parameters Km and Vmax are 
determined. The experiments described above have been carried out for both CeTK1 and 
the mutants of CeTK1 and HuTK1-C∆41, but for the sake of simplicity the procedures in 
the following sections will be described using the common name TK1 for all WT and 
mutant proteins. An overview of the experimental procedures applied for all TK1’s is 
presented in figure 8.1. 
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Figure 8.1: Schematic overview of experimental procedures applied with all TK1 wild type and 
mutant proteins. 
 
Apart from the experiments described in the text above and in figure 8.1, CeTK1-WT and 
CeTK1-C∆57 have also been examined with respect to changes in thymidine kinase 
activity upon ATP-incubation. The native molecular mass of HuTK1-C∆41-M28I and –
M28A along with CeTK1-WT with and without ATP has been determined by size exclusion 
chromatography.  
1 
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Creating the mutations 
Expression vector pGEX-2T 
The mutations on the CeTK1 and HuTK1-C∆41 genes are performed in the pGEX-2T 
expression vector (Amersham Pharmacia Biotech). The vector contains a glutathione S-
transferase (GST) sequence followed by a multi-cloning site, 2T. The GST sequence and 
the 2T region are separated by a thrombin cleavage site. TK1 has been cloned into the 
2T site by cutting and ligating at the restriction sites in the multi-cloning site (see 2T in 
figure 8.2). The vector also contains a gene providing resistance to ampicillin, Ampr, and 
a gene encoding the lac repressor, lac Iq. Positioned prior to the GST gene is a tac-
promotor. The Ampr is important for selecting colonies containing the vector after 
transformations. 
 
 
                
 
Figure 8.2: Expressions vector pGEX-2T [GST Gene Fusion System, laboratory manual, 3rd edition, 
Amersham Biosciences]. 
 
Transcription of the fusion protein GST-TK1 is initiated at the tac promoter which is 
regulated by the lac repressor. When the repressor is bound to the tac promotor 
transcription is prohibited. By providing the lactose analog isopropyl β-D-thiogalactosid 
2T
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(IPTG) the repressor is inhibited, and DNA-polymerase can bind to the promoter region 
and initiate transcription of GST-TK1. GST-protein binds to glutathione (GSH), and by 
fusing TK1 to GST the protein can be purified by affinity chromatography on a GSH 
column. In order to separate the two proteins after the purification they are linked by a 
thrombin cleavage site (figure 8.2).  
 
Site-directed mutagenesis 
Site-directed mutagenesis is a simple procedure involving a double-stranded plasmid 
containing the gene of interest and two complementary oligonucleotide primers carrying 
the desired mutation. The plasmid is amplified by temperature cycles after the principles 
of polymerase chain reaction (PCR). The first step is denaturation of the double-stranded 
DNA template by raising the temperature to 95 °C. Subsequently, the temperature is 
lowered to approximately 55 °C, allowing the primers to anneal to the site of interest. 
The optimal annealing temperature depends on the individual primers. This is followed by 
an increase in temperature to 68 °C, causing the DNA polymerase to elongate the 
primers with deoxynucleotides complementary to the template sequence. Incorporation 
of the primers results in a mutated plasmid containing staggered nicks. Due to these 
nicks the primers will only be able to anneal and elongate with parental DNA during the 
subsequent temperature cycles (figure 8.3). This gives a low yield, but reduces the risk of 
amplifying unwanted mutations caused by the DNA-polymerase.  
 
After temperature cycling the parental non-mutated DNA is digested by the endonuclease 
Dpn I which only digests methylated or hemimethylated DNA. In order for this procedure 
to work it is important that the template DNA is isolated from a bacterial strain that has 
methylated DNA. Most E. coli strains are dam+, and thus their DNA is susceptible to Dpn I 
digestion. After digestion of parental DNA the mutated plasmid is transformed into XL10-
Gold supercompetent cells where the nicked strands are repaired. The plasmid is 
controlled for the desired and for unwanted mutations by DNA sequencing. 
 
The primers for site-directed mutagenesis should be between 25 and 45 bases in length 
and should be complementary to the same sequence on opposite strands of the template 
plasmid on the site of mutation. The primers should have a GC content of minimum 40 
%, and the mutated bases are to be located in the middle of the primer. Both ends of the 
primers should end in one or more CG bases, and they should have a melting 
temperature higher than 78 °C. In order to calculate the melting temperature the 
following formula is provided: 
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T m = 81.5 + 0.41(%GC) - 675/ N - % mismatch 
 
%CG and %mismatch are whole numbers, and N is the total number of bases in the 
primer. [QuickChange® Site-directed Mutagenesis Kit, Instruction manual] 
 
 
 
 
Figure 8.3: Principles of site-directed mutagenesis. 
 
The PCR reaction is controlled by agarose gel electrophoresis, and after digestion of 
parental DNA the mutated plasmids are transformed into XL10-Gold supercompetent 
cells.  
 
Agarose gel electrophoresis 
DNA-fragments are sorted by size on an agarose gel. The DNA sample is loaded onto the 
agarose gel in a little well, and by applying voltage to the gel the negatively charged DNA 
Plasmid containing gene with a 
target site for mutation. 
 
 
 
Denaturation of plasmid and 
annealing of primers containing 
mutation. 
 
 
 
Elongation of primers by Pfu Ultra 
High Fidelity DNA polymerase. 
 
 
 
 
Repeat denaturation and 
annealing several times. 
 
 
Digestion of non-mutated 
parental DNA by Dpn I 
and repair of nicks by 
transformation of dsDNA 
into XL10-Gold super-
competent cells. 
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molecules will start migrating towards the anode. The rates with which they migrate vary 
exponentially with the size of the fragments since smaller fragments migrate faster 
through the gel network than the larger fragments. By loading a sample of marker DNA 
with known fragment sizes in another well the fragment sizes of the unknown DNA can 
be determined. 
The DNA on the gel is visualized by staining with ethidium bromide, which binds to DNA, 
and glows orange when subjected to UV light.  
 
Transformation of pGEX-2T-TK1 to XL10-Gold supercompetent cells 
The mutated plasmids are transformed to Epicurian coli XL10-Gold supercompetent cells 
by heat shock treatment. The heat shock treatment causes the cell wall to become more 
porous, thereby allowing the plasmids to pass through. The transformed bacteria are 
plated on ampicillin agar plates where only the bacteria containing the Ampr gene on the 
pGEX-2T vector will be able to grow. Some transformants are selected from the plates 
and grown overnight in order to purify the plasmid and control the mutation by 
sequencing. 
 
Sequencing of TK1 in pGEX-2T 
In this work the sequencing has been performed in two different ways. The first mutants 
have been sequenced by the method described below, and the following mutants have 
been sequenced by preparing and sending plasmid samples to MWG Biotech in Germany 
(see address in appendix A.VI). 
 
In order to determine the sequence of the mutated gene a PCR reaction is set up with 
primers complementary to the sequence on each side of the 2T region containing the 
TK1 gene. The basic principles of the procedure are similar to that described for site-
directed mutagenesis. The reaction contains template, primers, nucleotides and DNA 
polymerase, and is subjected to temperature cycles where the parental strands dissociate 
and the primers anneal and are elongated by the polymerase. The two exceptions are 
primer design and nucleotides.  
Instead of using two primers complementary to each other only one primer is needed for 
each sequencing reaction. The primers have to be complementary to one of the 
sequences right next to the 2T region of the pGEX-2T-TK1 plasmid, and it must be 
orientated so the sequence amplified is the gene in the multi-cloning site. In order to 
make sure that the result is not affected by errors during the PCR the gene is sequenced 
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in both directions. In sequence PCR the four naturally occurring deoxynucleotides, dATP, 
dCTP, dGTP and dTTP, are supplemented by four fluorescent dideoxynucleotides, ddATP, 
ddCTP, ddGTP and ddTTP. In the dideoxynucleotides (ddNTP’s) the 3`-hydroxyl group is 
replaced by a hydrogen atom, rendering them unable to bind to the 5`-phosphate group 
of the incoming nucleotide. Whenever the DNA polymerase inserts a ddNTP in place of a 
dNTP the elongation is terminated.  The proportion between dNTP’s and ddNTP’s is 
relatively high which results in a mixture of fragments with varying length, each ending 
with a ddNTP. Each ddNTP has a different fluorescent colour, and fragments of different 
length are therefore marked by the colour of their last base. The fragments can be 
separated by size using electrophoresis, and the fluorescence emission of the passing 
fragments can be detected by a laser detector at the bottom of the electrophoresis gel. 
The order of nucleotides can thus be determined by the order with which the fluorescent 
ddNTP’s pass the detector [Wilson & Walker, 2000; Nelson & Cox, 2000].  
 
 
Figure 8.4: Illustrating the principles of DNA sequencing [Nelson & Cox, 2000]. 
 
When the obtained sequence has confirmed that there are no errors in the TK1-gene the 
pGEX-2T-TK1 plasmid is transformed to the protein expression strain Escherichia coli 
BL21. 
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Production and purification of proteins 
IPTG-induction of GST-TK1 fusion protein 
By adding IPTG to a BL21-overnight culture the lac repressor from the pGEX-2T vector is 
inhibited, allowing the DNA polymerase access to the tac promotor. The fusion gene GST-
TK1 is transcribed and subsequently translated to protein on the ribosomes in the host 
cell. 
In order to determine the optimal induction time, time samples are taken during the 
induction experiment and examined for protein content and activity with the substrate 
thymidine. When the optimal induction time is determined a new BL21-overnight culture 
is induced with IPTG, and the main culture is harvested for purification.  
 
Lysis of time samples and main culture 
In order to measure thymidine activity and protein content of the time samples the cells 
are lysed by ultra sound sonication. This method is only suitable for smaller cell samples. 
A vibrating stick is submerged into the bacterial sample while emitting high frequency 
sound waves. The mechanical energy from the vibrations causes the formation of small 
air bubbles that send shock waves through the liquid when they implode. Since the 
sonication is heat-producing it is important to keep the sample on ice in order to prevent 
the enzyme from denaturing. The bacteria are submerged in a lysis buffer containing 
detergents that dissolves lipid:lipid, protein:protein and lipid:protein interactions in the 
cell wall, making it more fragile and easier to disrupt by sonication. 
 
In order to extract the protein from the main culture the cells must also be lysed, but due 
to the larger volume ultra sound sonication is not an efficient method, and instead the 
cells are disrupted by the French press. The French press is a mechanical disruption of 
the cell membrane resulting from forcing the cells through a very narrow passage at high 
pressure. In this type of lysis the cells are also suspended in a lysis buffer containing 
detergents that break interactions in the cell wall. Larger cell residues are removed by 
centrifugation, and the protein homogenate is subsequently purified by affinity 
chromatography.  
 
Purification of TK1 by GSH affinity chromatography 
The affinity chromatography column consists of a Sepharose matrix with glutathione 
(GSH) molecules covalently connected to the matrix. When the homogenate passes 
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through the column matrix the GSH molecules binds the GST part of the GST-TK1 fusion 
protein (figure 8.5). Thoroughly washing the column will remove unbound proteins and 
other cell debris components, leaving only GSH-TK1 in the column. Addition of a 
thrombin containing buffer causes TK1 to be cleaved from the GST protein, and it can 
thus be washed out of the column and collected [Berenstein et al., 2000]. 
 
The purity of protein in the different column fraction collected during the purification 
process is examined by SDS gel electrophoresis, Bradford protein determination and for 
thymidine activity. The purest fraction with the highest protein content (which is often 
the first cleavage fraction) is then used for further analysis of the enzyme.  
 
       
 
 
Analysis of proteins 
Bradford protein determination  
The protein content in a sample can be determined by the Bradford method. The 
Bradford reagent contains the dye Coomassie Brilliant Blue G250 that absorbs at two 
different wavelengths. The absorption maximum of the dye shifts from 465 nm to 595 
Figure 8.5: The principles of 
GSH chromatography. a) The 
crude bacterial homogenate 
is poured onto the column, 
and the column is washed 
with a buffer eluting 
unwanted proteins and cell 
debris while the GST-TK1 
fusion protein is bound to 
GSH molecules in the 
column. b) TK1 is cleaved 
from GST by addition of 
thrombin, and finally c) GST 
is eluted form the column by 
addition of GSH. 
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nm when it is bound to protein, and it is the increase in absorption at 595 nm that is 
monitored spectrophotometrically. The advantage of this procedure is that the colour 
complex is rapidly formed and is stable over a long period of time. The disadvantage is 
that the amount of dye bound to the protein varies with the amino acid composition since 
the dye only binds to the positively charged residues arginine and lysine [Bradford, 1976; 
Wilson & Walker, 2000]. 
 
SDS gel electrophoresis  
The proteins are separated by size and visualized by sodium dodecyl sulfate - 
polyacrylamide gel electrophoresis (SDS-PAGE). The method is similar to agarose gel 
electrophoresis which is applied for separation of DNA fragments. In both methods 
molecules are separated in a gel network by their different rate of migration towards the 
anode in an electric field. 
The protein sample is treated with SDS and loaded onto the gel in slim vertical wells 
(figure 8.6), and an electric field is applied. 
 
 
 
 
 
 
 
 
Figure 8.6: Illustration of an SDS gel. 
The protein molecules become linear 
by binding to SDS-molecules, and 
when placed in an electric field they 
migrate towards the anode. 
 
 
SDS (CH3-(CH2)10-CH2OSO3-Na+) is an anionic detergent. SDS binds to the protein in the 
ratio one SDS molecule per approximately two amino acids, causing the protein to 
denature. Due to the large negative charge the intrinsic charge of the protein is 
insignificant, and the speed of migration through the gel is mainly determined by the 
mass of the protein. Furthermore, the mass-per-charge ratio is the same for all proteins. 
Therefore, the SDS-covered proteins migrate with the same rate in an electric field. The 
sample buffer also contains DTT in order to break disulfide bonds in the proteins.  
The sample is not loaded directly onto the separating gel, but onto a stacking gel with 
lower pH (the pH of the stacking gel is 6.8 and that of the separating gel is 8.8). The 
purpose of the stacking gel is to concentrate the protein into a sharp band before it 
enters the separating gel. This is made possible by using different ionic strength and pH 
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in the running buffer and the stacking gel, and by the very large pore size of the stacking 
gel (due to a low concentration of acrylamide) that allows the proteins to move freely. 
The protein band is concentrated due to the fact that the glycinate ions of the buffer 
have a lower electrophoretic mobility than the protein-SDS complexes which again have 
lower mobility than the Cl- ions of the buffer and stacking gel. In order not to break the 
electrical circuit all the ionic species must migrate with the same rate though the gel. The 
glycinate ions can only migrate at the same rate as Cl- if they are in a region of higher 
field strength. Since concentration is proportional to conductivity, which is inversely 
proportional to field strength, the glycinate ions can only migrate at the same rate as Cl- 
if the glycinate concentration is lower than the Cl- concentration. Thus the concentration 
of the three ionic species is adjusted so that [Cl-]>[protein-SDS]>[glycinate]. In order to 
achieve the proper concentration the protein-SDS complex must concentrate into a very 
narrow band between Cl- and glycinate. When the glycinate enters the separating gel it 
becomes more ionized (more negative) due to a higher pH in the separating gel 
compared to the running gel, and thus its mobility increases, leaving the protein-SDS 
complex behind the Cl-/glycinate interface. The protein-SDS complexes are then free to 
move through the gel at their own rate depending only on their size [Wilson & Walker, 
2000; Nelson & Cox, 2000]. 
 
When the migration is terminated the protein is visualized by staining the gel in 
Coomassie Brilliant Blue that only binds to the proteins in the gel.  
 
Automated electrophoresis  
The primary cleavage fraction from the purification of each TK1 was analyzed by 
automated electrophoresis. They were all analyzed with the ExperionTM system from 
Biorad  
 
The automated electrophoresis is based on traditional electrophoretic principles 
transformed into a chip format. The chip contains a number of plastic wells connected to 
a network of micro channels in a glass plate. The channels are filled with a polymer mass 
and a fluorescent dye that binds to protein-SDS micelles in the sample. All wells are 
connected to separate electrodes, and when the sample is loaded the protein is driven 
through the polymer in the channels by a voltage gradient, similar to traditional SDS-
PAGE. Due to a constant mass-to-charge ratio the molecules are separated by size. When 
the protein-SDS micelle complex passes through a laser detector the bound fluorescent 
dye is detected, and the data are translated into peaks in electropherograms and bands 
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in gel-like images (figure 8.7). A molecular weight marker (ladder) is loaded in one of the 
wells in order to translate the proteins migration time through the channel to the 
appropriate molecular weights. 
 
Figure 8.7: Example of electropherogram and gel-like image. The abscissa shows the migration 
time, the ordinate shows fluorescence intensity and the numbers assigned to each peak is the 
molecular weight of the protein causing the peak. The protein sample on the image is a molecular 
weight marker (ladder). The lower and upper markers determining the measuring range are 3.5 
and 53 kDa, respectively. 
 
The advantage of automated electrophoresis over a traditional SDS-gel is the ability to 
obtain the concentration of individual proteins in a mixture of different proteins. Thus the 
accurate concentration of TK1 in the cleavage fractions can be determined even if the 
fractions contain impurities. The concentration of protein giving rise to a specific peak is 
determined by comparing the area under the peak with the area of peaks from marker 
proteins with known concentrations. Since the fluorescent dye binds to the SDS-
molecules, and the SDS molecules bind the protein in the ratio one SDS per two amino 
acids the protein determination with this method is independent of the amino acid 
composition of the protein. Thus, one of the disadvantages of Bradford protein 
determination is overcome [Agilent 2100 Bioanalyzer User Guide, November 2003; 
ExperionTM Pro260 Analysis Kit Instruction Manual]. 
 
Thymidine kinase assay  
Thymidine kinase activity is measured by employing a radioactively labelled substrate, 
tritium thymidine (3H-dThd), which emits β radiation.  
The thymidine kinase catalyzes the transfer of a phosphate group from ATP to dThd 
(figure 8.8). 
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Figure 8.8: Transfer of phosphate from ATP to dThd yielding the products dTMP and ADP. 
 
When 3H-dThd is phosphorylated to 3H-dTMP it becomes negatively charged and is 
capable of binding to an anion exchange filter consisting of positively charged 
diethylaminoethyl groups bound to cellulose fibres.  
The reaction is started by mixing enzyme with 3H-Thd and ATP in a suitable buffer, and 
the amount of product is determined by applying a sample of known volume on an anion 
exchange filter after fixed time intervals. In order to stabilize the enzyme the assay 
mixture also contains BSA and the detergent CHAPS, and in order to prevent the product 
from being dephosphorylated the phosphatase inhibitor NaF is added. 
The filters are subsequently washed free from unphosphorylated 3H-dThd, and the β 
radiation emitted from the product 3H-dTMP is measured in a scintillation counter. By 
taking samples at three different times during the reaction it is possible to determine a 
reaction velocity. 
 
The radioactivity from the product produced during the reaction is measured as counts 
per minute (CPM). CPM from the three time samples are plotted versus time, and the 
slope (∆CPM = increase in CPM per min) and correlation of the linear plot is determined.  
In order to convert CPM to concentration of product, the total radioactivity is determined 
by taking a few samples (standards) from the reactions. The radioactivities in the 
standards are measured in the scintillation counter without prior washing. The radiation 
emitted from the sample comes from a mixture of 3H-dThd and 3H-dTMP where the sum 
equals the total amount of 3H-dThd before the reaction took place. From these standard 
samples it is thus possible to create a conversion factor between CPM and 3H-thymine 
compounds (CPM/pmol 3H-thymine compound), i.e. the specific activity of the 3H-thymine 
compounds.  This figure is used to convert ∆CPM to dTMP produced per min.  
The velocity will be calculated from the following relation: 
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∆CPM is the change in CPM per unit time, Volassay is the total assay volume, Volspotted is 
the volume of reaction mixture spotted on the filter, Volenzyme is the volume of enzyme 
dilution in the assay, nsubstrate(std) is the number of substrate moles in the reaction 
mixture spotted on the standard filters and CPMstd is an average of the CMP values from 
the standard filters. CPMstd/ nsubstrate(std) is the specific radioactivity of the radiolabelled 
substrate. 
Activity is determined as nmole substrate converted to product in one minute by one ml 
of enzyme dilution (nmol/min/ml).  
The unit nmol/min is often referred to simply as units and is abbreviated u, and in some 
cases the capital U is used, denoting µmol/min.  
 
Assay with the substrates dThd, dCyd, dAdo, dGuo, AZT and AraC 
The purified enzymes are tested for activity with the four naturally occurring 
deoxynucleosides, dThd, dCyd, dAdo and dGuo, and the nucleoside analogs AZT and 
AraC. 
The principles of the assay are the same as described for the thymidine kinase assay 
above. All substrates are marked with tritium, and the activity is determined by taking 
time samples during the reaction and measuring β radiation from the product in a 
scintillation counter. 
 
All the enzymes showing a significant activity with a given substrate are examined further 
by a Michaelis-Menten assay where the activity is plotted as a function of substrate 
concentration in order to determine the kinetic parameters Km and Vmax. 
 
Data analysis 
The substrate concentrations and appropriate velocities, calculated in Microsoft Excel 
2002, are transferred to GraphPad Prism 2.0 for determination of kinetic parameters. The 
number of replicates varies with each enzyme/substrate combination. Most experiments 
have been repeated two or three times, and some have been repeated four times. In a 
few cases only one experiment was performed. The data from all replicative experiments 
are plotted in one graph with multiple Y-values per X-value, and the velocities are 
averages. Based on the P-value from the non-linear regression analysis the type of 
kinetics is decided. If the P-value is below the threshold of 5% the Hill equation is 
concluded to be the best fit. The kinetic parameters presented in the Results chapter are 
determined with the equation giving the best fit according to the P-value. In order to 
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compare all kinetic parameters, although some are only based on single experiments, the 
kinetic values are denoted with the fitting standard error. For each enzyme/substrate 
combination the number of experiments performed is denoted in the table. 
 
Determination of molecular weight by size-exclusion chromatography 
In order to deduce whether CeTK1 has the same dimerization/tetramerization abilities as 
HuTK1 when subjected to ATP the molecular weight of the enzyme was measured by 
size-exclusion chromatography (gel filtration) with and without prior ATP-incubation. 
 
The gel filtration column matrix consists of cross-linked polymer beads with pores of 
different sizes. Large molecules that are completely excluded from the beads are able to 
pass through the column unhindered in the mobile phase. They will appear in the effluent 
first. Proteins that are small enough to enter the polymer beads migrate more slowly 
through the column, being distributed between the beads and the mobile phase. The 
smaller molecules are able to enter more polymer beads, and hence they appear later in 
the effluent (figure 8.9). The elution volume of globular molecules is determined by their 
molecular mass (Mr) 
 
By collecting the effluent in small fractions the proteins loaded on the column can be 
separated by size, and by measuring thymidine activity in all fractions the fraction 
containing CeTK1 can be determined. The void volume (v0) of the column is determined 
by a polysaccharide, Blue Dextran (~2000 kDa), which is large enough to pass 
unhindered through the column. The ratio of the void volume and the elution volume (ve) 
of several marker proteins is proportional to the logarithm of the molecular mass of the 
proteins (ve/v0 = k ·log Mr). A calibration curve with proteins of similar shape and known 
Mr can be constructed. By adding Blue Dextran as an internal standard to the CeTK1 
protein sample when running it on the column the ve/v0 for CeTK1 can be determined, 
and the corresponding Mr can be read from the calibration curve of ve/v0 as a function of 
Mr. 
 
The molecular mass determined by gel filtration is the full size of the protein that possibly 
consists of several oligomerized subunits, whereas the molecular weight determined by 
SDS gel electrophoresis and automated electrophoresis is that of a single denatured 
subunit. 
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Figure 8.9: Separation of molecules of different size by size exclusion chromatography. Large 
molecules are the first to be eluted in the void volume. The fractions containing the thymidine 
kinase are found by measuring TK1 activity in all fractions. The Mr of the kinase is determined by 
converting ve/v0 of the activity peak to the corresponding Mr using a standard curve based on 
marker proteins. 
 
Spectrophotometric assay 
The first progress curve obtained from the thymidine kinase assay with radioactive 
substrate did not conform to a linear plot when applying the integrated Michaelis-Menten 
equation. The radio assay is laborious and involves a lot of waiting time in order to obtain 
results so a different and also less expensive assay was applied in an attempt to fine tune 
the method.  
With the faster spectrophotometric assay the idea was to determine the concentration 
and time range that provided good progress curves and then apply these with the radio 
assay. The purpose of obtaining kinetic parameters from progress curves rather than by 
initial velocities and steady-state kinetics was to obtain Km and Vmax for CeTK1 with dGuo 
as substrate. Due to the high Km and the low solubility of dGuo it was not possible to 
obtain the parameters from a traditional Michaelis-Menten curve. First, the method was 
tested with dThd in order to compare the results with those obtained with the Michaelis-
Menten equation. 
 
The principles of the applied spectrophotometric assay are to follow the coupled reactions 
in figure 8.10. The production of dTMP can be determined by measuring the decrease in 
NADH concentration at 340 nm.  
 
1 2 3
TK1 
Activity
ve/v0 
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Figure 8.10: The coupled reactions in the assay used to determine the progress curve of dTMP 
production (PEP = Phosphoenolpyruvate). The increase in dTMP concentration is directly 
proportional to the decrease in NADH concentration. The NADH concentration is followed by 
measuring the absorption at 340 nm. 
 
It is evident from the figure that the decrease in NADH concentration is directly 
proportional to the increase in dTMP concentration. Hence, every time a dThd molecule is 
converted to dTMP a NADH molecule is converted to NAD+. The advantage of this 
method over the radio assay is that the result can be read directly from the 
spectrophotometer, and only minor data treatments are necessary in order to convert the 
measured NADH absorbance into dTMP concentrations. 
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9 Results 
 
In a previous study TK1 from C. elegans was cloned and purified, and preliminary results 
showed activity with the natural substrate dThd and to a lower extent also dGuo 
[Skovgaard, 2004]. The aim of the present study is to characterize CeTK1 with respect to 
molecular weight, substrate specificity, kinetic parameters and stability. As mentioned 
previously, HuTK1 displays changes in kinetics and oligomerization upon incubation with 
ATP [Munch-Petersen et al. 1993]. In order to examine if there is a similar ATP-activating 
effect of CeTK1 the enzyme is incubated in an ATP-containing buffer and in an identical 
buffer without ATP prior to determinations of molecular weight and kinetic parameters. 
Removal of the 41 C-terminal amino acids of HuTK1 has shown to improve the activity 
and stability of the enzyme [Zhu et al., in press]. Therefore, a similar deletion is 
performed in CeTK1 by creating a stop codon in the corresponding position (the codon 
for Glu213 is mutated to a stop codon). The resulting enzyme lacks the 57 C-terminal 
amino-acids and is named CeTK1-C∆57. The truncated enzyme is purified and 
characterized with respect to substrate specificity, kinetic parameters, ATP-effect and 
stability.  
 
Besides from characterizing CeTK1 and its C-terminal deletion mutant a number of 
mutations are performed in the active site of both CeTK1 and HuTK1-C∆41. HuTK1-C∆41 
was chosen as the parental enzyme for the mutations due to its higher activity and 
stability compared to the WT enzyme. The purpose of the active site mutations is to 
observe the effect of the different amino acids on substrate specificity and thus, all 
mutations are made in the vicinity of the substrate base. All mutant enzymes are purified, 
and their substrate specificity is determined. Furthermore, kinetic parameters are 
determined for all the substrates displaying activity with the enzymes. 
 
Mutagenesis and induction of TK1 enzymes 
Site-directed mutagenesis on HuTK1 and CeTK1 
Site-directed mutagenesis has been performed on HuTK1 and CeTK1 genes inserted in 
the pGEX-2T vector. And the reactions were controlled on agarose gels (figure 9.1). 
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Figure 9.1: Left: λBst-EII marker. The two bands marked by “*” are DNA fragments containing 
cohesive ends (12 nucleotide overhangs) of bacteriophage lambda DNA. On the gels on the right 
these bands are conjugated, and instead of two bands of 5678 and 8453 bp there is one band of 
14144 bp. Right: The mutated pGEX-2T-TK1 fragments from site directed mutagenesis. The bands 
of the pGEX-2T-TK1’s are located between the λBst-EII marker bands 4822 and 6369 bp. 
 
The pGEX-2T vector alone is 4950 bp of length, and the CeTK1 and HuTK1 genes add an 
extra 830 and 700 bp, respectively. As would be expected, the fragments appear on the 
gel between the marker bands 4822 and 6369 bp. The minor difference in fragment size 
due to the different sizes of the inserted HuTK1 and CeTK1 genes is not perceptible on 
the gels. The mutated plasmids were transformed into E. coli XL10-Gold where they were 
amplified and subsequently, the mutations were controlled by sequencing. 
 
Sequencing of mutated genes 
All genes in the multi-cloning sites of the pGEX-2T vectors are sequenced both in the 
forward and reverse direction, applying the vector specific primers pGEX-for and pGEX-
rev. The full sequences are presented in an alignment with the respective WT TK1’s in 
appendix B, and the local mutated sequences are displayed in figure 9.2.  
 
The sequencings confirmed all the expected mutations, and with the exception of HuTK1-
C∆41-T163S and –L124A there were no additional mutations in the genes. The two 
mutations were repeated by site-directed mutagenesis, and the sequencing confirmed 
the expected mutations without additional mutations. 
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            Lys Ser Glu Glu Lys 
CeTK1-WT    AAG AGC GAA GAA AAA 
C∆57-for    AAG AGC TAA GAA AAA 
C∆57-rev    AAG AGC TAA GAA AAA 
                    Ter 
 
            Asn Phe Ser Phe Arg 
CeTK1-WT    AAC TTC TCA TTC CGC 
S182T-for   AAC TTC ACA TTC CGC 
S182T-rev   AAC TTC ACA TTC CGC 
                    Thr         
 
            Asn Phe Ser Phe Arg 
CeTK1-WT    AAC TTC TCA TTC CGC 
S182A-for   AAC TTC GCA TTC CGC 
S182A-rev   AAC TTC GCA TTC CGC 
                    Ala 
 
            Ala Ala Leu Asn Gly 
CeTK1-WT    GCT GCA CTC AAT GGA 
L143A-for   GCT GCA GCC AAT GGA 
L143A-rev   GCT GCA GCC AAT GGA 
                    Ala 
 
            Gly Pro Met Phe Ser 
CeTK1-WT    GGG CCA ATG TTC AGT  
M42I-for    GGG CCA ATT TTC AGT  
M42I-rev    GGG CCA ATT TTC AGT 
                    Ile  
            Ala Tyr Thr Lys Arg 
HuTK1-WT    GCC TAT ACC AAG AGG 
T163S-for   GCC TAT AGC AAG AGG 
T163S-rev   GCC TAT AGC AAG AGG 
                    Ser 
 
            Ala Tyr Thr Lys Arg 
HuTK1-WT    GCC TAT ACC AAG AGG 
T163A-for   GCC TAT GCC AAG AGG 
T163A-rev   GCC TAT GCC AAG AGG 
                    Ala 
 
            Ala Ala Leu Asp Gly 
HuTK1-WT    GCT GCA CTG GAT GGG 
L124A-for   GCT GCA GCG GAT GGG 
L124A-rev   GCT GCA GCG GAT GGG 
                    Ala 
 
            Gly Pro Met Phe Ser 
HuTK1-WT    GGG CCG ATG TTC TCA 
M28I-for    GGG CCG ATC TTC TCA 
M28I-rev    GGG CCG ATC TTC TCA 
                    Ile 
 
            Gly Pro Met Phe Ser 
HuTK1-WT    GGG CCG ATG TTC TCA 
M28A-for    GGG CCG GCG TTC TCA 
M28A-rev    GGG CCG GCG TTC TCA 
                    Ala  
 
Figure 9.2: Results from sequencing reactions for the different TK1 mutants. The CeTK1 and 
HuTK1 sequences (Ncbi nr. NM_069485 and NM_003258, respectively) and the translated amino 
acid sequence are shown for comparison. The prefixes -for and -rev denote the forward and 
reverse sequencing reactions, respectively. Mutated amino acids are marked with a grey box, _.  
 
Activity curves from induction 
In order to determine the optimal IPTG-induction time for the different mutant TK1 
enzymes the bacterial growth and the TK activity were followed by taking time samples 
during the induction. The bacterial growth, followed by OD600 measurements, was very 
similar between the different mutant enzymes induced (not shown), but the time of 
maximal activity during the induction varied to a great extent (figure 9.3). 
 
The optimal induction time, and thus the best time to harvest the cells for protein 
purification, is determined from the curves at the time where the TK activity per ml is the 
highest. In order to rule out that the increase in TK activity is due to E. coli TK, the 
protein content in each time sample is determined by the Bradford method, and the 
activity per mg total enzyme is plotted (with the exception of CeTK1-L143A and –M42I 
since the samples were accidentally thrown out before Bradford measurements). 
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Figure 9.3: Thymidine kinase activity curves measured with dThd substrate, showing optimal IPTG-
induction times of all TK1 mutants. C∆57, S182T, S182A, L143A and M42I are mutants of CeTK1, 
and T163S, T163A, L124A, M28I and M28A are mutants of HuTK1-C∆41. 
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Even if the induced poly peptide displays no TK1 activity the induction curve shown as 
u/ml may show increasing activity as a function of induction time since the amount of E. 
coli TK increases as the bacteria proliferate. But since the increase in total protein 
concentration overshadows the increase in E. coli TK due to the induction of inactive TK1 
fusion protein the ratio of E. coli TK to total protein decreases during the induction. 
Hence, the activity shown as u/mg will show a decrease in activity as a function of 
induction time when the induced protein is inactive even though the activity shown as 
u/ml will increase (figure 9.4) [Skovgaard, 2004]. 
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Figure 9.4: Induction of non-functional poly peptide (CeTK1 gene inserted in pGEX-2T out of 
frame). The total TK activity per volume of cell culture increases only due to the increase in E. coli 
TK as the bacteria proliferate. But the TK activity per mg of total protein decreases during the 
induction since the bacterial TK constitutes a smaller and smaller fraction of total protein as the 
induction proceeds [Skovgaard, 2004]. 
 
From figure 9.3 it is evident that only HuTK1-C∆41-T163A is inactive since it is the only 
curve where the TK activity decreases during the induction. However, it is noteworthy 
that not only does the activity per mg total protein decrease, but also the activity per ml 
culture. This indicates that the induced protein is not only inactive in itself, but it also 
seems to suppress the activity of E. coli TK. The bacterial growth, however, is not 
affected by the induction of the non-functional and seemingly TK1 activity suppressing 
enzyme (figure 9.5). 
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Figure 9.5: Bacterial growth during the induction of HuTK1-C∆41-T163A. The curve is similar to 
those of the other inductions. 
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The induction of HuTK1-C∆41-T163A was repeated in order to rule out experimental 
errors, and the presented results were confirmed.  
All the proteins were induced again, and the cells were harvested for lysis and protein 
purification. The harvest times were: 9½, 8, 8, 8, and 16 hours for CeTK1-C∆57, -S182T, 
-S182A, -L143A and –M42I, respectively, and 16, 16, 8 and 8 hours for HuTK1-C∆41-
T163S, -L124A, -M28I and –M28A, respectively. An extra IPTG induction of HuTK1-T163S 
and –L124A was initiated for taking time samples over 21 hours simultaneously with the 
cultures induced for harvesting. But when the time samples for CeTK1-L143A and –M42I 
were accidentally thrown out, so were those of HuTK1-T163S and –L124A from the 21 
hour induction. Therefore, the induction curves for HuTK1-T163S and –L124A presented 
in figure 9.3 only show the induction course until 14 hours even though the main cultures 
were harvested after 16 hours. 
 
Purification of TK1 enzymes 
During the purification procedure several fractions were collected from the column and 
analyzed with regard to total protein content (Bradford), molecular weight distribution of 
proteins (SDS-PAGE) and TK1 activity. The fractions were named with respect to their 
purpose: 
The crude bacterial homogenate (CBH) was loaded onto the column, and the eluate was 
collected (SET) followed by collection of five wash fractions (W1-W5). Prior to thrombin 
cleavage the column was equilibrated, and the eluted equilibration buffer was collected 
(EQ). Subsequently, three cleavage fractions were collected (CL1-CL3), and the bound 
GST was eluted from the column with reduced glutathione (GSH). With CeTK1-C∆57 an 
additional ATP wash fraction (ATP) was collected before the equilibration step. This wash 
step has proven to increase purity when purifying deoxynucleoside kinases of the dNK 
type since the ATP in the buffer helps to release heat shock proteins that can be bound 
to the deoxynucleoside kinase [Munch-Petersen et al., 2000]. The ATP wash is not 
usually applied when purifying TK1-type enzymes and was not applied during the 
purification of the other TK1 proteins in this work.  
 
Protein content and TK1 activity of purification fractions  
The total protein content and the total activity in each fraction were determined, and 
selected fractions are plotted in figure 9.6 and 9.7. It should be noted that the harvested 
culture volumes and the column volumes used for purification vary between some of the 
TK1’s (see details about harvest and fraction volumes in appendix A.XIV. and A.XV).  
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For most of the purified TK1’s the main part of the activity from the crude bacterial 
homogenate is found in the cleavage fractions, but there are exceptions.  
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For CeTK1-C∆57, CeTK1-L143A, CeTK1-S182T and CeTK1-S182 the activity in the SET 
fraction is higher than the combined activity from the cleavage fractions, suggesting that 
a large part of the induced TK1 is not bound to the column. However, the loss of protein 
in the SET fractions is of little importance in the present work as long as the amount of 
recovered TK1 is enough for analytical purposes. The amount of protein in the cleavage 
fractions of all the TK1 purifications is more than sufficient for the purpose of this study. 
Figure 9.6: Protein and activity content 
of selected fractions from protein 
purification of CeTK1 enzymes. The 
activity is measured with 100 µM dThd. 
CBH: Crude homogenate, SET: Flow-
through, W1-2: eluates from wash, 
ATP: eluate from ATP-incubation, EQ: 
eluate from column equilibration, CL1-3: 
eluate from thrombin cleavage, GSH: 
eluate from wash with reduced 
glutathione. All proteins with the 
exception of CeTK1-C∆57 have been 
purified on a 1 ml glutathione sepha-
rose column. The column volume for 
purification of CeTK1-C∆57 was 3 ml. 
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For the other TK1 purifications there is also activity to be found in the SET fractions. 
Some of that activity is likely due to unbound induced TK1 since the binding to the 
column is not likely to be 100 %, but part of the activity is also due to E. coli TK. 
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Figure 9.7: Protein and activity content of selected fractions from protein purification of HUTK1-
C∆41 enzymes. The activity is measured with 100 µM dThd. CBH: Crude homogenate, SET: Flow-
through, W1-2: eluates from wash, ATP: eluate from ATP-incubation, EQ: eluate from column 
equilibration, CL1-3: eluate from thrombin cleavage, GSH: eluate from wash with reduced 
glutathione. All proteins have been purified on a 1 ml glutathione sepharose column. 
 
 
By comparing the protein content in the input (CBH) and SET fractions of HuTK1-C∆41-
M28A and HuTK1-C∆41-M28I it is clear that most of the protein in the crude homogenate 
is eluted in the SET fraction. The activity in the crude homogenate is not eluted in SET, 
though, but in the cleavage fractions as wanted. This suggests that the two TK1’s bind 
well to the column, but they have been poorly induced since they only constitute a small 
fraction of the total protein in the crude homogenate. The induction curves in figure 9.7 
show a very low activity per ml of culture for those TK1’s and thus confirm the poor 
induction. Also, CeTK1-M42I in figure 9.6 indicates low induction, but the low activity per 
ml culture for CeTK1-M42I can also be due to low activity of the induced TK1 and is not 
necessarily due to a low concentration. The latter is difficult to determine from the 
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protein content displayed in figure 9.6 since not all the protein in the input is accounted 
for in the subsequent fractions. The purification results are summarized in table 9.1. 
 
 
 
Purification table 
 
Total 
activity 
(U) 
Total protein 
Bradford 
(mg) 
Specific 
activity 
(U/mg) 
Yield 
(%) 
Purification 
(Fold) 
CeTK1-C∆57  (360)      
    Input 1726 1010 1.7 100 1.0 
    Pooled fractions 175 43.1 4.1 10.2 2.4 
    Peak fraction 91.1 23.8 3.8 5.3 2.2 
CeTK1- S182T  (460)      
    Input 301 202 1.5 100 1.0 
    Pooled fractions 23.0 9.6 2.4 7.6 1.6 
    Peak fraction 19.2 6.5 2.9 6.4 2.0 
CeTK1- S182A  (460)      
    Input 114 226 0.50 100 1.0 
    Pooled fractions 22.0 9.9 2.2 19.3 4.4 
    Peak fraction 15.4 2.1 7.5 13.6 15 
CeTK1- L143A  (270)      
    Input 26.4 106 0.25 100 1.0 
    Pooled fractions 9.5 11.0 0.86 35.9 3.4 
    Peak fraction 8.9 7.8 1.1 33.7 4.6 
CeTK1- M42I  (230)      
    Input 4.4 221 0.02 100 1.0 
    Pooled fractions 3.2 8.18 0.39 73.0 20 
    Peak fraction 2.3 5.8 0.40 53.2 20 
HuTK1-C∆41-T163S (230)    0  
    Input 189 237 0.79 100 1.0 
    Pooled fractions 49.4 16.3 3.0 26.2 3.8 
    Peak fraction 36.4 12.1 3.0 19.3 3.8 
HuTK1-C∆41-L124A  (230)      
    Input 193 142 1.4 100 1.0 
    Pooled fractions 51.2 11.3 4.5 26.5 3.3 
    Peak fraction 36.7 8.1 4.5 19.0 3.3 
HuTK1-C∆41-M28I   (230)      
    Input 6.3 165 0.04 100 1.0 
    Pooled fractions 4.1 5.0 0.83 65.5 22 
    Peak fraction 2.5 3.3 0.76 40.1 20 
HuTK1-C∆41-M28A  (270)      
    Input 15.8 151 0.10 100 1.0 
    Pooled fractions 10.2 6.4 1.6 64.4 15 
    Peak fraction 6.6 4.0 1.7 41.9 16 
Table 9.1: The harvested culture volumes are 1080 ml for CeTK1-C∆57, 460 ml for CeTK1-S182T 
and CeTK1-S182A, 270 ml for CeTK1-L143A and 230 ml for CeTK1-M42I, HuTK1-C∆41-T163S, 
HuTK1-C∆41-L124A and HuTK1-C∆41-M28I. All proteins with the exception of CeTK1-C∆57 have 
been purified on a 1 ml glutathione sepharose column. The column volume for purification of 
CeTK1-C∆57 was 3 ml. The numbers in parentheses indicate the ratio of harvested culture 
volume/column volume. 
 
The yield differs greatly between the different TK1’s, but it is clear that the lowest yield is 
observed for the purifications with the highest ratio of harvested culture volume/column 
volume. The purification fold is rather low for all the TK1’s, but it is clearly higher for the 
poorly expressed TK1’s (HuTK1-C∆41-M28I, HuTK1-C∆41-M28I, and CeTK1-M42I). This 
could mean one of two things. Either the low purification fold for many of the TK1’s is 
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due to contamination of the proteins or the ratio of induced TK1 to other proteins in the 
crude homogenate is very high. The purity of the proteins in the different fractions is 
analyzed by SDS-PAGE. 
  
SDS-PAGE of protein purification 
Selected fractions from each purification were loaded on a SDS-gel along with marker 
proteins (figure 9.8 and 9.9). The proteins expected to be found on the gels are GST with 
a molecular mass of 28 kDa, CeTK1-C∆57 at 23.9 kDa, full length CeTK1 proteins at 30.0 
kDa, and for the HuTK1-C∆41 mutants the expected protein sizes are 21.1 kDa. The GST-
TK1 fusion proteins are only expected to be present in the crude and to some extent 
perhaps also in the SET fractions where the exact sizes of the proteins can be hard to 
determine due to large amounts of E. coli proteins. The expected and experimentally 
determined TK1 protein sizes are summarized in table 9.2 at the end of the next section. 
 
The purity of the protein in the cleavage fractions differs greatly between the different 
TK1’s. For some of the proteins the low purification degree mentioned in the previous 
section (table 9.1) is clearly due to impurities in the cleavage fractions (i.e. CeTK1-
S182T). For others it is more likely caused by a high percentage of induced TK1 in the 
crude homogenate since the purity is high (i.e. HuTK1-C∆41-T163S).  
The ATP wash fraction from the purification of CeTK1-C∆57 shows several bands of 
different molecular mass, but in spite of that the TK1 protein in the cleavage fractions 
does not appear to be pure. Even if the ATP wash seems not to remove all the impurities 
before cleavage it does remove some, and at first glance it would seem to be a 
reasonable extra step to add to the purification procedure of TK1-type enzymes. From 
the graph showing the total activity in the different purification fractions (figure 9.6) it 
appears that some of the eluted protein in the ATP wash fraction is in fact CeTK1-C∆57. 
This is confirmed by the location of one band at approx. 23 kDa in the ATP lane on the 
SDS gel. Hence, the ATP wash removes the high molecular heat shock proteins, but it 
also causes a loss of TK1 protein. Whether the loss of TK1 protein is worth the improved 
purity depends on individual purifications and whether the protein is subjected to 
subsequent purification procedures.  
The cleavage of TK1 protein from the GST tag has been efficient for all purifications. Only 
for HuTK1-C∆41-M28A a very weak band just below 50 kDa above the GST band can be 
observed in the GSH lane. The band is most likely uncleaved GST-HuTK1-C∆41-M28A 
fusion protein. 
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Figure 9.8: SDS-PAGE of purification fractions from CeTK1 mutants. L: Page Ruler Protein Ladder 
molecular weight marker, MW: Protein MW Marker, CBH: Crude homogenate, SET: Flow-through, 
W1-2: eluates from wash, ATP: eluate from ATP-incubation, EQ: eluate from column equilibration, 
CL1-3: eluate from thrombin cleavage, GSH: eluate from wash with reduced glutathione. 
 
Looking closer into the cleavage fractions, several unexpected bands appear. For CeTK1-
C∆57 the expected band in the cleavage fraction should be TK1 protein of 23.9 kDa, but 
instead two bands are observed corresponding to proteins with molecular masses of 
approx. 27 kDa and 20 kDa. The bands are blurry so the exact molecular mass is difficult 
to determine. Blurry bands are often a result of proteolytic breakdown of the protein due 
to contamination with proteases in the sample or gel-solutions. By performing a new 
SDS-PAGE of the CL1 fraction a single band corresponding to a molecular weight of about 
22 kDa appears which is more consistent with the expected subunit size. This suggests 
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that the two blurry bands on the first SDS-gel are caused by proteases in the gel-
solutions.   
Bands of unusual size also appear for CeTK1-S182T and –S182A. Besides from the 
expected band at 30.0 kDa they both display an extra band at approx. 35 kDa in the 
cleavage fractions.  
The gel for CeTK1-L143A shows a weak band corresponding to a molecular mass of 
approx. 35 kDa which is higher than the expected 30.0 kDa. The only CeTK1 purification 
resulting in the expected subunit size in the cleavage fraction is CeTK1-M42I showing a 
band corresponding to a protein of approx. 30 kDa on the gel. There also seems to be a 
very weak band from a contaminant at 35 kDa, but due to blurry bands it is only just 
detectable. 
 
    
 
   
Figure 9.9: SDS-PAGE of purification fractions from HuTK1-C∆41 mutants. L: Page Ruler Protein 
Ladder molecular weight marker, MW: Protein MW Marker, CBH: Crude homogenate, SET: Flow-
through, W1-2: eluates from wash, ATP: eluate from ATP-incubation, EQ: eluate from column 
equilibration, CL1-3: eluate from thrombin cleavage, GSH: eluate from wash with reduced 
glutathione.  
 
The purification of HuTK1-C∆41-T163S and –L124A are successful. Both gels show a 
band corresponding to a protein of approx. 20 kDa in the cleavage fractions and no 
contaminants. The expected subunit size of HuTK1-C∆41 mutants is 21.1 kDa.  
The two final HuTK1-C∆41 mutants –M28I and –M28A also display the expected band of 
21.1 kDa in the cleavage fractions, but a weak band at approx. 70 kDa is also observed 
for HuTK1-C∆41-M28A. The latter is most likely heat shock protein expressed by E. coli 
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as a response to over-expression of TK1 protein, and it could probably be removed by 
incubating the column with ATP prior to cleavage.  
The cleavage fractions were further analyzed by automated electrophoresis. 
 
Analysis of cleavage 1 fractions by automated electrophoresis 
All CL1 fractions were analyzed by Experion automated electrophoresis from Biorad, 
using a chip that detects proteins with molecular masses ranging from approx. 15 to 260 
kDa. Also, CeTK1-WT was analyzed by this method in order to compare subunit sizes.  
The observed data are in some cases inconsistent with those obtained by SDS-PAGE. The 
theoretical and experimentally determined subunit sizes and protein concentrations are 
summarized in table 9.2 at the end of this section. 
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Figure 9.10: Electropherograms of Experion automated electrophoresis on CL1 fractions from 
purification of all CeTK1 proteins, including CeTK1-WT purified prior to this work. Molecular mass in 
kDa is assigned to peaks from proteins that constitute more than 5 % of the total protein content. 
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The electropherograms of CeTK1-S182T and –S182A are strongly inconsistent with the 
results obtained from SDS-PAGE. They both show a main peak at approx. 40 kDa which 
is clearly above the expected subunit size. Protein with this molecular mass was not 
observed on any of the two SDS-gels, but instead both gels show two bands at 30 and 
35 kDa. On the electropherogram of CeTK1-S182A two smaller bands at 26.6 kDa and 
33.3 kDa are observed, but neither corresponds to the theoretical subunit size of 30.0 
kDa. The molecular mass distributions of the peaks shown in all the electropherograms in 
figure 9.10 and 9.11 were confirmed by a single previous run. The protein content 
corresponding to the different peaks was not viable from that run, however, since 
excessive concentrations of detergent in the samples disturbed the measurement of 
protein concentration, but it does not affect peak location. The molecular masses 
determined from SDS-PAGE have also been confirmed by repetition so it is difficult to 
determine which method provides the most reliable results. In order to compare 
subsequent experiments the protein concentrations of CeTK1-S182T and –S182A are 
determined from the peaks in the electropherogram at approx. 41 kDa. 
For CeTK1-L143A the electropherogram shows a peak at 35.1 kDa in combination with 
two smaller peaks at 38.1 and 40.1 kDa. The large peak is consistent with the result from 
the SDS-gel, but the protein from the smaller peaks was not visible on the gel. This is 
likely due to excessive dilution of the sample loaded on the gel. The protein in the main 
peak at 35.1 kDa is assumed to be CeTK1-L143A even though the subunit size is 
expected to be 30.0 kDa. The pattern is similar in the electropherogram of CeTK1-M42I 
which is strongly inconsistent with the results from SDS-PAGE. Two peaks are observed, 
one at 35.5 kDa and another of similar intensity at 40.4 kDa. The molecular mass of the 
protein shown on the SDS-gel of CeTK1-M42I in figure 9.8 is consistent with the 
expected subunit size of 30.0 kDa, but since the position of the peaks in the 
electropherogram has been confirmed twice with high accuracy the peak at 35.5 kDa is 
expected to arise from CeTK1-M42I. It is also noteworthy that bands on the SDS-gel are 
very blurry which suggests proteolytic breakdown due to contamination with proteases. 
 
HuTK1-C∆41-T163S and –L124A both show the expected peaks at approx. 21 kDa, 
confirming the results from SDS-PAGE. Additionally, they each show a very small peak at 
74.9 kDa and 88.0 kDa in the electropherograms of HuTK1-C∆41-T163S and –L124A, 
respectively, which most likely originate from small amounts of E. coli heat shock protein 
that has been bound to the TK1’s on the column. 
 
 83
13
.71
20
.78
67
.75
74
.85
87
.31
15
6.5
1
17
1.9
3
0
20
40
60
80
100
120
140
160
180
200
25 30 35 40
Sample 7
Flu
or
es
ce
nc
e
Time (seconds)       
13
.91
15
.19
16
.48
21
.66
26
.22
68
.26
75
.49
83
.10
88
.01
21
4.3
0
0
50
100
150
200
250
300
25 30 35 40 45
Sample 8
Flu
or
es
ce
nc
e
Time (seconds)  
 
20
.69
85
.59
-6
-4
-2
0
2
4
6
8
26 28 30 32 34 36
Sample 4
Flu
or
es
ce
nc
e
Time (seconds)       
20
.96
66
.76
86
.43
-10
0
10
20
30
40
50
26 28 30 32 34 36
Sample 3
Flu
or
es
ce
nc
e
Time (seconds)  
Figure 9.11: Electropherograms of Experion automated electrophoresis on CL1 fractions from 
purification of all HuTK1-C∆41 proteins. Molecular mass in kDa is assigned to peaks from proteins 
that constitute more than 5 % of the total protein content. 
 
HuTK1-C∆41-M28I and –M28A show nearly the same results as the SDS-gels of the same 
fractions. Both show a peak at approx. 21 kDa and a smaller one at approx. 86 kDa. This 
is consistent with the expected subunit size of 21.1 kDa. The protein with the high 
molecular mass was not visible on the SDS-gel of HuTK1-C∆41-M28I and is only just 
visible on the electropherogram. Due to excessive protein dilution the electropherogram 
of HuTK1-C∆41-M28I shows a lot of “noise”. 
 
The results from automated gel electrophoresis on the CL1 fractions are summarized in 
table 9.2, and the concentration of total protein is compared with those determined by 
the Bradford method. Also, the concentrations of TK1 protein in the CL1 fractions are 
listed. 
 
With a few exceptions the protein concentrations measured by Experion analysis are 
slightly lower than the concentrations measured by the Bradford method. The difference 
is not unexpected since the two methods rely on different molecular mechanisms. In the 
automated gel electrophoresis the protein concentration is determined from fluorescent 
molecules bound to SDS-molecules which are bound to the protein in the ratio of one 
SDS-molecule per two amino acids. In the Bradford method the protein concentration is 
determined from the coloured complex of protein and Coomassie Brilliant Blue G250, a 
HuTK1-C∆41-T163S20.8 
74.9 
21.7
88.0 
HuTK1-C∆41-L124A
HuTK1-C∆41-M28A 21.0
86.420.7 
85.6
HuTK1-C∆41-M28I 
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dye that only binds to the positively charged residues arginine and lysine. The latter 
method is therefore dependent on the amino acid composition of the protein whereas the 
Experion analysis is independent of individual residues. Another advantage of 
determining protein concentration by automated gel electrophoresis is that the 
concentration can be determined for proteins corresponding to single peaks, and thus the 
concentration of impurities can be subtracted. Hence, the protein concentrations applied 
for further analysis of the TK1’s are the ones determined by Experion analysis.  
 
 
 
Subunit size, protein concentration, and purity of TK1’s 
 
 
 
Expected 
MW 
(kDa) 
Experion 
MW 
(kDa) 
Experion 
Total protein 
(mg/ml) 
Experion 
TK1 % of 
total protein 
Experion 
TK1 
 (mg/ml)  
Bradford 
Total protein 
(mg/ml) 
 
 
CeTK1        
    WT  30.0 31.3 1.95 87.4 1.71 2.19 
    C∆57  23.9 24.1 3.52 88.3 3.11 5.28 
    S182T  30.0 40.5 2.34 91.2 2.13 1.45 
    S182A  30.0 40.8 2.64 60.6 1.60 1.66 
    L143A  30.0 35.1 0.85 64.3 0.55 1.86 
    M42I  30.0 35.5 1.31 49.4 0.65 1.49 
 
 
HuTK1-C∆41       
    T163S  21.1 20.8 2.21 84.9 1.88 3.11 
    L124A  21.1 21.7 2.88 86.9 2.50 1.86 
    M28I  21.1 20.7 0.05* 78.8 0.04* 0.74 
    M28A  21.1 21.0  0.69 65.2  0.45 0.88 
Table 9.2: Summary of results obtained for CL1 fractions of all TK1’s by automated gel 
electrophoresis and Bradford protein determination. *Due to experimental error the concentration 
of HuTK1-C∆41-M28I determined with Experion is not reliable, but the fraction of HuTK1-C∆41-
M28I in percentage of total protein is.  
 
The high noise to peak ratio on the electropherogram of HuTK1-C∆41-M28I (figure 9.11) 
indicates that either the protein has been excessively diluted by mistake or an air bubble 
was present in the chip-well. Thus the total protein concentration determined from this 
electropherogram is invalid. The percentage distribution of different proteins in the 
sample is not affected by the dilution error, however, and the concentration used for 
further analysis of the protein is determined by the percentage of HuTK1-C∆41-M28I 
determined from the Experion electropherogram compared to the total protein 
concentration measured by the Bradford method. According to the table 78.8 % of the 
protein in CL1 is HuTK1-C∆41-M28I, and the total concentration is measured by the 
Bradford method to be 0.74 mg/ml, hence the expected concentration of HuTK1-C∆41-
M28I is 0.58 mg/ml (78.8 % of 0.74 mg/ml). 
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Characterization of CeTK1-WT and CeTK1-C∆57 
In order to deduce whether CeTK1-WT and –C∆57 displays the same ATP dependent 
transition between a tetrameric high affinity form and a dimeric low affinity form as has 
been observed for both HuTK1-WT and HuTK1-C∆41 [Munch-Petersen et al., 1993; 
Berenstein et al., 2000; Zhu et al., in press], both enzymes are incubated with and 
without ATP. They are analyzed with respect to kinetic parameters with the substrate 
dThd, and CeTK1-WT is also analyzed with respect to native molecular mass. In order to 
see if the C-terminal truncation increases the stability and activity, like it has been 
observed for HuTK1-C∆41 [Zhu et al., in press], the stability of both CeTK1-WT and –
C∆57 with and without ATP-incubation is also examined. 
 
ATP dependence of CeTK1-WT  
When HuTK1 has been incubated with ATP it shifts from a dimer conformation with a 
native molecular mass of approx. 50 kDa to a tetramer conformation with a mass of 
approx. 100 kDa. The two forms of the enzyme display the same maximal velocity, but 
the dimer has a lower overall activity than the tetramer as expressed by a higher Km.  
[Munch-Petersen et al., 1993]. 
The pre-incubated CeTK1-WT was analyzed by gel filtration, and the protein eluted as a 
dimer with a molecular mass of ~66 kDa regardless of ATP-incubation. 
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Figure 9.12: CeTK1-WT pre-incubated with and without ATP subjected to gel-filtration 
chromatography on Superdex 200. ve/v0 for the marker proteins, β-Amylase (200 kDa), Bovine 
Serum Albumin (66 kDa), Ovalbumin (45 kDa) and Carbonic anhydrase (29 kDa) are shown above 
the plot. 
 
The results in figure 9.12 suggest that the native size of CeTK1-WT, in contrast to 
HuTK1, is not changed by the presence of ATP. The pre-incubated enzyme was 
subsequently assayed with varying concentrations of dThd (figure 9.13).  
200 kDa            66 kDa     45 kDa      29 kDa    
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Figure 9.13: Kinetic properties of CeTK1-WT pre-incubated with and without 2.5 mM ATP. Initial 
velocities are plotted against varying concentrations of dThd. The curves represent a fit of the data 
points to the Michaelis-Menten equation. 
 
In spite of the fact that ATP does not change the native molecular mass of CeTK1-WT it 
is evident from figure 9.13 that it affects the enzyme activity. The Vmax of the enzyme is 
nearly twice as high when the enzyme has been pre-incubated with ATP compared to 
when it is incubated without ATP. The Km remains unchanged, however. Hence, ATP 
activates both HuTK1 and CeTK1, but whereas the increase in activity for the human 
enzyme is expressed as a lower Km the increase in activity of CeTK1 is expressed as an 
increase in Vmax. Kinetic parameters for CeTK1-WT and –C∆57 are summarized along with 
the values of HuTK1-WT and -C∆41 in table 9.3 in the next section. 
 
The ATP-effect on HuTK1 depends on enzyme concentration and incubation time. At 
concentrations below 10 ng/ml the HuTK1-WT is a permanent low activity dimer, and the 
ATP-effect at higher enzyme concentrations takes approx. 1-2 hours when incubated at 4 
°C [Munch-Petersen et al., 1993]. The ATP-transition for CeTK1-WT is displayed in figure 
9.14 with regard to both enzyme concentration and incubation time. 
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Figure 9.14: ATP-transition of CeTK1-WT. The activities are measured with 50 µM dThd as 
substrate and 3.42 ng/ml (0.058 nM) CeTK1-WT. The open circles represent enzyme that has been 
pre-incubated with 2.5 mM ATP. 
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At enzyme concentrations below 0.078 µg/ml (1.3 nM) there is no ATP-induced transition 
from the low activity to the high activity form of CeTK1-WT, but at concentrations above 
0.39 µg/ml (6.6 nM) the transition takes place (figure 9.14.A). Unlike the ATP-transition 
for HuTK1-WT the transition for CeTK1-WT occurs instantly (figure 9.14.B). The low 
concentration of CeTK1-WT at assay conditions (3.42 ng/µl = 0.058 nM) explains the 
linear progression curves and absence of transition to the higher activity form during the 
kinase assay although there is 2.5 mM ATP in the standard assay mixture. 
The concentration of ATP in the assay mixture does of course affect the enzyme activity 
to some extent, even at low enzyme concentrations since it is also a substrate for the 
enzyme. However, this is only significant at very low ATP concentrations. When the 
enzyme is saturated with ATP, which it is at concentration above approx. 10 µM ATP 
(figure 9.15), the reaction velocity is constant. 
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Figure 9.15: Kinetic properties of CeTK1-WT (-ATP) with the substrate ATP. Initial velocities are 
plotted against varying concentrations of ATP. dThd is at a saturating concentration of 100 µM. The 
curve represents a fit of the data points to the Michaelis-Menten equation. 
 
The data points in figure 9.15 have been fitted to the Michaelis-Menten and the Hill 
equations, and CeTK1-WT displays classical Michaelis-Menten kinetics with ATP with a Km 
value of 1.41 ± 0.46 µM and a Vmax of 11900 ± 1000 nmol min-1 mg-1 (kcat: 5.88 ± 0.50 s-
1. Kinetic parameters are presented with the fitting standard error). By comparing the 
Michaelis-Menten curve at saturating concentrations of dThd and varying concentrations 
of ATP (figure 9.15) with the one made with saturating concentrations of ATP and 
varying concentrations of dThd (figure 9.13), it is clear that if the enzyme has not been 
pre-incubated with ATP the two curves approach the same maximal velocity. This is 
expected since the enzyme is saturated with both substrates at Vmax. 
 
Effect of C-terminal truncation on activity and stability 
The removal of 41 amino acids from the C-terminal of HuTK1 has shown to increase the 
overall activity of the enzyme by increasing kcat and lowering Km compared to the WT 
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enzyme (table 9.3) [Zhu et al., in press]. Enzyme activity for CeTK1-C∆57 at varying 
concentrations of the substrate dThd has been determined and is plotted in figure 9.16. 
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Figure 9.16: Kinetic properties of CeTK1-C∆57 pre-incubated with and without ATP. Initial velocities 
are plotted against varying concentrations of dThd. The curves represent a fit of the data points to 
the Michaelis-Menten equation. 
 
CeTK1-C∆57 displays the same ATP dependent transition to a high-activity form of the 
enzyme as observed for the WT enzyme. The +ATP and –ATP versions of CeTK1-C∆57 
display similar Km values, but they differ markedly with regard to Vmax. The kinetic 
parameters for the WT and truncated enzyme are determined by non-linear regression 
and shown in table 9.3. 
 
 
 
Activity parameters with substrate dThd 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
 
 
CeTK1-WT -ATP (n=2) 2.29 ± 0.24 12700 ± 256 6.30 ± 0.13 2.75×106 
CeTK1-WT +ATP (n=3) 2.45 ± 0.23 22600 ± 472 11.2 ± 0.23 4.56×106 
CeTK1-C∆57 -ATP (n=2) 7.41 ± 0.80 4580 ± 166 1.80 ± 0.07 2.43×105 
CeTK1-C∆57 +ATP (n=2) 6.17 ± 0.84 15800 ± 698 6.21 ± 0.27 1.00×106 
HuTK1-WT -ATP * 16 ± 3.4  6.3 ± 0.9 0.4×106 
HuTK1-WT +ATP * 0.7 ± 0.2  6.9 ± 0.2 9.9×106 
HuTK1-C∆41 -ATP * 1.4 ± 0.6  9.5 ± 1.1 6.8×106 
HuTK1-C∆41 +ATP * 0.6 ± 0.1  9.7 ± 0.2 1.6×10 7 
Table 9.3: Kinetic parameters for CeTK1 enzymes determined by non-linear regression to the 
Michaelis-Menten or Hill equation. The molecular masses applied to calculate kcat for the two 
enzymes are 30.0 kDa and 23.9 kDa for CeTK1-WT and –C∆57, respectively. All parameters are 
presented with standard error on the curve fitting, and n denotes the number of separate 
experiments from which the data are determined. * From Zhu et  al., in press. 
 
From the kinetic parameters the ATP-effect on the maximum velocity is very clear. For 
CeTK1-WT the ATP incubated enzyme has a 1.8 times higher kcat than the enzyme 
incubated without ATP, and for CeTK1-C∆57 the difference is even greater. kcat for 
CeTK1-C∆57 incubated with ATP is 3.5 times higher than the enzyme incubated without 
ATP. For both WT and the truncated enzyme the ATP-effect on Km is negligible.  
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The C-terminal truncation, however, does not seem to improve enzyme activity like it 
does for HuTK1. On the contrary the kcat/Km is several times higher for the WT enzyme 
that for the truncated enzyme, regardless of whether the enzymes have been pre-
incubated with or without ATP. The reduced activity is expressed by both a decreased 
Vmax and an increased Km. 
 
The stability of the two enzymes has been tested at 4 °C and at room temperature, and 
the relative activity as a function of incubation time is plotted in figure 9.17. 
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Figure 9.17: Relative activity of CeTK1-WT and -C∆57 pre-incubated with and without ATP plotted 
as a function of incubation time. A: Incubation at 4 °C and B: incubation at room temperature. The 
activity is measured as initial velocities at 100 µM concentrations of dThd. 
 
After 200 hours (approx. 8 days) incubation at 4 °C there is no visible change in activity 
for any of the two enzymes, and addition of ATP to the incubation buffer does not seem 
to have any effect on stability. By monitoring the stability at room temperature (approx. 
22 °C) for 330 hours (approx. 2 weeks) a visible decrease in activity is observed. At the 
end of the experiment the WT enzyme has a higher activity than the truncated enzyme, 
but ATP does not seem to affect the enzyme stability for either one. The time at which 
the enzymes have reached half their initial activities has been determined by fitting the 
data points to a curve of exponential decay. The half times are 201 and 222 hours for 
CeTK1-WT incubated with and without ATP respectively and 123 and 126 hours for 
CeTK1-C∆57 incubated with and without ATP, respectively. It is therefore clear that 
removal of the C-terminal of CeTK1 lowers the stability of the enzyme. Again, this is in 
contrast to the findings for HuTK1 where the stability increases upon removal of the 
corresponding C-terminal amino acids [Zhu et al., in press]. 
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Enzyme kinetics with active site mutants  
All the mutants of CeTK1 and HuTK1-C∆41 and CeTK1-WT are examined with regard to 
their affinity for different substrates, and kinetic parameters are determined for the 
substrates showing activity with the enzymes. 
 
Substrate specificity for all TK1 enzymes  
The activity with the four natural deoxynucleosides dThd, dAdo, dCyd and dGuo, and the 
nucleoside analogs AZT and AraC were measured as initial velocities at 100 µM substrate 
for all TK1 enzymes. The activities for the different substrates relative to the activity with 
dThd are given in table 9.4. 
 
 
 
Relative substrate specificity for all TK1 enzymes 
 dThd dAdo dCyd 
 
 
dGuo AZT AraC 
 
 
CeTK1-WT -ATP 1000 (1000) 
 
 
0.001 0.002 2.50 900 n.d. 
CeTK1-C∆57 -ATP 1000 (360) 0.02 0.02 0.27 741 0.01 
CeTK1-S182T 1000 (200) 0.06 0.20 21.6 919 0.01 
CeTK1-S182A 1000 (70) n.d. 0.09 1.00 264 n.d. 
CeTK1-L143A 1000 (190) 0.04 0.71 0.08 47.1 0.05 
CeTK1-M42I 1000 (76) 0.21 0.38 0.47 63.5 0.08 
 
 
HuTK1-C∆41* (1000) 
 
    
HuTK1-C∆41-T163S 1000 (180) 
 
 
0.02 0.16 0.19 433 0.003 
HuTK1-C∆41-L124A 1000 (140) n.d. 0.02 0.03 920 0.01 
HuTK1-C∆41-M28I 1000 (38) n.d. 0.07 0.04 32.5 0.03 
HuTK1-C∆41-M28A 1000 (94) 0.01 0.03 0.06 250 0.10 
Table 9.4: Substrate specificity in the table is denoted as initial velocity with 100 µM substrate 
relative to the initial velocity with 100 µM dThd. Estimation of kinetic parameters has been 
attempted for the enzyme/substrate combinations marked with bold. n.d. = not detectable. In the 
column depicting dThd specificity the relative activity of the mutated enzymes compared to CeTK1-
WT and HuTK1-C∆41 is noted in parentheses. * The activity of HuTK1-C∆41 with 100 µM dThd is 
estimated to be approx. 27000 nmol min-1 mg-1. from the kcat value presented by Zhu et al. (in 
press). It is assumed that the enzyme has obtained maximal velocity at 100 µM dT since it has a 
low Km.  
 
It is clear that dThd is the preferred substrate for all the TK1 enzymes, but several 
enzymes also show a high affinity for the analog AZT. The other analog AraC is a very 
poor substrate for all TK1’s, as is the natural deoxynucleoside dAdo. Some of the TK1’s 
appear to have a weak affinity for dGuo and some also for dCyd. None of the mutated 
enzymes appear to have improved activity with dThd compared to the enzyme on which 
the mutations have been made. Estimation of kinetic parameters has been attempted for 
the TK1/substrate combinations marked with bold in table 9.4. It is noticeable that the 
activity of CeTK1-WT with AZT is almost the same as with dThd, and that CeTK1-S182T 
has a considerable dGuo activity compared to the other enzymes.  
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Kinetic parameters with the substrate dThd 
Kinetic parameters with dThd have been estimated for all TK1’s. The initial velocities as a 
function of dThd concentrations are plotted in figure 9.18 and fitted to the Michaelis-
Menten equation and the Hill equation. The curve with the best fit is shown on the figure. 
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Figure 9.18: Kinetic properties of CeTK1 and HuTK1-C∆41 mutants. Initial velocities are plotted 
against varying concentrations of dThd. 
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The kinetic parameters and standard deviations deduced from the plots are listed in table 
9.5.  
 
 
 
Activity parameters with substrate dThd 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
 
 
CeTK1-WT (n=2) 2.29 ± 0.24 12700 ± 256 6.30 ± 0.13 2.75×106 
    S182T (n=2) 1.04 ± 0.19 2080 ± 63.5 1.03 ± 0.03 9.90×105 
    S182A (n=2) 73.7 ± 12.6 1470 ± 111 0.73 ± 0.05 9.87×103 
    L143A (n=1) 252 ± 63 13200 ± 1260 6.53 ± 0.62 2.59×104 
    M42I (n=2) 565 ± 94 5590 ± 410 2.77 ± 0.20 4.90×103 
 
 
HuTK1-WT * 16 ± 3.4  6.3 ± 0.9 3.9×105 
 
 
HuTK1-C∆41 * 1.4 ± 0.6  9.5 ± 1.1 6.8×106 
    C∆41-T163S (n=2) 58.6 ± 13.4 7690 ± 653 2.70 ± 0.23 4.61×104 
    C∆41-L124A (n=2) 36.2 ± 3.6 5210 ± 175 1.83 ± 0.06 5.06×104 
    C∆41-M28I (n=3) 349 ± 29 4180 ± 155 1.47 ± 0.05 4.21×103 
    C∆41-M28A (n=2) 354 ± 25 12100 ± 337 4.26 ± 0.12 1.20×104 
Table 9.5: Kinetic parameters for CeTK1 (above) and HuTK1 (below) enzymes determined by non-
linear regression to the Michaelis-Menten or Hill equation. The molecular masses applied to 
calculate kcat are 30.0 kDa for CeTK1 enzymes and 21.1 kDa for HuTK1-C∆41 enzymes. The 
parameters are presented with standard error on the curve fitting, and n denotes the number of 
separate experiments from which the data are determined.  * Values from Zhu et al., in press. 
 
Mutation of Ser182 to Thr in CeTK1 appears to lower the Km, but the maximum velocity is 
also decreased resulting in a lower specificity compared to CeTK1-WT. By mutating the 
same amino acid to Ala there is a similar decrease in kcat, but this time Km increases. The 
mutation of Leu143 to Ala seems to slightly increase kcat compared to kcat for CeTK1-WT, 
but Km is also increased so the specificity constant is lower than that of the WT enzyme. 
Mutation of Met42 to Ile in CeTK1 has a negative effect on the dThd activity with respect 
to both kcat and Km. Overall, the CeTK1-WT has a greater specificity constant for dThd 
than any of the mutated enzymes. 
All of the mutations performed on HuTK1-C∆41 have resulted in decreased kcat values 
compared to the non-mutated HuTK1-C∆41 and to the WT enzyme, and all have 
increased Km values. Even though the Km for both Met28 mutants are strongly increased 
the kcat for HuTK1-C∆41-M28A is only reduced slightly compared to the WT. The mutation 
of Met28 to Ile seems to be more damaging than mutation of the same amino acid to 
Ala.  
 
Kinetic parameters with the analog AZT 
All the TK1 enzymes displayed activity with the substrate AZT although it was with 
different specificity. The initial velocities for the different TK1’s are plotted as a function 
of varying AZT concentrations, and the points are fitted to the Michaelis-Menten and the 
Hill equation (figure 9.19). For CeTK1-WT the experiment was performed with enzyme 
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that had been pre-incubated both with and without ATP in order to see if the ATP-
activating effect was also occurring for other substrates than dThd. 
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Figure 9.19 (also see previous page): Kinetic properties of CeTK1 and HuTK1-C∆41 mutants. Initial 
velocities are plotted against varying concentrations of AZT. 
 
It is evident from the figure that the ATP-activating effect on CeTK1-WT is also prevalent 
with regard to AZT activity although the effect seems to be far less pronounced than with 
dThd as the substrate. From the curve displaying the results from CeTK1-L143A it is 
evident that this mutant has a very poor activity with AZT. The kinetic parameters 
obtained by non-linear regression to the Michaelis-Menten and Hill equations are 
displayed for all enzymes along with the parameters for HuTK1-WT in table 9.6. 
 
 
 
Activity parameters with substrate AZT 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
 
 
Hill kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
 
 
CeTK1-WT -ATP (n=1) 15.5 ± 1.6 13100 ± 407 - 6.48 ± 0.20 4.18×105 
CeTK1-WT +ATP (n=1) 12.7 ± 1.2 15100 ± 558 - 7.47 ± 0.28 5.89×105 
    C∆57 (n=2) 71.5 ± 7.8 5520 ± 202 - 2.17 ± 0.08 3.03×104 
    S182T (n=1) 29.1 ± 3.9 2830 ± 117 - 1.40 ± 0.06 4.81×104 
    S182A (n=1) 406 ± 51 1160 ± 49 - 0.57 ± 0.02 1.41×103 
    L143A (n=2) 4760 ± 1200 4830 ± 884 - 2.39 ± 0.44 5.02×102 
    M42I (n=3) 984 ± 220 1010 ± 135 - 0.50 ± 0.07 5.08×102 
 
 
HuTK1-WT * 1.7  ~4000 - ~1.7 ~1×106 
    C∆41-T163S (n=2) 0.58 ± 0.05 5140 ± 214 1.26±0.10 1.81 ± 0.04 3.12×106 
    C∆41-L124A (n=1) 48.6 ± 5.5 4960 ± 208 - 1.74 ± 0.07 3.59×104 
    C∆41-M28I (n=2) 449 ± 35 179 ± 5 - 0.063 ± 0.00 1.40×102 
    C∆41-M28A (n=2) 444 ± 36 3380 ± 97 - 1.19 ± 0.03 2.68×103 
Table 9.6: Kinetic parameters for CeTK1 and HuTK1-C∆41 enzymes determined by non-linear 
regression to the Michaelis-Menten or Hill equation. The molecular masses applied to calculate kcat 
are 30.0 kDa for CeTK1 enzymes (with the exception of CeTK1-C∆57 for which it is 23.9 kDa) and 
21.1 kDa for HuTK1-C∆41 enzymes. Numbers written in italics are rough estimates. The 
parameters are presented with standard error on the curve fitting, and n denotes the number of 
separate experiments from which the data are determined. * Values from Munch-Petersen et al., 
1995b. 
 
CeTK1-WT incubated without ATP has nearly the same kcat with AZT as with dThd (dThd 
= 6.30 ± 0.13 s-1), but the Km is increased by a factor 7 resulting in a lowered specificity 
constant with AZT compared to dThd. When the enzyme has been incubated with ATP it 
becomes slightly more active compared to the non-ATP incubated CeTK1-WT. The 
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difference is expressed as a small increase in kcat, but also a slight decrease of Km is 
observed. If the ATP-activating effect is compared to the activating effect with the 
substrate dThd it is less with AZT. The ratio of the specificity constants for CeTK1-WT 
with dThd shows 1.7 fold activation by ATP (table 9.3: 4.56×106/2.75×106) whereas for 
the same enzyme with AZT the ATP-activation is only 1.4 fold (table 9.6: 
5.89×105/4.18×105). 
 
All the mutations performed on CeTK1, including the C-terminal truncation, have resulted 
in a decreased activity with AZT compared to the WT enzyme. For all the mutants the 
activity decrease is expressed by a decrease in kcat combined with an increase in Km. For 
the mutant CeTK1-L143A the decrease is so pronounced that it has been difficult to 
obtain reliable kinetic parameters. The parameters presented in table 9.6 are therefore 
rough estimates based on data points showing maximal obtainable velocities far from 
Vmax. Also, by comparing the specificity constants in table 9.3, 9.5 and 9.6 it is evident 
that all the mutants of CeTK1 show lower specificity constants for AZT than they do for 
dThd. 
One of the more interesting mutations has turned out to be the change of amino acid 
Thr163 to Ser in HuTK1-C∆41. It is evident from table 9.6 that this mutant has an 
increased specificity constant with AZT compared to the WT enzyme. Since no kinetic 
parameters have yet been reported for HuTK1-C∆41 with the substrate AZT it is unknown 
whether the increased specificity for AZT is due to the C-terminal truncation or to the 
mutation of Thr163 to Ser. In contrast to all the other enzymes HuTK1-C∆41-T163S 
appears to display positive cooperativity with AZT. Like HuTK1-C∆41-T163S the other 
HuTK1-C∆41 mutant, L124A, also displays a high kcat, but the Km is approx. 100 times 
higher than the one for T163S so the specificity is strongly reduced. The two mutants 
HuTK1-C∆41-M28I and -M28A both display lower kcat and higher Km with AZT than the 
WT enzyme, and –M28I represents the lowest specificity constant of the four HuTK1-
C∆41 mutants. 
  
Kinetic parameters with the substrates dCyd and dGuo 
Two of the mutated enzymes were examined with regard to dCyd activity. From the plots 
in figure 9.20 it is evident that they both displayed surprisingly low Km values with this, 
for TK1 enzymes, untraditional substrate. 
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Figure 9.20: Kinetic properties of CeTK1-L143A and CeTK1-M42I. Initial velocities are plotted 
against varying concentrations of dCyd. 
 
The kinetic parameters for CeTK1-L143A and –M42I are determined by non-linear 
regression to the Michaelis-Menten and Hill equations and shown in table 9.7. 
 
 
 
Activity parameters with substrate dCyd 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
CeTK1-L143A (n=1) 5.41 ± 0.59 1.06 ± 0.04 5.23×10-4 ± 2.0×10-5 97 
CeTK1-M42I (n=2) 3.57 ± 0.78 0.34 ± 0.02 1.70×10-4 ± 8.2×10-6 48 
Table 9.7: Kinetic parameters for two CeTK1 mutants determined by non-linear regression to the 
Michaelis-Menten or Hill equation. The molecular mass applied to calculate kcat is 30.0 kDa. The 
parameters are presented with standard error on the curve fitting, and n denotes the number of 
separate experiments from which the data are determined. 
 
The observed Km values are in the same range as Km for the WT enzyme with the natural 
substrate dThd, but the kcat values are many times lower and hence, the specificity 
constants are also very low. Activity of TK1-type enzymes with the substrate dCyd has 
not been previously reported in the literature, however.  
 
The determination of kinetic parameters for four of the TK1 enzymes with the substrate 
dGuo has also been attempted, but as shown in figure 9.21 all the enzymes display very 
high Km values for this substrate. Due to the limited solubility of dGuo the velocities in the 
vicinity of Vmax are not obtained for any of the TK1’s. 
 
CeTK1-WT was again tested for the ATP-activating effect, and the effect was also 
observed with the substrate dGuo. The curve for the ATP incubated enzyme is clearly 
displaying a higher activity with dGuo than the enzyme incubated without ATP. The best 
dGuo-phosphorylating enzyme appears to be CeTK1-S182T with a reaction velocity of 
approx. 1500 nmol min-1 mg-1 at 3000 µM substrate. 
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Figure 9.21: Kinetic properties of CeTK1 enzymes. Initial velocities are plotted against varying 
concentrations of dGuo. 
 
In order to determine the kinetic parameters with dGuo a different kinetic approach has 
been attempted. Instead of measuring initial velocities at different substrate 
concentrations the progress curve of the reaction is analyzed with the integrated 
Michaelis-Menten equation. 
 
Analysis of progress curves  
A few attempts have been made to obtain progress curves with the traditional radio 
assay. In order to compare the obtained kinetic parameters with the ones previously 
obtained the method was first tested with the substrate dThd in combination with CeTK1-
WT. An example is shown in figure 9.22.  
 
By fitting the linear part of the curve in figure 9.22.B to the equation 
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Vmax can be determined from the reciprocal value of the ordinate intersection, and Km can 
be determined from the slope and Vmax. The values obtained from the plot in figure 
9.22.B are; Vmax = 18500 ± 296 nmol min-1 mg-1 and Km = 24.59 ± 18.46 µM. 
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Figure 9.22: A: Progress curve for CeTK1-WT showing dTMP production as a function of time. The 
results are obtained by radio assay. B: Attempt to convert the data from the progress curve in A to 
a linear form that correlates to the integrated Michaelis-Menten equation. By removing the six 
highest values of t/P, corresponding to the last six points in the progress curve where the dTMP 
concentration is no longer increasing, the remaining points forms a linear curve. 
 
In the presented experiment the dThd concentration was 150 µM so in order to proceed 
to reaction completion within a reasonable time span the enzyme concentration in this 
assay is far higher (~0.5 µg/ml) than in the assays mentioned previously where steady-
state conditions were essential. Hence, the ATP present in the assay solution most likely 
converts the enzyme to the high activity +ATP form. The obtained Vmax is not far from 
the one obtained for the +ATP form of CeTK1-WT by the steady-state assay (22600 nmol 
min-1 mg-1). The Km obtained by the present assay is 10 times higher than the one 
obtained previously (2.45 µM), however, and it has been determined with a high 
standard deviation. 
 
From a theoretical point of view the starting substrate concentration with which the assay 
is performed is important for reliable determination of Km and Vmax. If the substrate 
concentration is too high the enzyme will be saturated, and the progress curve will 
approximate a straight line dominated by Vmax. If the substrate concentration is to low, 
however, the progress curve will approximate an exponential first-order curve with a 
shape reflecting only Vmax/Km, but the curve would not contain much information from 
which to determine either value separately. In between those extremes the curve will 
represent a combination of linear and exponential elements which is optimal for accurate 
determination of both Vmax and Km. The best results should be obtained at initial 
substrate concentrations of approx. two to three times the value of Km [Duggleby & 
A B
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Clarke, 1991; Duggleby, 2001]. This explains the overestimation of Km by the progress 
curve from the radio assay. 
 
The radio assay involves a lot of waiting time in order to obtain results so due to time 
limitations a faster spectrophotometric assay was applied in an attempt to fine-tune the 
method.  
Eight experiments have been performed with the spectrophotometric method at varying 
concentrations of dThd, and the results are highly inconsistent. 
 
 
 
 
 
µM dT 3 5 5 10 10 15 50 50 
 
 
 
Vmax    (nmol min-1 mg-1) 4600 1400 5800 1100 2000 2400 800 4700 
Km      (µM) 2.9 1.2 4.3 1.8 3.0 5.6 27 74 
Table 9.8: Kinetic parameters for CeTK1-WT estimated by progress curves obtained by 
spectrophotometric assay and analyzed with the integrated Michaelis-Menten equation. 
 
All assays are performed at enzyme concentrations that are above the ATP-activation 
limit, and thus the kinetic parameters are to be compared to those previously determined 
for CeTK1-WT +ATP. It is clear that lower dThd concentrations result in the Km 
estimations that are closest to the values observed with the steady-state radio assay, but 
the estimations of Vmax are lower for all dThd concentrations (CeTK1-WT +ATP: Km = 
2.45 ± 0.23 µM and Vmax = 22600 ± 472 nmol min-1 mg-1). Analysis of data from 
progress curves by the integrated Michaelis-Menten equation is a method that is highly 
sensitive regarding smaller deviations, and removal of single data points can occasionally 
affect the determination of the kinetic parameters greatly. A typical progression curve is 
presented in figure 9.23 along with the corresponding linearized plot before and after 
removal of “flying” data points. 
 
It is clear that some data points are inconsistent with the supposedly straight line in 
figure 9.23.B. The “flying” points are those corresponding to the beginning and the end 
of the progress curve, and they have been removed previous to the determination of the 
kinetic parameters (figure 9.23.C). From the progression curve (figure 9.23.A) it is 
evident that those points only present very minor “bumps” on the curve. Nonetheless, 
those minor “bumps” are enough to cause major deviations from the straight line in the 
linearized plot. 
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The deviation in the kinetic parameters estimated with the spectrophotometric assay and 
the integrated Michaelis-Menten equation is not only due to the high inaccuracy in 
determining the parameters from the linearized plot, but also due to the assay method 
based on a coupled enzyme system. By calculating the initial velocity from the linear part 
of the progress curves the results are also deviating. They are mainly deviating from the 
velocities determined by the radio assay, but also velocities determined at the same dThd 
concentrations can vary several fold.* 
 
Native molecular mass of HuTK1-C∆41-M28I  and -M28A  
Unlike non-ATP incubated HuTK1-WT and HuTK1-C∆41 all HuTK1-C∆41 mutants are 
displaying classical hyperbolic Michaelis-Menten kinetics with dThd. The same was 
observed for an early clone of HuTK1, which appeared to have a Met as amino acid 106 
                                                 
* The idea of changing to the faster spectrophotometric assay simultaneously with changing from 
analyzing initial velocities to progress curves has appeared to be a bad call. A few more attempts to 
obtain good progress curves at lower substrate concentrations by the radio assay would most likely 
have lead to better estimation of the kinetic parameters, but due to time limitations this cannot be 
proven. Either way, the estimation of kinetic parameters with the substrate dGuo would most likely 
have proven difficult since the best estimations are based on experiments performed at substrate 
concentrations two to three times the value of Km. From the initial velocity curves in figure 9.21 it is 
evident that Km is very high with dGuo, and thus the limited solubility of the substrate will also 
cause problems with respect to creating good progress curve. 
A 
B C
Figure 9.23: A: Progress curve for CeTK1-WT 
showing dTMP production as a function of time. 
The results are obtained by spectrophotometric 
assay. B: Attempt to convert the data from the 
progress curve in A to a linear form that 
correlates to the integrated Michaelis-Menten 
equation. C: By removing “flying” points on plot 
B, corresponding to the first and the last points 
in the progress curve, the remaining points form 
a linear curve, from which the kinetic parameters 
are estimated. 
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instead of a Val. This HuTK1-M106 was a permanent tetramer [Bradshaw & Deininger, 
1984; Berenstein et al., 2000]. By examining two of the HuTK1-C∆41 mutants, -M28I and 
-M28A, by gel filtration the native molecular mass of the proteins can be determined. The 
results are displayed in figure 9.24. 
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Figure 9.24: HuTK1-C∆41-M28I and –M28A subjected to gel-filtration chromatography on Superdex 
200. ve/v0 for the marker proteins, β-Amylase (200 kDa), Bovine Serum Albumin (66 kDa), 
Ovalbumin (45 kDa), Carbonic anhydrase (29 kDa), and Cytochrome C (12.4 kDa) are shown above 
the plot. 
 
Both HuTK1-C∆41-M28I and -M28A elutes at 39 and 43 kDa, respectively. This suggests 
that the native enzymes are dimers consisting of approx. 21 kDa subunits. The elution 
profile of both enzymes also show a small “bump” at approx. 90 kDa before the main 
peak, indicating the presence of low amounts of tetramer enzyme. Besides, HuTK1-C∆41-
M28A displays a smaller peak at approx. 17 kDa, suggesting that the enzyme can also 
function as a monomer. These results show the existence of several oligomerization 
forms of the two enzymes like it has been observed for HuTK1-C∆41 [Zhu et al., in 
press]. 
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10 Discussion 
 
Comparison of HuTK1 and CeTK1 
According to the sequence comparison and the structural prediction modelled with 
SWISS-MODEL the thymidine kinases from human and C. elegans appear to be 
structurally very similar. The N- and the C-terminal are longer in CeTK1 than in HuTK1, 
however, and they are also the regions displaying the largest sequence deviations. Since 
the N- and C-terminals in HuTK1 are mainly believed to be of importance for regulation 
the deviations in those regions could suggest differences in regulation mechanisms of the 
two enzymes.  
Clearly, CeTK1 is not regulated like HuTK1 with regard to the ATP-induced 
dimer/tetramer transition since it has been shown to be a permanent dimer regardless of 
ATP-incubation. HuTK1 has been shown to be a permanent tetramer when Val106 is 
replaced with more bulky amino acid like Met, Leu or Lys, but replacement with 
structurally similar amino acids like Ala, Ile or Thr does not affect the transition ability 
[Frederiksen et al., 2004]. Even though the corresponding amino acid in CeTK1 is an Ala 
the enzyme does not tetramerize upon ATP-incubation which indicates that other amino 
acids are responsible for the inability to tetramerize.  
Unlike HuTK1 CeTK1 does not harbour the Cdk1 recognition sequence Ser/Thr-Pro in the 
N-terminal, but it does have an identical sequence in the C-terminal of the protein. Since 
the phosphorylation of this particular Ser in HuTK1 affects the ability to tetramerize it can 
be concluded that the Cdk1 consensus sequence in the C-terminal of CeTK1 does not 
play the same part in regulation as the corresponding sequence in the N-terminal of 
HuTK1. Knowing that HuTK1 is unable to tetramerize when a negative charge is 
introduced in the N-terminal may however give a clue as to why CeTK1 is only a dimer. 
In the N-terminal of TK1’s from humans, mice and chicks no acidic amino acids are to be 
found, but in the N-terminal of CeTK1 the presence of four acidic amino acids (two Asp 
and two Glu) may have the same effect as Ser13 phosphorylation in HuTK1. Even though 
the exact location of all the amino acids in the N-terminal is not determined in any of the 
crystal structures [Welin et al, 2004; Birringer et al., 2005] it is clear that it is located 
near the interface consisting of interactions between the antiparallel β6-strands. 
Introduction of negative charges in this region is likely to disturb the interface 
interactions. 
Even though incubation with ATP does not result in a CeTK1 tetramer the nucleotide still 
causes an increase in enzymatic activity. The ATP-activation is of a different character 
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than the one observed for HuTK1. When HuTK1 activity is improved upon ATP-incubation 
it is expressed as a reduced Km, whereas the ATP-activation of CeTK1 is expressed as a 
higher Vmax. A major difference in the ATP-effect on the two enzymes is that the non-ATP 
incubated HuTK1 displays an apparent biphasic Hofstee plot showing negative 
cooperativity (n = 0.7) [Munch-Petersen et al., 1993], whereas CeTK1 incubated without 
ATP displays classical Michaelis-Menten rectangular hyperbolic kinetics.  
It has been suggested that the biphasic pattern observed for HuTK1 without ATP is 
caused by the simultaneous presence of two forms of the TK1 enzyme displaying 
different Km and kcat values [Munch-Petersen et al., 1993; Munch-Petersen et al., 1995a]. 
The dimeric enzyme has a lower kcat and higher Km value than the tetramer and is 
believed to be dominating at low dThd concentrations, while the tetramer is believed to 
dominate at high dThd concentrations. Hence, the Km and kcat values determined for the 
non-ATP incubated HuTK1 do not reflect the true kinetic parameters for the dimeric 
enzyme alone, but rather an equilibrium of the dimer and tetramer changing with the 
substrate concentrations. For CeTK1 the kinetic parameters for the ATP incubated and 
the non-ATP incubated enzymes appear to reflect only one enzyme form each since both 
forms display rectangular hyperbolic kinetics. It is, however, also a possibility that the 
two forms are present in the assay simultaneously, but if so, there is no change in 
equilibrium between the forms during the assay since the progression curves are linear 
for at least one hour. From the hyperbolic Michaelis-Menten curves it is also clear that a 
possible equilibrium between the two forms is not affected by the dThd concentration. A 
possible mechanism is that the binding of ATP in the active site induces a minor 
conformational change in the enzyme that makes the catalytic reaction between the two 
substrates proceed more efficiently when the enzyme-ATP complex is subsequently 
subjected to dThd. But why ATP is unable to improve the catalytic activity at low enzyme 
concentrations is unclear. 
 
Another remarkable finding is that CeTK1 apparently also displays an ATP-activating 
effect when tested with the poorer substrate dGuo. This is unexpected since the enzyme 
concentration in the dGuo assay far exceeds (by a factor 10) the 0.39 µg/ml above which 
ATP should activate the enzyme. Hence, no enzyme in the low activity form was expected 
to be observed. This indicates that not only is the ATP-activating effect absent at low 
enzyme concentrations, but maybe the dGuo present in the assay mixture prevents the 
activation from taking place during the assay even at higher enzyme concentrations.  
 
The kcat values for ATP and non-ATP-incubated HuTK1 with dThd are approx. the same 
(6.9 s-1 and 6.3 s-1, respectively) as the one for non-ATP-incubated CeTK1 (6.3 s-1), but 
 104
the kcat for ATP-incubated CeTK1 is around twice as high (11.2 s-1) (A fold out overview 
of kinetic parameters is presented in appendix E). But due to the very low Km value of the 
ATP-incubated HuTK1 the specificity constant for ATP-incubated CeTK1 is only half that 
of HuTK1. For the non-ATP-incubated enzymes CeTK1 has a specificity constant that is 
over 10 times higher than HuTK1. Nearly all the amino acids surrounding dThd in the 
active site are identical in HuTK1 and CeTK1 with the exception of Thr163 in HuTK1 
which is replaced by Ser182 in CeTK1. The mutation of those amino acids shows that this 
particular structural difference in the active site is not the sole cause of the difference in 
dThd kinetics. 
In HSV1TK the space around the 5-methyl of dThd is larger than in HuTK1, and it is able 
to phosphorylate thymidine analogs substituted with groups as large as 2-bromovinyl in 
the 5-position of thymine [Cheng et al., 1981]. Since CeTK1 also has a larger space 
around the 5-methyl group of dThd it is likely that it is also able to phosphorylate 
thymidine analogs with 5-substituents larger than the bromine, fluorine and ethyl groups 
that are allowed for phosphorylation by HuTK1 [Eriksson et al., 1991b]. This has not yet 
been tested experimentally, though. 
 
Both HuTK1 and CeTK1 display activity with the thymidine analog AZT, and they both 
show rectangular hyperbolic kinetics with the substrate regardless of whether the 
enzymes have been pre-incubated with or without ATP. For HuTK1 the Km values with 
AZT are reported to be in the range of 0.6-3.0 µM for both the ATP-incubated and the 
non-ATP-incubated enzyme, and the kcat values for both form (Vmax ≈ 5000 nmol min-1 
mg-1 => kcat ≈ 2 s-1) are approx. half of the kcat observed with dThd [Furman et al., 
1986; Munch-Petersen et al., 1991; Munch-Petersen et al., 1995b]. It has been 
suggested that the parameters for the ATP and the non-ATP-incubated enzymes are so 
similar because only the tetramer form of HuTK1 reacts with AZT [Munch-Petersen et al., 
1995b]. CeTK1 is clearly able to phosphorylate AZT even though it only exists as a dimer, 
but the ATP-activating effect is strongly reduced compared to the effect observed for the 
substrate dThd. The kcat values with AZT are in the same range for CeTK1 with and 
without ATP, and they are slightly higher than the value for non-ATP-incubated CeTK1 
with dThd. The large difference in Km values with AZT and dThd indicates that AZT fits 
more poorly in the substrate binding pocket than dThd. That the kcat values for ATP and 
non-ATP incubated enzyme are only slightly different suggests that the catalysis with AZT 
is not improved to a very large extent by the pre-incubation with ATP. The ATP-effect 
with the substrate dGuo appears to be nearly as pronounced as with dThd, but since it 
has not been possible to obtain full Michaelis-Menten curves with this substrate the 
kinetic parameters cannot be compared. It can be concluded that apparently, the ATP-
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activation is not equally effective for all substrates. If the ATP-activation is in fact caused 
by conformational changes in the active site these results suggests that they are not near 
the 3`-azido group in AZT since the activity with this substrate is not affected much by 
ATP compared to dThd. 
The ability of CeTK1 to phosphorylate the substrate dGuo is unusual and has not been 
observed previously for thymidine kinases of the TK1-type. The kinetic parameters with 
dGuo have not been obtained in this work since the Km is very high relative to the 
solubility of dGuo. Since Km for a substrate is often in the approximate area of the 
intracellular concentration of the substrate [Segel, 1993] the high Km with dGuo suggests 
that either the intracellular concentration of dGuo in C. elegans is extremely high 
compared to that of dThd, or dGuo is unlikely to function as a substrate at cellular 
condition. The latter is probably the most likely explanation.  
 
The lack of a KEN box in the C-terminal of CeTK1 indicates that the enzyme is not cell 
cycle regulated via ubiquitin-dependent proteolytic degradation like HuTK1. However, the 
sequence KEQ could prove to be an alternative recognition site for the APC/Cdh1 
complex since the amino acid Gln (Q) in this sequence is similar in structure to Asn (N). 
Besides, the KEQ sequence is located at the same distance from the C-terminal as the 
one with which the KEN box is located from the C-terminal of HuTK1. Whether KEQ 
functions as a recognition site for an eventual APC/Cdh1 complex in C. elegans and thus 
makes CeTK1 suspect for cell cycle-dependent degradation cannot be deduced from 
sequence comparison alone. In order to solve this question experimental analyses are 
required. From a strictly theoretical point of view it is likely that CeTK1 is not cell cycle-
regulated since it appears to be the only deoxynucleoside kinase present in C. elegans. If 
the TK1 is not present in quiescent cells the cells would have to rely solely on the much 
more energy-demanding de novo pathway. This would be energetically unfavourable. 
Removal of the 41 C-terminal amino acids in HuTK1 increased the activity and stability of 
the enzyme and enabled it to be crystallized [Zhu et al., in press; Welin et al., 2004], but 
apparently the function of the C-terminal in CeTK1 is markedly different. Removal of the 
57 C-terminal amino acid residues in CeTK1 results in an enzyme that is truncated in the 
same position as HuTK1-C∆41. In contrast to HuTK1-C∆41 the C-terminal deletion in 
CeTK1 results in an enzyme with lower activity and stability compared to the WT enzyme. 
The structural basis of this functional difference in the C-terminal is difficult to surmise 
since the C-terminal of HuTK1 has not been crystallized. Besides from the importance for 
maintaining stability and activity, only little can be concluded about the C-terminal of 
CeTK1. It appears that none of the C-terminal residues in CeTK1 are required in order for 
the ATP-activation to take place, since the ATP-effect is also observed for the truncated 
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enzyme. In fact, the difference in kcat with dThd is even greater for CeTK1-C∆57 than for 
CeTK1-WT, so removal of the C-terminal seems to improve the ATP-activating effect. Like 
the WT enzyme CeTK1-C∆57 is able to phosphorylate AZT, though with reduced affinity, 
but the ability to phosphorylate dGuo is strongly diminished and estimation of kinetic 
parameters has not been attempted. 
 
Thymidine kinases with unexpected subunit sizes. 
Several of the purified TK1 enzymes appear to have diverging subunit sizes compared to 
the one determined from the expected amino acid sequence. One explanation that could 
account for this observation is that the thrombin cleavage, which should separate the 
TK1 from the GST tag, has been unsuccessful. The normal recognition sequence for 
thrombin cleavage is LVPRGS, but occasionally it also cleaves at two other sequences 
[GST Gene Fusion System Handbook, Edition AA, Amersham Biosciences]. One 
alternative cleavage site is X1X2P(R/K)X3X4 where X1 and X2 have to be hydrophobic, and 
X3 and X4 must not be acidic amino acids. Another alternative cleavage site is X1(R/K)X2 
where either X1 or X2 are Gly. In both sequences the protein is cleaved after (R/K).  
According to the results from automated electrophoresis the two CeTK1 proteins, M42I 
and L143A, appeared to be larger than the expected 30 kDa. The estimated molecular 
mass for both proteins is 35 kDa, and by examining the amino acid sequence of GST-
CeTK1 fusion protein it becomes clear that the alternative thrombin cleavage site AFPKLV 
is located 35.5 kDa from the C-terminal (see appendix C for alternative thrombin 
cleavage sites). Cleavage of this site instead of the normal thrombin cleavage site will 
result in a CeTK1 protein with an additional 5.5 kDa polypeptide from GST in the N-
terminal. It is remarkable, however, that no normally cleaved protein is observed at 30 
kDa on any of the two electropherograms. 
Two other CeTK1 mutants, S182T and S182A, were expected to have subunit sizes of 30 
kDa, but they also appear to be larger. The molecular masses determined by automated 
electrophoresis are approx. 41 kDa for both proteins, and by examining the sequence of 
the CeTK1-GST fusion protein for alternative cleavage sites there is only one possible site 
that would result in fragments of this size. The alternative cleavage site, RGK (can be 
cleaved both before and after G), is located 41.5 kDa from the N-terminal of the fusion 
protein, and cleavage in that site would result in a protein consisting of a full GST protein 
linked to a 14.7 kDa N-terminal fraction of CeTK1 protein. This cleavage is highly unlikely 
to result in a functional enzyme since it splits the CeTK1 protein between α3 and β5 and 
hence, the entire lasso loop and some of the α/β-domain will be separated from the 
remaining part of the α/β-domain. Besides, the GST tag is bound to the GSH column and 
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hence, the 41.5 kDa fragment of the alternative cleavage should appear in the GSH 
fraction instead of the cleavage factions. Therefore, the large sizes of CeTK1-S182T and 
–S182A are not likely to be caused by alternative thrombin cleavage.  
Another possible explanation is that the E. coli strain (BL21) used for expression of the 
proteins does not obey the stop codon at the end of the CeTK1 genes.  
 
It is well known that E. coli has very different preferences for the three stop codons UAA, 
UGA and UAG [Brown et al., 1990]. The preferred stop codon is UAA, but the nucleotide 
located right after this codon is also important for the termination efficiency. The 
hierarchy of termination signals in decreasing order of efficiency is believed to be: UAAU 
> UAAG > UAAA/C, with UGA or UAG followed by A or C being the least efficient. There 
is a pronounced preference for UAAU [Brown et al., 1990]. The true stop codon in CeTK1 
has the sequence UAAG, but searching the sequence after this codon another more 
efficient stop codon, UAAU, is found in the pGEX vector (see appendix D for all 
alternative stop codons). There are several other stop codons in between, but they are all 
the low efficiency UGA codons. If the translation of CeTK1 is terminated at the UAAU 
instead of the UAAG codon the resulting protein has a molecular mass of approx. 40 kDa. 
This is similar to the subunit size estimated by automated electrophoresis (41 kDa).  
It is also likely that some of the other stop codons in the region after the true termination 
sequence can account for the large sizes of CeTK1-M42I and -L143. They both display 
more than one peak in the electropherogram (figure 9.10), suggesting different 
termination sites. They have an intense peak at approx. 35 kDa and another peak at 
approx. 40 kDa which is less intense for CeTK1-L143A than for CeTK1-M42I. It is 
noteworthy, however, that none of the mutants CeTK1-S182T, -S182A, -L143A, and –
M42I display any protein with the expected molecular mass on the electropherograms. 
The purified CeTK1-WT only displays one peak at the expected 30 kDa, but a previous 
purification of this protein displayed two bands at 30 and 38 kDa on a SDS-gel 
[Skovgaard, 2004] which is similar to the SDS-gels of CeTK1-S182T, -S182A (figure 9.8). 
The discrepancies between the molecular masses observed on the SDS-gels and the 
electropherograms are only for CeTK1 proteins. By loading the cleavage and GSH 
fractions from several of the HuTK1-C∆41 and CeTK1 proteins on a SDS-gel it appears 
that all the bands of the CeTK1 cleavage fractions are broad and blurry, and bands from 
GST and HuTK1-C∆41 proteins are all sharp and well-defined (not shown). This could 
indicate that the CeTK1 proteins are either extremely sensitive towards small amounts of 
proteases present in the gel buffer or that other things in the gel, loading buffer or 
running buffer may cause the protein to be degraded.  
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CeTK1 mutants 
The mutation of Ser182 in CeTK1 alters the area around the 5-methyl group of dThd. By 
mutating Ser182 to a Thr the Km with dThd is reduced compared to WT, but the kcat is 
also reduced and consequently, the specificity is nearly three times higher for the WT. 
Mutation of the same amino acid to an Ala also results in a decrease in kcat, but this 
mutation also leads to a higher Km which results in a specificity 100 times lower than for 
CeTK1-S182T. This shows that both a decrease (S182T) and an increase (S182A) in the 
space around the 5-methyl group of dThd lower the overall specificity for the substrate, 
but to a very different degree. The pattern is similar with the nucleoside analog AZT. 
Both mutations result in lowered specificity compared to WT, but with AZT the decrease 
in specificity is expressed as both higher Km and lower kcat values. CeTK1-S182T has the 
highest specificity with AZT of the two mutated enzymes. 
When S182 is mutated to Thr the amino acids surrounding the substrate in CeTK1 are 
the same as in HuTK1. One interesting difference between the human and C. elegans 
TK1’s is the ability of CeTK1 to phosphorylate dGuo. This ability is improved by changing 
the Ser in CeTK1 to a Thr, suggesting that other amino acids must be responsible for the 
difference in substrate specificity between the human and C. elegans kinases.  
At 3000 µM dGuo the activity is approx. 1500 nmol min-1 mg-1 for CeTK1-S182T, whereas 
it is only 30 nmol min-1 mg-1 for CeTK1-S182A. Thus, the additional increase in space 
around the substrate base that follows from mutating the Ser to an Ala does not increase 
the dGuo specificity, but only seems to decrease the specificity for both dGuo, dThd and 
AZT compared to WT. The activity with 3000 µM dGuo is 3-4 times higher for CeTK1-
S182T than for CeTK1-WT (figure 9.21; approx. 1500 nmol min-1 mg-1 compared to 
approx. 400 nmol min-1 mg-1), and CeTK1-S182T is hence the best dGuo-phosphorylating 
enzyme of all the TK1’s presented in this thesis.  
 
By substituting Leu143 with an Ala the space above the 6`-carbon of dThd on the α/β-
domain side is increased. This change appears to have no effect on the maximum 
velocity of the enzyme with dThd, but the Km is dramatically increased compared to the 
WT resulting in an approx. 100 times decrease of the specificity constant. With the 
nucleoside analog AZT the increase in Km is so pronounced that the kinetic parameters 
have only been determined with high inaccuracy. The estimated kcat is also decreased 
compared to the WT enzyme, resulting in a specificity constant for AZT estimated to be 
approx. 1000 times lower than for the WT enzyme. Leu143 is located exactly on the 
opposite side of the deoxyribose ring compared to the 3`-azido group of AZT, so why the 
mutation has such a drastic effect on AZT specificity is difficult to explain from the 
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modelled structure of CeTK1. The mutation of the big and bulky Leu to the much smaller 
Ala most likely gives rise to the displacement of several other amino acids around the 
substrate deoxyribose. The amino acid substitution also appears to induce changes in the 
area around the 4-oxygen and 5-methyl group in dThd since the mutated protein has 
gained the ability to phosphorylate dCyd. dCyd has an amino group instead of an oxygen 
at the 4-position of the base and lacks the methyl group at the 5-position. The maximum 
reaction velocity with dCyd is very low compared to those with dThd and AZT, but the Km 
is approx. 50 times lower than with dThd and nearly 1000 times lower than the estimated 
Km for AZT. As a result of the low Km with dCyd the specificity constant is only approx. 
250 times lower that the one for dThd.  
 
The last mutation performed in the active site of CeTK1 is the substitution of Met42 with 
the slightly shorter, but more branched amino acid, Ile. This mutation results in a minor 
increase in the space on the side of the thymine base in the area near the 6`-carbon and 
a greater spatial increase above the 2`- and 3`-positions of the deoxyribose. Like all the 
other mutations in CeTK1 the Km with dThd for this mutant is increased compared to WT. 
The kcat has also decreased which results in an approx. 500 times lower specificity 
constant than for the WT enzyme. The reduced specificity for dThd can be caused by the 
fact that the branching Ile extends into the area near the triphosphates where it might 
interfere with the phosphates. CeTK1-M42I phosphorylates AZT even more poorly than 
dThd, but like CeTK1-L143A it has gained the ability to phosphorylate dCyd. For CeTK1-
M42I the kcat with dCyd is also low compared to those for dThd and AZT, but the Km is 
approx. 150 times lower than for dThd and over 250 times lower than for AZT. As a 
consequence the specificity constant with dCyd is only 10 and 100 times lower than those 
of AZT and dThd, respectively. Like CeTK1-WT it is also able to phosphorylate dGuo, but 
with far lower velocity. Kinetic parameters have not been obtained with dGuo, but 
whereas the activity at 3000 µM dGuo is only around 15 nmol min-1 mg-1 for CeTK1-M42I 
it is around 400 nmol min-1 mg-1 for the WT enzyme. 
 
Though the specificity constants for CeTK1-L143A and –M42I with dCyd may not appear 
impressive compared to specificity constants of TK1’s with other substrates they are in 
the same range as the one for dGK with dCyd. dGK has been shown to have Km and kcat 
values with dCyd of 336 µM and 0.030 s-1, respectively, resulting in kcat/Km of 89 s-1 M-1 
[Sjöberg et al., 1998]. This specificity constant is similar to those of CeTK1-L143A and –
M42I (97 s-1 M-1 and 48 s-1 M-1, respectively). dCyd is the preferred substrate for dCK with 
a Km value of 0.8-2.0 µM [Bohman & Eriksson, 1988; Datta et al., 1989; Eriksson et al., 
1991b]. This is only slightly lower than the values observed for the two CeTK1 enzymes 
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(5.4 and 3.6 µM for CeTK1-L143A and –M42I, respectively). However, the kcat for dCK is 
much higher, the exact value varies greatly in different publications; from 145 nmol min-1 
mg-1 in Bohman & Eriksson, 1988 to 8000 nmol min-1 mg-1 in Datta et al., 1989). 
Unfortunately, neither of the dCyd-phosphorylating mutants were able to phosphorylate 
the cytidine analog AraC. 
 
Since none of the HuTK1 mutants are able to phosphorylate dCyd the altered substrate 
specificity with respect to this substrate could be associated with the combination of the 
smaller Ser instead of Thr near the 5-methyl of dThd and increased space around the 
deoxyribose and the base (where L143 and M42 are located in CeTK1). The increased 
space leaves room for a slight shift in substrate position in the active site pocket that may 
provide space for the amino group of dCyd. Such a shift could explain the lowered 
catalysis with dCyd since it would also affect the location of the 5`-OH that receives the 
phosphate upon catalysis. 
 
HuTK1 mutants 
The mutation of Thr163 in HuTK1-C∆41 affects the surroundings of the 5-methyl group 
of dThd. Mutation to Ser, which is a similar to but slightly smaller polar amino acid, 
lowers the specificity constant with dThd compared to HuTK1-C∆41, and mutation of 
Thr163 into an Ala creates a completely inactive enzyme. Ala is also smaller than Thr, but 
unlike Ser it is hydrophobic. When creating the mutation T163S in the HuTK1 structure 
file (with PDB-viewer) it is evident that both Ser and Thr in HuTK1 make hydrogen bonds 
to the main chain amino group of the neighbouring Met28. By mutating Thr to the 
hydrophobic Ala this hydrogen bond is lost which may cause the large Met28 to shift 
orientation. The corresponding CeTK1 enzyme (S182A) has not completely lost activity, 
but a drastic decrease in specificity compared to CeTK1-WT is observed with both dThd 
and AZT. This suggests that other amino acid interactions in the vicinity of the active site 
assist in stabilizing the local structure in CeTK1-S182A so the enzyme remains functional 
in spite of the loss of hydrogen bonding. Besides from being inactive, HuTK1-C∆41-
T163A also appears to inhibit the activity of E. coli TK from the expression host. Since 
HuTK1-C∆41 is known to tetramerize it is possible that the induced HuTK1-C∆41-T163A 
protein is able to form inactive tetramers with E. coli TK. This would explain why the TK 
activity decreases to zero when the induction is initiated. 
Another interesting finding regarding Thr163 is that the mutation to a Ser, besides from 
decreasing the dThd specificity compared to WT, also increases the specificity towards 
the analog AZT. The specificity constant for HuTK1-C∆41-S163S with AZT is approx. 100 
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times higher than with dThd. The great difference in specificity for the two substrates is 
expressed by a large decrease in Km with AZT compared to dThd. Not only is the 
specificity constant for this mutant higher with AZT than with dThd, it also has a slightly 
higher specificity with AZT than the HuTK1-WT. Unfortunately, no kinetic parameters 
have yet been reported for HuTK1-C∆41 with AZT so whether the increased AZT 
specificity for HuTK1-C∆41-T163S compared to WT is due to the C-terminal truncation or 
to the active site mutation or both is still unclear. 
 
The mutation of Leu124 to Ala produces an enzyme with nearly the same specificity 
towards dThd as the one displayed by HuTK1-C∆41-T163S. Both the kcat value and Km 
are poorer than the ones for the WT enzyme. The mutant also displays activity with the 
analog AZT, and with a kcat similar to those of HuTK1-WT and HuTK1-C∆41-T163S, but 
the Km with AZT is strongly increased resulting in a specificity constant approx. 100 times 
lower than the one for –T163S. Neither T163 nor Leu124 are located near the 3`-azido 
group of AZT so mutations of those amino acids must lead to changes on the other side 
of the substrate through several other amino acids. Mutation of the similar Leu to Ala in 
CeTK1 (L143A) leads to an even greater loss of AZT activity, but unlike HuTK1-C∆41-
L124A it has also obtained the ability to phosphorylate dCyd. The only difference in 
amino acid composition around the substrate between those two mutants is near the 5-
methyl group of dThd where Thr in HuTK1-C∆41 is replaced by a Ser in CeTK1. Perhaps 
a HuTK1-C∆41 double mutant L124A-T163S would harbour sufficient space around the 
substrate base to be able to phosphorylate dCyd also. 
 
Met28 is positioned on the side of the thymine base with the sulphur pointing towards 
the 6`-carbon atom of the base and the tip extending above 2`- and 3`- carbon of the 
deoxyribose. By mutating it to an Ile the space above the deoxyribose becomes more 
open, but the space near the thymine base is only slightly increased. The mutation, M28I 
in HuTK1-C∆41, greatly reduces the specificity for dThd. The kcat is reduced approx. 6 
times, and the Km is increased 250 times compared to HuTK1-C∆41. By mutating the 
same Met into an Ala the space is greatly increased both on the side of the base and 
above the 2`- and 3`-positions of the deoxyribose, and, unlike Ile, Ala does not extend 
into the phosphate-binding area. The specificity of HuTK1-C∆41-M28A with dThd is 
approx. three times higher than for –M28I, manifested by a higher kcat. Both mutants 
display activity with the analog AZT, but with the same pattern as for dThd. Both 
enzymes have a very high Km with AZT and a reduced kcat compared to WT, but the kcat 
of HuTK1-C∆41-M28I is nearly 20 times lower than the one for –M28A. Generally, the 
decrease in specificity for the two mutants compared to the WT is much more 
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pronounced with AZT than with dThd. This suggests that the mutation of Met28 
interferes more with the catalysis of AZT than dThd which makes sense considering the 
location of Met28 just above the 3`-azido group in AZT. Besides, the bulky Ile appears to 
have a greater impact on catalysis than Ala, and especially with AZT. This is likely to be 
due to the methyl branch of this amino acid extending into the area near the phosphates. 
In CeTK1 mutation of the corresponding Met (M42) into Ile results in activity with the 
uncommon substrate dCyd. This is not the case for HuTK1-C∆41-M28I which suggests 
that dCyd activity also requires the extra space around the 5-methyl group of the 
thymine base (the position, which is occupied by a Ser in CeTK1 and a Thr in HuTK1).  
 
Unlike HuTK1-WT and HuTK1-C∆41 none of the HuTK1-C∆41 mutants display negative 
cooperativity with dThd. This could indicate that they are all either permanent dimers or 
tetramers. However, native molecular weight determination for two of the mutants, 
HuTK1-C∆41-M28I and –M28A, shows that besides from being active as dimers they are 
also active as tetramers. And HuTK1-C∆41-M28A also appears to function as a monomer. 
All the enzyme kinetics assays with HuTK1-C∆41 mutants have been measured at 
enzyme concentrations much higher than the ATP-activation threshold for HuTK1 so if 
they are all able to tetramerize, it is likely that the activities are measured on the 
tetramer form. This explains why no negative cooperativity is observed. 
 
Summary of discussion and future work 
Unlike the human enzyme, which shifts from a low activity dimer to a high activity 
tetramer upon ATP-incubation, CeTK1 only exists as dimer with a molecular mass of 
approx. 60 kDa. Incubation with ATP affects the enzyme activity by doubling the maximal 
velocity with dThd. However, the Km is not affected. By deleting the 57 C-terminal amino 
acid residues in CeTK1 the enzyme activity and stability is reduced. This is opposite to 
the effect observed by deleting the corresponding residues in HuTK1, suggesting that the 
C-terminals of the two kinases have different functions. This is also supported by the fact 
that the amino acid sequence in both the N- and C-terminals deviates highly between the 
two enzymes, indicating different mechanisms of regulation. One thing that may provide 
information about the reduced activity and stability of the C-terminally truncated CeTK1 is 
to solve the structure. The high stability of the CeTK1 enzyme does indicate that it should 
be easier to crystallize than HuTK1, and a crystal structure could also disclose which 
subunit interface is prevailing in the dimeric enzyme. 
The exact mechanism of the ATP-activating effect upon CeTK1 is not clear from the 
present results, but it is evident that the effect is not equally pronounced for all 
 113
substrates. However, since CeTK1 displays classical hyperbolic Michaelis-Menten kinetics 
it should be possible to deduce the true Km and Vmax values, and to determine whether 
the reaction mechanism is ping-pong or sequential (ordered/random) by performing a 
series of experiments with varied dThd and different, fixed ATP concentration. The 
results from such experiments may provide further information that could help solve the 
mechanism of the ATP-activating effect.  
The ability of CeTK1 and not HuTK1 to phosphorylate dGuo was initially suspected to be 
caused by the presence of the smaller amino acid Ser instead of Thr near the 5-methyl 
group of dThd in CeTK1. This has proven to be wrong since the mutation of Ser to Thr in 
CeTK1 appears to increase the activity with dGuo compared to the WT enzyme. 
Regarding analog specificity it would be worth examining if the increased space around 
the 5-methyl of dThd in CeTK1 allows the enzyme to phosphorylate thymidine analogs 
with larger substituents like 2-bromivinyl, which is allowed by HSV1TK.  
With respect to the active site mutants the most interesting findings are the high 
specificity of HuTK1-C∆41-T163S with the analog AZT, and the ability of CeTK1-M42I and 
–L143A to phosphorylate dCyd.  
Since it appears that the CeTK1 enzymes are more flexible regarding substrate specificity 
than the HuTK1 enzymes it would also be interesting to examine all the CeTK1’s with 
regard to several other nucleoside analogs than the ones tested so far. CeTK1–M42I, 
HuTK1-C∆41-M28I and –M28A should be tested with AraT since they have more space 
around the 2`-position in dThd, leaving room for the 2`-OH of this substrate. 
Finally, some of the CeTK1 enzymes appeared to have larger subunit sizes than 
expected, and those will have to be examined in more detail. The nucleotide sequence 
has already been tested by additional sequencing (not shown) so a possible approach 
would be to repeat induction and purification, and if the results are unchanged the 
proteins would have to be subjected to further analysis. One possibility is to analyze 
them by gel filtration in order to see if they co-elute with CeTK1-WT. But since this 
method is not so accurate, and the differences in molecular weights between some of the 
proteins are fairly small, it may not provide any clear evidence of the actual subunit sizes. 
Besides, the gel filtration would not provide any information about a reason for the 
possibly increased size of the proteins. The best way to determine from where the extra 
mass originates would be amino acid sequencing or x-ray crystallography. 
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Abbreviations and glossary 
 
 
ACV Acyclovir, 9-[(2-hydroxyethoxy)methyl]guanine 
ADP Adeonsine-5`-diphosphate 
AgdNK Anopheles gambiae deoxynukleosidkinase, multisubstrate kinase from mosquito 
AMP Adeonsine-5`-monophosphate 
Apaf-1 Apoptose-activating factor which is able to form a complex with cytochrome-c 
called the apoptosome 
APC Anaphase promoting complex (cyclosome). Ubiquitin ligase protein complex in the 
ubiquitin-dependent protein degradation pathway 
ATP Adeonsine-5`-triphosphate 
AraC 1-β-D-arabinofuranosylcytosine 
AraT 1-β-D-arabinofuranosylthymine 
AZT Azidothymidine, 3`-azido-2`-3`-dideoxythymidine, Retrovir® 
Benzamidine Amino acid analog, protease inhibitor 
BLAST Basic Local Alignment Search Tool 
BmdNK Bombyx mori deoxynukleosidkinase, multisubstrate kinase from butterfly 
BSA Bovine serum albumin 
BVDU E-5-bromovinyl-2`-deoxyuridine 
CBH Crude bacterial homogenate 
2-CdA Cladribine, 2-chloro-2`-deoxyadenosine, Leustatin® 
DC95 Death receptor that is activated by the ligand CD95-L. Activation eventually 
initiates the caspase cascade and leads to apotosis. 
Cdk Cyclin dependent kinase (Cdk1 is synonymous to Cdc2). Group of cell cycle 
regulating protein kinases 
Cdh1 Activator of the APC complex that recognizes the consensus sequence KEN 
Cdc20 Activator of the APC complex 
CDP Cytidine-5`-diphosphate 
CeTK1 Caenorhabditis elagans thymidine  kinase 
CHAPS 3-[(3-Cholamidopropyl)-dimethylammonium]-1-propanesulfonate, detergent  
CobA Adenosyltransferase that transfers the adenosyl group from ATP to corrinoid 
substrates like hydroxocobalamin and cobinamide. Similar in structure to the α/β-
domain of HuTK1 
CPM Counts per minute 
dAdo Deoxyadenosine 
dADP Deoxyadeonsine-5`-diphosphate 
dAMP Deoxyadeonsine-5`-monophosphate 
dATP Deoxyadeonsine-5`-triphosphate 
dCDP Deoxycytidine-5`-diphosphate 
dCK Deoxycytidine kinase 
dCMP Deoxycytidine-5`-monophosphate 
dCTP Deoxycytidine-5`-triphosphate 
dCyd Deoxycytidine  
dGDP Deoxyguanosine-5`-diphosphate 
dGK Deoxyguanosine kinase 
dGMP Deoxyguanosine-5`-monophosphate 
dGTP Deoxyguanosine-5`-triphosphate 
dGuo Deoxyguanosine 
dIDP Deoxyinosine-5`-diphosphate 
dIMP Deoxyinosine-5`-monophosphate 
dIno Deoxyinosine 
dITP Deoxyinosine-5`-triphosphate 
DmdNK Drosophila melanogaster deoxynukleosidkinase, multisubstrate kinase from the 
fruit fly 
DNC Deoxynucleotide carrier 
dNK Multisubstrate kinase 
dNDP Deoxynucleotide-5`-diphosphate 
dNMP Deoxynucleotide-5`-monophosphate 
dNTP Deoxynucleotide-5`-triphosphate 
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dTDP  Deoxythymidine-5`-diphosphate, the same as TDP 
dThd Deoxythymidine, the same as Thd 
dTMP Deoxythymidine-5`-monophosphate, the same as TMP 
DTT Dithiothreitol 
dTTP Deoxythymidine-5`-triphosphate, the same as TTP 
dUDP Deoxyuridine-5`-diphosphate 
dUMP Deoxyuridine-5`-monophosphate 
dUTP Deoxyuridine-5`-triphosphate 
dUrd Deoxyuridine  
EcTK Escherichia coli thymidine kinase 
EDTA Ethylenediaminetetraacetic acid 
FADD Death domain protein that is involved in triggering the caspase cascade and 
inducing apoptosis. 
F-AraA Fludarabine, 9-β-D-arabinofuranosyl-2-fluoroadenine, Fludara® 
G0 Cells in G0 phase are quiescent, non-proliferating 
G1 phase The period in the cell cycle where the cell prepares for DNA synthesis 
G2 phase The period in the cell cycle where the cell prepares for mitosis 
GCV Ganciclovir, 9-[(1,3-Dihydroxy-2-propoxy) methyl]guanine 
GSH Reduced glutathione 
GST Glutathione S-transferase 
HSV1TK Herpes simplex virus type 1 thymidine kinase 
IPTG Isopropyl-β-D-thiogalactopyranosid 
kcat The turn over number of an enzyme (Vmax divided by the total enzyme 
concentration) 
KEN box Amino acid recognition sequence for APC-Cdh1 complex. A target site for 
degradation by the ubiquitin dependent protein degradation pathway 
Km The michaelis constant. Also the substrate concentration at ½Vmax 
M phase Period in the cell cycle where the cell undergoes mitosis 
MDS Mitochondrial DNA depletion syndrome 
n The Hill constant. If it is higher than 1 the enzyme displays positive cooperativity, 
and if it is lower it displays negative cooperativity 
NADH Nicotinamide-adenine dinucleotide 
NaF Sodium fluoride, phosphatase inhibitor 
p53 Tumour suppressor protein 
PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
PMSF Phenylmethylsulfonyl flouride, protease inhibitor 
PRPP 5-phosphoribosyl-1-pyrophosphate, intermediate in de novo pathway of 
(deoxy)nucleotide synthesis 
RecA-F1ATPase  Family of proteins that has ATP-binding domain with similar structure to the α/β-
domain of HuTK1 
S phase Period in the cell cycle where the DNA is duplicated 
SDS Sodiumdodecylsulfate 
SET The first fraction collected during purification of TK1 proteins on an affinity column 
TBE Tris Borate EDTA buffer 
TEMED N,N,N’,N’-tetramethylendiamina 
TK Thymidine kinase 
TK1 Thymidine kinase 1, cytosolic 
TK2 Thymidine kinase 2, mitochondrail 
UuTK Ureaplasma urealyticum thymidine kinase 
Vmax The maximal velocity 
VvTK Vaccinia virus thymidine kinase 
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Appendix A – Materials and methods 
 
 
Materials and methods for the different procedures are here brought in the same order 
as the procedures are carried out. A general overview is presented in the report in figure 
8.1. 
 
 
I - QuickChange site-directed mutagenesis  
Templates: pGEX-2T-CeTK1 and pGEX-2T-HuTK1-C∆41. 
 
Primers for all mutants:  
Primers beginning with CeTK1 are used with the template pGEX-2T-CeTK1 and primers 
beginning with HuTK1 are used with the template pGEX-2T-HuTK1-C∆41. The second 
part of the name denotes the amino acid change that the primer causes, and F and R 
denotes Forward and Reverse since the primers work in pairs. 
 
 
CeTK1-E213st-F:  5’ gc aga gaa tgt tat gtt caa aag agc taa gaa aaa gat gc 3’ 
 
CeTK1-E213st-R:  5’ gc atc ttt ttc tta gct ctt ttg aac ata aca ttc tct gc 3’ 
 
CeTK1-S182T-F: 5’ gc gga tcg caa gca aac ttc aca ttc cgc agc 3’ 
 
CeTK1-S182T-R: 5’ gct gcg gaa tgt gaa gtt tgc ttg cga tcc gc 3’  
 
CeTK1-S182A-F: 5’ gc gga tcg caa gca aac ttc gca ttc cgc agc 3’ 
 
CeTK1-S182A-R: 5’ gct gcg gaa tgc gaa gtt tgc ttg cga tcc gc 3’  
 
CeTK1-L143A-F:  5’ gct gca gcc aat gga aca ttc gag aga aag ccg ttc c3’ 
   
CeTK1-L143A-R:  5’ g gaa cgg ctt tct ctc gaa tgt tcc att ggc tgc agc 3’ 
 
CeTK1-M42I-F:  5’ g ggg cca att ttc agt ggc aaa acc acc g 3’ 
 
CeTK1-M42I-R: 5’ c ggt ggt ttt gcc act gaa aat tgg ccc c 3’ 
  
HuTK1-T163S-F: 5’ gg gaa gcc gcc tat agc aag agg ctc gg 3’  
 
HuTK1-T163S-R: 5’ cc gag cct ctt gct ata ggc ggc ttc cc 3’  
 
HuTK1-T163A-F: 5’ gg gaa gcc gcc tat gcc aag agg ctc gg 3’  
 
HuTK1-T163A-R: 5’ cc gag cct ctt ggc ata ggc ggc ttc cc 3’  
 
HuTK1-L124A-F:  5’ cc gta att gtg gct gca gcg gat ggg acc ttc c 3' 
 
HuTK1-L124A-R:  5’ g gaa ggt ccc atc cgc tgc agc cac aat tac gg 3’ 
 
HuTK1-M28I-F: 5’ g gtg att ctc ggg ccg atc ttc tca gga aaa agc 3’ 
 
HuTK1-M28I-R: 5’ gct ttt tcc tga gaa gat cgg ccc gag aat cac c 3’ 
 
HuTK1-M28A-F: 5’ g gtg att ctc ggg ccg gcg ttc tca gga aaa agc 3’ 
 
HuTK1-M28A-R: 5’ gct ttt tcc tga gaa cgc cgg ccc gag aat cac c 3’ 
 
 
Nucleotide changes are marked with grey. 
 
The reactions are performed with the kit QuickChange Site-Directed mutagenesis from 
Stratagene, but with a different DNA-polymerase. 
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PCR reaction: 50-100 ng template (pGEX-2T-CeTK1 or pGEX-2T-HuTK1-C∆41) 
 5 µl 10 x Pfu Ultra buffer 
 1 µl 10 mM dNTP-mix 
 2.5 µl 50 ng/µl Primer F 
 2.5 µl 50 ng/µl Primer R 
 1 µl 2.5 U/µl Pfu-Ultra High Fidelity DNA-polymerase 
 H2O to a final volume of 50 µl 
 
 
95ºC for 30’’ 
95ºC for 30’’ 
55ºC for 1’ 
68ºC for 5’ 30’’ 
68ºC for 5’ 30’’ 
 
 
 
II - Agarose gel electrophoresis 
1×TBE-buffer: 108 g Tris-base 
 55 g Boric acid 
  7.5 g EDTA  
  Add H2O to a volume of 2000 ml. 
  Autoclave and dilute 5 times with H2O. 
 
1% Agarose gel: 50 ml 1 × TBE 
  0.5 g agarose 
Agarose is dissolved by heating in a microwave oven for approx. 2 
minutes, and is subsequently cooled to ~60°C. 
  5 µl 4 mg/ml Ethidium bromide (Notice: EtBr is a carcinogen) 
  Pour in a form and leave to set for approx. half an hour. 
 
Running buffer:  750 ml 1 × TBE 
  90 µl 4 mg/ml Ethidium bromide  
 
Loading buffer: 50 mM Tris-HCl (pH 8.0) 
 25 mM EDTA 
 20% sucrose 
 Add H2O to a volume of 100 ml. 
 Add bromo phenol blue until a strong blue colour is observed. 
 
MW Markers:  
 
1 Kb Plus DNA Ladder (Invitrogen):  
Provides fragments of: 100, 200, 300, 400, 500, 650, 850, 1000 1650, 2000, 3000b, 
4000, 5000, 6000, 7000, 8000, 9000, 10.000, 11.000 and 12.000 bp. 
 
λ-BstE-II-marker: 
Provides fragments of: 117, 224, 702, 1264, 1371, 1929, 2323, 3675, 4324, 4822, 5686, 
6369, 7242, 8485 and 14144 bp. 
 
 
 
16 x 
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III - Preparation of Epicurian coli XL10-Gold super competent cells. 
Competency buffer I: 100 ml H2O 
20 ml 1 M KCl 
  1.2 ml 5 M Potassium acetate 
  12 ml 1 M CaCl2 
  30 ml ultrapure glycerol 
 
Mix to homogeneity and titrate to pH 5.8 with 0.2 M acetic acid. Bring to a final volume 
of 200 ml with H2O and filter sterilize. Store at 4 °C. 
 
Competency buffer II: 100 ml H2O 
  4 ml 0.5 M MOPS 
  2 ml 1M KCl 
  15 ml 1 M CaCl2 
  30 ml ultrapure glycerol 
 
Mix to homogeneity and titrate to pH 6.8 with 10 N NaOH. Bring to a final volume of 200 
ml with H2O and filter sterilize. Store at 4 °C. 
 
 
An Epicurian coli XL10-Gold (from Stratagene) glycerol culture is inoculated to 5 ml LB-
medium and incubated in a 37°C water bath with shaking over night. 
The overnight (ON) culture is diluted 100 times by transferring 1 ml ON culture to 99 ml 
LB-medium, and the new culture is left to grow at 37°C until OD600 =  0.3-0.5. The flask 
is placed in an ice/water bath for 15 min., and the culture is transferred to pre-cooled 
centrifuge glasses and spun down in a Sorvall centrifuge at 3000 rpm and 4°C for 15 
min. The supernatant is discarded, and the pellet is suspended in 1/3 culture volume 
(~33 ml) ice-cold competency buffer I. After 1 hour of incubation on ice the cells are 
centrifuged again at 3000 rpm and 4°C for 15 min., and the supernatant is discarded. 
The cells are resuspended in 1/25 culture volume (~4 ml) competency buffer II and 
incubated on ice for 15 min. The cells are now competent and can be stored in small 
portions at -80°C. 
 
 
IV - Transformation of plasmids to Epicurian coli XL10-Gold competent cells. 
Epicurian coli XL10-Gold super competent cells must be stored at -80°C and kept on ice 
at all times during work. 
 
Sterile test tubes for the transformation are cooled on ice, and 100 µl XL10-Gold super 
competent cells plus ~1 µl of Dpn1 treated PCR products from Site Directed Mutagenesis 
are added. An extra control tube is prepared without addition of DNA. The tubes are 
incubated on ice for 30 min. and then heat-shocked for 2 min at 42°C. The bacteria are 
placed on ice for 2 min., and 1 ml of pre heated LB-medium is added. The transformed 
cells are incubated at 37°C for 60 min. 
 
20 µl and 100 µl of the each tube is plated respective halves of an LB-ampicillin plate. 
From the control tube 50 µl is plated on both a LB and a LB-ampicillin plate. The two 
plates with non-transformed XL10-Gold function as a control of bacterial growth (LB 
plate) and unwanted ampicillin resistance (LB-ampicillin plate). The plates are incubated 
at 37°C over night. 
 
One colony from each of the transformants is inoculated to test tubes containing 5 ml LB 
medium and 100 µg/ml ampicillin, and the cultures are grown overnight in a 37°C 
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shaking water bath. Plasmids from the cultures are purified on the following day and 
subjected to sequencing. 
 
 
V - Miniprep and determination of plasmid concentration. 
Plasmids are purified from 2 ml of overnight culture by harvesting at 12000 x g for 1 
minute. The plasmids are purified with the ”GenEluteTM Plasmid Miniprep Kit from Sigma 
by following the provided protocol. They are eluted in 100 µl H2O.  
 
The plasmids are controlled for insert by restriction with EcoRI and XmaI. 
 
Restriction reaction: 2 µl plasmid preparation 
  1 µl  10 x Cfr9I buffer (buffer for XmaI) 
  0.5 µl 10 U/ml XmaI 
  0.5 µl 10 U/ml EcoRI 
  6 µl H2O 
 
Plasmids are incubated with restriction enzyme for 1 hour at 37°C, and all 10 µl is loaded 
on an agarose gel. It is checked that all plasmids contain an insert of the correct size, 
and the approximate plasmid concentration can be determined by comparing the 
intensity of the bands to the marker on the gel.  
 
 
VI - Sequencing of mutated TK1-genes in the pGEX-2T vector 
In some cases, sequencing was carried out on location as described in the procedure 
below, and in other cases the service of MWG Biotech Germany was used. Approximately 
1 µg of each plasmid were dried at 60 °C and shipped to the following address: MWG 
Biotech AG, Frauenhoferstr. 22, 82152 Martinsried, Germany (website: www.MWG-
boitech.com). 
 
Plasmids sequenced on location were prepared for sequencing by the BigDye® 
Terminator v1.1 Cycle Sequencing Kit from Applied Biosciences. The procedure was in 
accordance with the kit protocol. 
Two reactions are performed with each plasmid, one with a 5`-primer and one with a 3`-
primer that anneal on separate sides of the 2T multi-cloning site in the pGEX vector. 
After preparation the samples were sequenced by the ABI PRISM® 310 system for 
sequencing and fragment analysis.4 
 
  
VII - Preparation of Epicurian coli BL21 competent cells. 
A BL21 glycerol culture is inoculated to 5 ml LB-medium and incubated in a 37°C water 
bath with shaking overnight. 4 ml of the ON culture is transferred to 100 ml LB-medium 
and the new culture is left to grow at 37°C until OD600 = 1-1.5. The cells are harvested in 
a Sorvall centrifuge at 8000 rpm and 4 °C for 1 min. The supernatant is discarded, and 
the pellet is resuspended in 50 ml sterile ice-cold 50 mM CaCl2 and incubated on ice/in 
water bath for 30 min. The cells are harvested again by centrifugation at 8000 rpm and 4 
°C for 1 min., and the pellet is resuspended in 5 ml 50 mM ice cold CaCl2. The cells are 
incubated on ice for one hour, and can be used right away or stored in small portions in 
12.5 % glycerol at -80 °C. 
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VIII - Transformation of plasmids to Epicurian coli BL21 competent cells. 
1µl plasmid from plasmid preparation is carefully mixed with 100 µl competent BL21 in a 
sterile test tube on ice. In another test tube only BL21 is added for control of the 
bacteria. The tubes are incubated on ice for 30 min. and heat-shocked for 2 min. at 42°C. 
After heat-shock they are placed on ice for 2 min. 1 ml preheated LB-medium is added, 
and the tubes are incubated at 37°C for 60 min. 20 µl and 100 µl of the each tube is 
plated on each their half of an LB-ampicillin plate. From the control tube 20 µl and 100 µl 
BL21 are plated on a LB and LB-ampicillin plate, respectively. The two plates with non-
transformed BL21 are a control of bacterial growth (LB plate) and unwanted ampicillin 
resistance (LB-ampicillin plate). The plates are incubated at 37°C overnight. 
 
 
IX - IPTG induction of BL21 cultures. 
A colony from each of the plates containing the transformants is inoculated to tubes 
containing 5 ml LB-medium and 100 µg/ml ampicillin, and the tube is placed in a 37°C 
water bath with shaking for 5-6 hours. The culture is transferred to a 500 ml erlenmeyer 
flask containing 100 ml LB-medium with 100 µg/ml ampicillin. This culture is incubated 
overnight in a 37°C water bath with shaking. 30 ml of the ON culture is transferred to a 1 
L erlenmeyer flask containing 250 ml LB-medium with100 µg/ml ampicillin. And OD600 is 
measured. If OD600 is not between 0.5 and 0.6 the flask is incubated at 37°C until this 
value is reached. The flask is transferred to a 25°C water bath and left for 10-15 minutes 
for the temperature to adjust. 
At time 0 h just prior to induction, 2 ml culture is harvested (5 min at 20,000 G and 4°C) 
and OD600 is measured. The induction is initiated by adding IPTG to a concentration of 
0.1 mM. The time from dilution of the ON culture to induction should not exceed one 
hour. Time samples are taken for harvest and OD600 at appropriate times during the 
induction. The pellets are lysed by sonication right away or stored at -80 °C. 
 
For first-time inductions the protein production and bacterial growth are followed by 
taking out time samples as described above. When the optimal induction time has been 
determined a new culture is induced with IPTG with the purpose of harvesting the whole 
culture for purification of protein. This main culture is harvested in a Sorvall centrifuge at 
4000 rpm and 4 °C for 15 min., and is lysed in the French press as described in section 
XIV. 
Glycerol stock cultures are prepared by mixing 900 µl of the ON culture with 900 µl 87 % 
glycerol, and they are stored at -80°C. 
 
 
X - Lysis of time samples by sonication.  
Lysis buffer:  1 x PBS 
 10 % Glycerol 
 5 mM EDTA 
 1 % Triton X-100  
 5 mM DTT 
 150 µg/ml Lysozyme 
 0.1 mM PMSF 
 5 mM Benzamidine 
 50 mM ε-amino capronic acid 
 
The pellet from the time samples are suspended in 400 µl lysis buffer and sonicated on 
ice for 3 x 5 seconds with 1 min. intervals. The samples are centrifuged for 10 min. at 
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20,000 G and 4°C and the supernatant is transferred to new e-tubes. The pellet is 
discarded. 
 
 
XI - Bradford – determination of protein concentration. 
A Bradford standard curve is produced with the following concentrations of BSA: 10, 20, 
30, 40, 50, 60, 80, 100 and 120 µg/ml. 100 µl of each concentration is transferred to a 
cuvette, and 900 ml Bradford reagent is added. A595 is measured after 5 minutes with 
100 µl H2O and 900 µl Bradford reagent as a reference. 
 
The sample is diluted appropriately, 100 µl is transferred to a cuvette, and 900 µl 
Bradford reagent is added. Again, A595 is measured after 5 minutes, and the protein 
content in the sample can be determined from the BSA standard curve. The A595 reading 
of the sample should lie in the linear interval of the standard curve. 
 
 
XII - SDS-page gel electrophoresis 
SDS-gels have been pre-fabricated from Biorad or made by the following procedure. 
 
Lower gel:  2 ml 1.5 M Tris/Cl pH 8.8 
  3.33 ml 30 % Acryl amide 
  80 µl 10 % SDS 
  160 µl 10 Ammonium persulfate 
  2.42 ml H2O 
4.7 µl  TEMED 
 
Upper gel:  375 µl 1.5 M Tris/Cl pH 6.8 
  498 µl 30 % Acryl amide 
  30 µl 10 % SDS 
  60 µl 10 Ammonium persulfate 
  2.03 ml H2O 
3 µl TEMED 
 
 
6 × Loading buffer:  25% Glycerol 
1% SDS 
0.6 M DTT 
0.125 M TRIS-HCl pH 6.8  
0.01% Bromo phenole blue 
 
5 × Running buffer:  15 g Tris-base 
   72 g Glycine 
   5 g SDS 
   Dissolve in H2O to a final volume of 1000 ml 
   Dilute 5 times before use 
 
 
Coomassie Brilliant Blue solution:  1g Coomassie Brilliant Blue G-250 
    250 g ice dissolved in 450 ml 96% ethanol  
    424 ml H2O 
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SDS molecular weight markers: 
 
PageRulerTM Protein Ladder (Fermentas): 
10; 15; 20; 25; 30; 40; 50; 60; 70; 85; 100; 120; 150; 200 kDa 
 
Protein Molecular Weight Marker (Fermentas): 
14.4; 18.4; 25; 35; 45; 66,2 og 116 kDa.  
 
The gel is cast by first pouring the separation gel between two glass plates and carefully 
covering the surface with water. The gel is left to set, and when it has congealed the 
water is removed. The upper gel is poured on top of the separating gel, and a comb is 
inserted between the plates at the top of the gel in order to create wells for sample 
loading. The gel is ready for use when the upper gel has congealed.   
 
The gel (prefabricated or home made) is submerged in running buffer, and the samples 
and markers are loaded in the wells. Prior to loading the samples should be mixed with 6 
x loading buffer and preheated to 95 °C for approx. 2 min. in order to denature proteins. 
The voltage is set to 80 V, and is eventually raised to 120 V when the proteins enter the 
separating gel. 
 
The gel is stained with Coomassie Brilliant Blue solution for a minimum 15 min., and 
sometimes overnight and destained with boiling water until the protein bands appear 
clearly. 
 
 
XIII - Thymidine assay 
Radioactive dThd is from Moravek or PerkinElmer. 
 
Ammonium formiate 5 mM 
Elution liquid: 0,2 M KCl in 0,1 M HCl  
Scintillation liquid ECO-SCINT 
 
Enzyme-dilution buffer:  50 mM Tris-HCL (pH 7.5) 
1 mM CHAPS 
3 mg/ml BSA 
5 mM MgCl2  
H2O 
 
10 × MIX:   0.5 M Tris-HCL (pH 7.5) 
0.1 M DTT 
0.025 M ATP 
0.025 M MgCl2 
H2O 
 
Assay mix (one assay):  5 µl 10 × MIX 
2.5 µl 60 mg/ml BSA 
1 µl 0.15 M NaF 
1 µl 25 mM CHAPS 
1 µl 5 mM 0.18 Ci/mmol 3H-Thd 
29.5 µl H2O 
 
The enzymes are diluted in enzyme dilution buffer, and 10 µl of each enzyme dilution are 
transferred to an assay tube. The reaction is started by adding 40 µl assay mix resulting 
in a final 3H-Thd concentration of 100 µM and placing the tube in a 37°C water bath. 13 
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µl of the reaction mixture is transferred to marked DE81 filters at three different times 
(i.e. 5, 10 and 15 minutes). 5 µl reaction mixtures are also transferred from four random 
tubes to four standard filters in order to determine the number of radioactivity counts 
corresponding to a certain dThd concentration. The standard filters are not washed. All 
other filters are first left to dry for approx. 15 min. and then washed 3 × 5 min. with 400 
ml 5 mM ammonium formiate and 1 × 5 min. with 400 ml H2O. 
After washing, the filters are transferred to scintillation tubes, and 500 µl elution liquid is 
added. The product is eluted from the filters after approx. 30 min of shaking. 2.5 ml 
scintillations liquid ECO-SCINT is added in the fume hood, and the tubes are closed and 
mixed by inverting. The amount of substrate spotted on the filter is determined by 
radioactivity counting in a scintillation counter.  
 
 
XIV - Lysis of cells in the French press 
Lysis buffer for French press:  10 % Glycerol 
   5 mM EDTA 
   1 % Triton X-100  
   5 mM DTT 
   0.1 mM PMSF 
   5 mM Benzamidine 
  50 mM ε-amino capronic acid 
  
The harvested cells are resuspended on ice in lysis buffer (1/20 of the harvested 
volume). The resuspended bacteria are disrupted by running them through the French 
press three times, and the resulting solution is centrifuged at 20,000 G and 4°C for 15 
min. The supernatant is subsequently filtered through 1 µm and 0.45 µm filters, and 100 
µl of the bacterial homogenate is stored for later analysis before purifying the protein on 
a GSH column. The homogenate is abbreviated CBH for crude bacterial homogenate. The 
harvested culture volumes are 1080 ml for CeTK1-C∆57, 460 ml for CeTK1-S182T and 
CeTK1-S182A, 270 ml for CeTK1-L143A and 230 ml for CeTK1-M42I, HuTK1-C∆41-T163S, 
HuTK1-C∆41-L124A and HuTK1-C∆41-M28I. 
 
XV - Purification of proteins on GSH column 
1 × PBS wash buffer: 1 × PBS 
1 mM DTT 
10 % Glycerol 
0.1 % Triton X-100 
0.1 mM PMSF 
5 mM Benzamidine 
50 mM ε-amino capronic acid 
5 mM MgCl2 
H2O 
 
Thrombin cleavage buffer: 1 x PBS 
  0.1 % Triton X-100 
  50 u/ml Thrombin 
 
Glycerol buffer: 30 % Glycerol 
  3 % Triton X-100  
15 mM DTT 
15 mM MgCl2 
H2O 
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(0.3 % Triton is better in the case of low-protein yield since Triton interferes with 
Bradford protein determination and with Experion automated electrophoresis) 
 
10 x PBS:  1.4 M NaCl 
27 mM KCl 
100 mM Na2HPO4 
18 mM KH2PO4 
pH 7.3 
 
Reduced GSH buffer: 50 mM Tris-HCl (pH 8.0) 
   10 mM Reduced glutathione (GSH) 
 
The protein is purified from the CBH on a GSH affinity column.  
 
CBH is diluted in 1 x PBS wash buffer (2:1) and applied on the column at 4°C with a drop 
speed of 4-6 drops per minute. The flow-through is collected (SET), and 100 µl is stored 
for later analysis. From all of the following fractions 100-200 µl is saved for analysis. 
The column is then washed 5 times with 10 ml (10 bed volumes) of 1 × PBS- wash buffer 
with full flow. The wash fractions are named W1-W5. 
The column is equilibrated with 10 ml (10 bed volumes) 1 × PBS (full flow), and the flow-
through is collected as the EQ fraction. 
The column is moved to room temperature, and 3 ml thrombin cleavage buffer is applied 
on the column and is recirculating with 4-6 drops per minute with the tube placed on ice. 
The recirculation time varies from 3-15 hours, and finally the first cleavage fraction 
containing the protein is collected (CL1). Two times 2 ml of 1 × PBS/0.1 % Triton X-100 
is applied to the column. It flows trough with 4-6 drops per minute, and is collected on 
ice as cleavage fractions 2 and 3 (CL2, CL3). The GST bound to the column material is 
washed out with 3 ml (3 bed volumes) of reduced GSH buffer and collected on ice as 
fraction GSH. 
To the fractions EQ, CL1-3 and GSH Glycerol buffer is added (1/3 of the fraction volume), 
and 100-200 µl is saved for analysis. The fractions can be stored at 80°C. 
 
Note: In the purification of CeTK1-C∆57 an additional ATP wash was performed with 2½ 
column volume 1 × PBS wash buffer + 10 mM ATP/MgCL2 prior to column equilibration. 
The collected fraction (ATP) was also added glycerol buffer. 
 
The input and collected volumes (in ml) are listed in the table below (with the exception 
of all W3-5 fractions since they are all approx. 10 ml and contain no measurable protein) 
 
 CeTK1 HuTK1-C∆41 
 C∆57 S182T S182A L143A M42I T163S L124A M28I M28A 
Column 
volume 3 1 1 1 1 1 1 1 1 
CBH 50 15.5 20 9 12.5 13.5 11 12 11.5 
SET 52 30 39 26 35.5 40 32 36 32 
W1 30 9.9 10.5 10.1 10 10 11.5 10 10 
W2 30 10 10 10 10 10.1 10.4 10 10 
ATP 9.9 - - - - - - - - 
EQ 45 19.8 16.4 14.85 14.85 15 15 15 15 
Cl1 4.5 4.5 4.5 4.2 3.9 3.9 4.35 4.5 4.5 
CL2 9 3 3 3 3 2.85 3 3 3 
CL3 9 3 3 3 3 3 2.85 3 3 
GSH 14.25 4.5 4.5 4.8 4.5 4.8 4.8 4.5 4.5 
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Most of the collected fractions are analyzed for protein concentration by the Bradford 
method (section XI), size of proteins on an SDS gel (section XII) and for dThd activity by 
a thymidine assay (section XIII). 
 
 
XVI - Experion automated gel electrophoresis 
Procedure according to the instruction manual [ExperionTM Pro260 Analysis Kit Instruction 
Manual]. All enzymes were diluted 20 times prior to Experion analysis. 
  
 
XVII - ATP-incubation of CeTK1-WT and  CeTK1-C∆57 
ATP-incubation buffer: 50 mM Tris-HCl (pH 7.5) 
  5 mM MgCl2 
  0.1 M KCl 
  2 MM CHAPS 
  10 % Glycerol 
  5 mM DTT 
  2.5 mM ATP (replaced with H2O for –ATP incubated TK1’s) 
  1.9 µg/ml CeTK1-WT or 2.0 µg/ml CeTK1-C∆57 
 
The enzymes were incubated in the buffer with or without ATP for two hours on ice and 
stored at –80 °C. 
 
 
XVIII - Gel filtration on Superdex-200 column 
The native molecular mass of CeTK1-WT (incubated with and without ATP), HuTK1-
C∆41-M28I, and –M28A were determined on a Superdex-200 column connected to an 
ÄKTAprimeTM automatic sampler. 
 
IMK buffer: 50 mM Imidazole-HCl 
  5 mM MgCl2 
  0.1 M KCl 
  5 mM DTT 
  2 mM CHAPS 
 
DTT and CHAPS are added just prior to the experiment.  
The column was equilibrated and eluted with IMK buffer. The following standard proteins 
were injected onto the column together with Blue Dextran 2000 in order to create a MW 
standard curve: β-amylase (200 kDa), bovine serum albumin (66 kDa), Ovalbumin (45 
kDa), carbonic anhydrase (29 kDa),and cytochrome C (12.4 kDa). Protein samples were 
diluted appropriately in IMK buffer, and 400 µl samples were loaded onto the column 
together with 8 µl 10 mg/ml Blue Dextran 2000 as an internal standard. 200 µl aliquots 
were collected and immediately transferred to an ice bath. To each tube was added 100 
µl IMK-buffer with 30 % glycerol and 2 mM MgCl2. All fractions were assayed with dThd 
as described in section XIII in order to determine the elution volume of the TK1. 
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XIX - Specificity assay with the substrates dThd, dCyd, dAdo, dGuo, AZT, and 
AraC 
All fractions from the purification, with the exception of the last three wash fraction, are 
assayed for dThd activity, and the CL1 fractions are also assayed for dCyd, dAdo, dGuo, 
AZT and AraC activity. 
 
Recipes for 10 × MIX and enzyme dilution buffer is shown in section XIII. 
 
Assay mix (one assay):  5 µl 10 × MIX 
2.5 µl 60 mg/ml BSA 
1 µl 0.15 M NaF 
1 µl 25 mM CHAPS 
X µl radio labelled substrate 
H2O to a final volume of 40 µl 
 
The different substrates are added to the assay mix to a final concentration in the assay 
(vol. = 50 µl) of 100 µM. In the dThd and AZT assays 1 µl 5 mM 0.18 Ci/mmol 3H-
Thd/AZT is added per assay, and in the dCyd, dAdo, dGuo and AraC assays 10 µl 0.5 mM 
1.8 Ci/mmol 3H-dCyd/dAdo/dGuo/AraC is added per assay.  
All radioactive substrates are from Moravek, and radioactive dThd is from Moravek or 
PerkinElmer. 
 
The enzymes are diluted appropriately in enzyme dilution buffer, and the reaction is 
started by adding 40 µl assay mix to 10 µl of enzyme dilution, resulting in a substrate 
concentration of 100 µM. The tube is placed in a 37°C water bath. 13 µl reaction mixture 
is spotted on marked DE81 filters at three different times within the interval of steady-
state. For the dThd and AZT assays time samples are taken after 5, 10, and 15 min., but 
with the poorer substrates the times are extended to 10, 20, and 30 min. in order to get 
better correlations on the progress curves. From four tubes of each substrate 5 µl 
reaction mixture is added to standard filters. All filters except from the standards are left 
to dry for approx. 15 minutes and then washed. 
 
Filters from dThd, dGuo, dAdo and AZT assays are washed 3 × 5 min. with 400 ml 5 mM 
ammonium formiate and 1 × 5 min. with 400 ml H2O. The filters from dCyd and AraC 
assays are washed 3 × 5 min in 400 ml 1 mM ammonium formiate and 1 × 5 min. in 400 
ml H2O. 
 
After washing the filters are transferred to scintillation tubes, and 500 µl elution liquid is 
added. The product is eluted from the filters after approx. 30 min of shaking. 2.5 ml 
scintillation liquid, ECO-SCINT, is added in the fume hood, and the tubes are closed and 
mixed by inverting before counting in the scintillation counter.  
 
 
XX - Enzyme kinetics assay with selected substrates and enzymes 
10-16 substrate dilutions are made in order to cover the concentration range from well 
below and well above Km for the different enzyme/substrate combinations. Substrates are 
diluted in H2O, and the enzymes are diluted appropriately in enzyme dilution buffer. No 
more than 10-20 % of the substrate should be consumed during the reaction. 
 
Recipes for 10 × MIX and enzyme dilution buffer is shown in section XIII. 
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Assay mix (one assay):  5 µl 10 × MIX 
2.5 µl 60 mg/ml BSA 
1 µl 0.15 M NaF 
1 µl 25 mM CHAPS 
10 µl TK1 dilution 
H2O to a final volume of 25 µl 
 
The reaction is started by adding 25 µl assay mix to 25 µl of substrate dilution, and the 
rest of the assay is performed at described in the previous section. Time samples vary 
with the individual assays. 
 
 
XXI - ATP-activation of CeTK1-WT 
The dependence of the ATP-activation on incubation time was determined by incubating 
CeTK1-WT in the ATP-incubation buffer listed in section XVII. Just prior to ATP addition a 
5 µl sample is diluted to an assay concentration of 3.4 ng/ml CeTK1-WT, and assayed 
with 50 µM dThd as described in section XIII. Upon ATP addition another sample is 
diluted and assayed accordingly, and within 140 minutes a total of 9 time samples taken 
after ATP addition were assayed. 
 
The dependence of the ATP-activation on CeTK1-WT concentration was also determined 
by incubating the enzyme in the ATP-incubation buffer (both with and without ATP) listed 
in section XVII, but with varying concentrations of enzyme. 7 different enzyme 
concentrations were tested in the range 0.017 to 3.9 µg/ml. The enzyme was left to 
incubate in the buffer on ice for 5 minutes and was then assayed with 50 µM dThd. Just 
prior to the assay all incubated enzymes were diluted to the assay concentration, 3.4  
ng/ml. The assay was performed as described in section XIII. 
 
The variation of reaction velocity with ATP concentration was determined at a fixed dThd 
concentration of 100 µM and ATP concentrations ranging from 0.5 to 20 µM 
 
Recipes for 10 × MIX and enzyme dilution buffer is shown in section XIII. 
 
Assay mix (one assay): 5 µl 10 × MIX without ATP/MgCL2 
2.5 µl 60 mg/ml BSA 
1 µl 0.15 M NaF 
1 µl 25 mM CHAPS 
25 mM MgCl2 
10 µl 0.5 mM 1.8 Ci/mmol 3H-Thd 
10 µl CeTK1-WT dilution 
4.25 µl H2O 
 
The reaction is started by adding 35 µl assay mix to 15 µl of ATP dilution, and the rest of 
the assay is performed as described in section XIX. 
 
 
XXII - Stability 
The stability of CeTK1-WT and –C∆57 is determined by diluting the enzymes in the ATP-
incubation buffer (with and without ATP) listed in section XVII and leaving one of each 
sample at 4 °C and one of each at room temperature. For the protein at 4 °C four time 
samples were taken and assayed during 200 hours of incubation, and for protein at room 
temperature five samples were taken and assayed during 330 hours of incubation. 5 µl of 
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each sample was diluted appropriately and assayed with 100 µM dThd as described in 
section XIII 
 
 
XXIII - Progress curve with radio assay 
Recipes for 10 × MIX and enzyme dilution buffer is shown in section XIII. 
 
Assay mix:  20 µl 10 × MIX 
10 µl 60 mg/ml BSA 
4 µl 0.15 M NaF 
4 µl 25 mM CHAPS 
6 µl 5 mM 0.18 Ci/mmol 3H-Thd  
H2O to a final volume of 160 µl 
 
The reaction is started by addition of 40 µl CeTK1 in the appropriate dilution. 13 time 
samples of 10 µl were spotted on DE81 filters from time 0 to 75 min and subsequently, 
four standard samples of 5 µl were spotted on separate filters not to be washed. 
Washing, elution and scintillation counting of time samples were performed as described 
in section XIII. The progress curve was analyzed by the integrated Michaelis-Menten 
equation. 
 
 
XXIV - Progress curves with spectrophotometric assays 
Assay mix:  50 mM Tris/HCl pH 7.8 
  5 mM MgCl2 
  0.1 M KCl 
  0.15 mM ATP 
  2.2 u/ml Pyruvate kinase 
  3.1 u/ml Lactate dehydrogenase 
  0.15 mM NADH 
  0.5 mM Phosphoenol pyruvate 
  X µM dThd 
  H2O to a final volume of 400 µl 
 
The assay was started by addition of CeTK1-WT in the appropriate dilution, and the 
reaction was monitored by measuring the decrease in NADH spectrophotometrically at 
340 nm. When the dThd has all been converted to dTMP the reaction is stopped, and the 
progression curve is analyzed by the integrated Michaelis-Menten equation. 
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Appendix B – Nucleotide sequencing results 
 
 
 
CLUSTAL X (1.83) multiple sequence alignment of nucleic acid sequences from 
CeTK1 mutants 
 
All genes in the multi-cloning site of the pGEX-2T vector are sequenced both in the 
forward and reverse direction applying the vector specific primers pGEX-for and pGEX-
rev. The resulting sequences are shown below in a multiple sequence alignment with the 
wild type CeTK1 (Ncbi number: NM_069485). 
 
The reverse sequence reaction with CeTK1-S182T displays three mismatches in the 
beginning of the sequence (above the missing *) that are not observed for the forward 
sequence reaction. By viewing the chromatogram below it becomes evident that the 
mismatches are most likely due to interpretation errors by the peak translation program. 
 
 
 
 
 
Successful mutations are marked in the sequences by a box, _. The * below the 
sequences denotes matching nucleotides. 
 
 
 
 
WT              -------------------ATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
M42I-for        CGCGTGGATCCCC--GGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
M42I-rev        CGCGTGGATCCCC--GGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
L143A-for       -GCGTGGATCCCC--GGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
L143A-rev       CGCGTGGATCCCC--GGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
S182A-for       ---------------------------------GGCCAAGAATGAG-ATGACTTGCTGCT 
S182A-rev       CGCGTGGATCCCC--GGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
S182T-for       CGCGTGGATCCCC--GGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
S182T-rev       CGCGGGGATCCCCCGGGGCAGGGACATTGAAGCGGCCAAGAATGAGGATGACTTGCTGCT 
C∆57-for        CGCGCGTGGATCCCCGGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT  
C∆57-rev        CGCGCGTGGATCCCCGGGCATGGACATTGAAGCGGCCAAGAATGAG-ATGACTTGCTGCT 
                                   * ************************* ************* 
 
 
 
WT              CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
M42I-for        CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
M42I-rev        CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
L143A-for       CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
L143A-rev       CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
S182A-for       CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
S182A-rev       CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
S182T-for       CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
S182T-rev       CGTACAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
C∆57-for        CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT  
C∆57-rev        CGTCCAATTCATCTCTATCAGATTTCAACACTTTGCCCAGATGCCCGAATCGTGTTGGCT 
                *** ******************************************************** 
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                                       M42 
WT              CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
M42I-for        CTATCACTGTTATTCTGGGGCCAATTTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
M42I-rev        CTATCACTGTTATTCTGGGGCCAATTTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
L143A-for       CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
L143A-rev       CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
S182A-for       CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
S182A-rev       CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
S182T-for       CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
S182T-rev       CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
C∆57-for        CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
C∆57-rev        CTATCACTGTTATTCTGGGGCCAATGTTCAGTGGCAAAACCACCGAACTTCTTCGTCTTC 
                ************************* ********************************** 
                                        I 
 
 
WT              ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
M42I-for        ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
M42I-rev        ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
L143A-for       ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
L143A-rev       ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
S182A-for       ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
S182A-rev       ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
S182T-for       ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
S182T-rev       ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
C∆57-for        ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
C∆57-rev        ATGATCGTCAGATAATTGCAAAAAGAACATGTGTTCTTGTCAAGTATGCAGGAGACACTC 
                ************************************************************ 
 
 
 
WT              GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA  
M42I-for        GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA  
M42I-rev        GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
L143A-for       GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
L143A-rev       GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
S182A-for       GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
S182A-rev       GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
S182T-for       GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
S182T-rev       GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
C∆57-for        GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
C∆57-rev        GTTACGATGCCGATCTCGTGGCTACTCATAGCAAGATGACTGGCCAGGGACGGACTGTCA 
                ************************************************************ 
 
 
 
WT              AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
M42I-for        AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
M42I-rev        AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
L143A-for       AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
L143A-rev       AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
S182A-for       AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
S182A-rev       AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
S182T-for       AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
S182T-rev       AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
C∆57-for        AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
C∆57-rev        AGGCTCATCGTCTCTCTGAAGTTCAATCTCAGATCTTCAACGATGAGGTTCAAGTCGTTT 
                ************************************************************ 
 
 
 
WT              CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
M42I-for        CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
M42I-rev        CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
L143A-for       CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
L143A-rev       CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
S182A-for       CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
S182A-rev       CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
S182T-for       CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
S182T-rev       CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
C∆57-for        CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
C∆57-rev        CGATTGACGAGGGACAGTTCTTTGAAGATCTCGCCGAAACTTGCGAAGAACTTGCTCAAA 
                ************************************************************ 
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                                          L143 
WT              GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
M42I-for        GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
M42I-rev        GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
L143A-for       GAGGGAAAGTTGTTTGTGTCGCTGCAGCCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
L143A-rev       GAGGGAAAGTTGTTTGTGTCGCTGCAGCCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
S182A-for       GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
S182A-rev       GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
S182T-for       GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
S182T-rev       GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
C∆57-for        GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
C∆57-rev        GAGGGAAAGTTGTTTGTGTCGCTGCACTCAATGGAACATTCGAGAGAAAGCCGTTCCCAC 
                **************************  ******************************** 
                                           A 
 
 
WT              AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
M42I-for        AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
M42I-rev        AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
L143A-for       AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
L143A-rev       AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
S182A-for       AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
S182A-rev       AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
S182T-for       AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
S182T-rev       AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
C∆57-for        AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
C∆57-rev        AAATTTCTTTGCTACTTCCGTACGCGAATGAAATCAAGCAAGTTACCGCTGTATGTGTCG 
                ************************************************************ 
 
 
                                       S182 
WT              AATGCGGATCGCAAGCAAACTTCTCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
M42I-for        AATGCGGATCGCAAGCAAACTTCTCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
M42I-rev        AATGCGGATCGCAAGCAAACTTCTCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
L143A-for       AATGCGGATCGCAAGCAAACTTCTCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
L143A-rev       AATGCGGATCGCAAGCAAACTTCTCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
S182A-for       AATGCGGATCGCAAGCAAACTTCGCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
S182A-rev       AATGCGGATCGCAAGCAAACTTCGCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
S182T-for       AATGCGGATCGCAAGCAAACTTCACATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
S182T-rev       AATGCGGATCGCAAGCAAACTTCACATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
C∆57-for        AATGCGGATCGCAAGCAAACTTCTCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
C∆57-rev        AATGCGGATCGCAAGCAAACTTCTCATTCCGCAGCACATTGGACAAAAAGGTTGAGGTGA 
                *********************** ************************************ 
                                       A/T 
 
                                                                        E213 
WT              TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
M42I-for        TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
M42I-rev        TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
L143A-for       TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
L143A-rev       TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
S182A-for       TCGGAGGTTCGGACACTTATACAGCTCTC------------------------------- 
S182A-rev       TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
S182T-for       TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
S182T-rev       TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCGAAG 
C∆57-for        TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCTAAG 
C∆57-rev        TCGGAGGTTCGGACACTTATACAGCTCTCTGCAGAGAATGTTATGTTCAAAAGAGCTAAG 
                ******************************************************** ***                              
                                                                        Stop 
 
 
WT              AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
M42I-for        AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
M42I-rev        AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
L143A-for       AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
L143A-rev       AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
S182A-for       ------------------------------------------------------------ 
S182A-rev       AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
S182T-for       AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
S182T-rev       AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
C∆57-for        AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
C∆57-rev        AAAAAGATGCTGAAGAACAGATGAAAACTGGTTGTGATAAGAACGAAAACGATATTACTG 
                ************************************************************  
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WT              GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
M42I-for        GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
M42I-rev        GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
L143A-for       GGAT-------------------------------------------------------- 
L143A-rev       GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
S182A-for       ------------------------------------------------------------ 
S182A-rev       GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
S182T-for       GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
S182T-rev       GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
C∆57-for        GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
C∆57-rev        GGATTTTCTTGGCGAAAAAAGAGCAAAGATCTGATGGATCCGTGTCTCCTCCACGAAAGA 
                ************************************************************                         
 
 
WT              AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAA---------- 
M42I-for        AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAAGAATTCATCG 
M42I-rev        AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAAGAATTCATCG 
L143A-for       ------------------------------------------------------------ 
L143A-rev       AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAAGAATTCATCG 
S182A-for       ------------------------------------------------------------ 
S182A-rev       AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAAGAATTCATCG 
S182T-for       AAATCGGATTGAGCAAGTCAATGGCTCTGGA----------------------------- 
S182T-rev       AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAAGAATC----- 
C∆57-for        AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAAGAATTCATCG 
C∆57-rev        AAATCGGATTGAGCAAGTCAATGGCTCTGGAGGCCACAGCTCGGACTTAAGAATTCATCG 
                **************************************************  
 
 
 
 
CLUSTAL X (1.83) multiple sequence alignment of nucleic acid sequences from 
HuTK1-C∆41 mutants 
 
All genes in the multi-cloning site of the pGEX-2T vector are sequenced both in the 
forward and reverse direction applying the vector specific primers pGEX-for and pGEX-
rev. The resulting sequences are shown below in a multiple sequence alignment with the 
wild type HuTK1 (Ncbi number: NM_003258, but codon ATG for M106 is manually 
changed to codon GTG for V106 which is the correct amino acid in this position according 
to Berenstein et al., 2000).  
 
The reverse sequence reaction with HuTK1-C∆41-M28I displays one mismatch in the 
beginning of the sequence (above the missing *) which is not observed for the forward 
sequence reaction. By viewing the chromatogram below it becomes evident that the 
mismatch is most likely due to interpretation errors by the peak translation program. 
 
 
  
 
Successful mutations are marked in the sequences by a box, _, as are the stop codon 
mutation creating the C∆41 enzymes. The * below the sequences denotes matching 
nucleotides.  
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WT              ---------------------------------------------------ATGAGCTGC 
M28A-for        ----------------------------CGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
M28A-rev        TTTGGTGGTGGCGACCATCGTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
M28I-for        --------------------------------------TCCGCGTGGATC-ATGAGCTGC 
M28I-rev        TTTGGTGGTGGCGACCTTCCTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
L124A-for       -----------------------------GGATCTGGTTCCGCGTGGATCCATGAGCTGC 
L124A-rev       TTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
T163S-for       ----------------------------CGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
T163S-rev       TTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
T163A-for       --------------------------ATCGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
T163A-rev       TTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGAGCTGC 
                                                                   ********* 
 
 
 
WT              ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
M28A-for        ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
M28A-rev        ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
M28I-for        ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
M28I-rev        ATTAACCTGCCTCACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
L124A-for       ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
L124A-rev       ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
T163S-for       ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
T163S-rev       ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
T163A-for       ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
T163A-rev       ATTAACCTGCC-CACTGTGCTGCCCGGCTCCCCCAGCAAGACCCGGGGGCAGATCCAGGT 
                *********** ************************************************ 
 
 
                             M28 
WT              GATTCTCGGGCCGATGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
M28A-for        GATTCTCGGGCCGGCGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
M28A-rev        GATTCTCGGGCCGGCGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
M28I-for        GATTCTCGGGCCGATCTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
M28I-rev        GATTCTCGGGCCGATCTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
L124A-for       GATTCTCGGGCCGATGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
L124A-rev       GATTCTCGGGCCGATGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
T163S-for       GATTCTCGGGCCGATGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
T163S-rev       GATTCTCGGGCCGATGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
T163A-for       GATTCTCGGGCCGATGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
T163A-rev       GATTCTCGGGCCGATGTTCTCAGGAAAAAGCACAGAGTTGATGAGACGCGTCCGTCGCTT 
                *************   ******************************************** 
                             A/I 
 
 
WT              CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
M28A-for        CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
M28A-rev        CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
M28I-for        CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
M28I-rev        CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
L124A-for       CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
L124A-rev       CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
T163S-for       CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
T163S-rev       CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
T163A-for       CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
T163A-rev       CCAGATTGCTCAGTACAAGTGCCTGGTGATCAAGTATGCCAAAGACACTCGCTACAGCAG 
                ************************************************************ 
 
 
 
WT              CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
M28A-for        CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
M28A-rev        CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
M28I-for        CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
M28I-rev        CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
L124A-for       CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
L124A-rev       CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
T163S-for       CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
T163S-rev       CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
T163A-for       CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
T163A-rev       CAGCTTCTGCACACATGACCGGAACACCATGGAGGCGCTGCCCGCCTGCCTGCTCCGAGA 
                ************************************************************ 
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WT              CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
M28A-for        CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
M28A-rev        CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
M28I-for        CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
M28I-rev        CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
L124A-for       CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
L124A-rev       CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
T163S-for       CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
T163S-rev       CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
T163A-for       CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
T163A-rev       CGTGGCCCAGGAGGCCCTGGGCGTGGCTGTCATAGGCATCGACGAGGGGCAGTTTTTCCC 
                ************************************************************ 
 
 
                       V106  
WT              TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
M28A-for        TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
M28A-rev        TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
M28I-for        TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
M28I-rev        TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
L124A-for       TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
L124A-rev       TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
T163S-for       TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
T163S-rev       TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
T163A-for       TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
T163A-rev       TGACATCGTGGAGTTCTGCGAGGCCATGGCCAACGCCGGGAAGACCGTAATTGTGGCTGC 
                ************************************************************ 
 
 
                 L124 
WT              ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
M28A-for        ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
M28A-rev        ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
M28I-for        ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
M28I-rev        ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
L124A-for       AGCGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
L124A-rev       AGCGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
T163S-for       ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
T163S-rev       ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
T163A-for       ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
T163A-rev       ACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTGGC 
                *  ********************************************************* 
                  A 
 
                                                                          T163 
WT              CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAC 
M28A-for        CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAC 
M28A-rev        CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAC 
M28I-for        CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAC 
M28I-rev        CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAC 
L124A-for       CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAC 
L124A-rev       CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAC 
T163S-for       CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAG 
T163S-rev       CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATAG 
T163A-for       CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATGC 
T163A-rev       CGAGAGCGTGGTGAAGCTGACGGCGGTGTGCATGGAGTGCTTCCGGGAAGCCGCCTATGC 
                **********************************************************   
                                                                          S/A 
 
 
WT              CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
M28A-for        CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
M28A-rev        CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
M28I-for        CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
M28I-rev        CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
L124A-for       CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
L124A-rev       CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
T163S-for       CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
T163S-rev       CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
T163A-for       CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
T163A-rev       CAAGAGGCTCGGCACAGAGAAGGAGGTCGAGGTGATTGGGGGAGCAGACAAGTACCACTC 
                ************************************************************ 
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WT              CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTCAGGCCAGCCTGCCGGGCCGGACAACAA 
M28A-for        CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
M28A-rev        CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
M28I-for        CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
M28I-rev        CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
L124A-for       CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
L124A-rev       CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
T163S-for       CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
T163S-rev       CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
T163A-for       CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
T163A-rev       CGTGTGTCGGCTCTGCTACTTCAAGAAGGCCTGAGCTCAGCCTGCCGGGCCGGACAACAA 
                ******************************** **  *********************** 
         C∆41 
 
 
WT              AGAGAACTGCCCAGTGCCAGGAAAGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
M28A-for        AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
M28A-rev        AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTT-GC 
M28I-for        AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
M28I-rev        AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
L124A-for       AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
L124A-rev       AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTT-GC 
T163S-for       AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
T163S-rev       AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
T163A-for       AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
T163A-rev       AGAGAACTGCCCAGTGCCAGGAAGGCCAGGGGAAGCCGTGGCTGCCAGGAAGCTCTTTGC 
                *********************** ********************************* ** 
 
 
 
WT              CCCACAGCAGATTCTGCAATGCAGCCCTGCCAACTGA----------------------- 
M28A-for        CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAATTCATCGTGACTGACTGAC 
M28A-rev        CCCACAGCTGATTGGGCGAAGCGAGC---------------------------------- 
M28I-for        CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAATTCATCGTGACTGACTGAC 
M28I-rev        CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGATTCC---------------- 
L124A-for       CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAATTCATCGTGACTGACTGAC 
L124A-rev       CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAAT-CATC------------- 
T163S-for       CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAATTCATCGTGACTGACTGAC 
T163S-rev       CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAATTCATCGTGACTGACTGAC 
T163A-for       CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAATTCATCGTGACTGACTGAC 
T163A-rev       CCCACAGCAGATTCTGCAATGCATGCAAGCTTGATATCGAATTCATCGTGACTGACTGAC 
                ******** ****  ** * **   *                                    
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Appendix C – Alternative thrombin cleavage sites 
 
 
The common sequence for thrombin to cleave is LVPRGS where the cleavage occurs 
between R and G, but it has also been observed to cleave at the following alternative 
sequences [GST Gene Fusion System Handbook, Edition AA, Amersham Biosciences]: 
 
1) P4 P3 P R/K P1 P2 
 
Where P1 and P2 must not be acidic amino acids and P3 and P4 have to be 
hydrophobic amino acids. In this sequence thrombin can cleave between R/K and P1. 
 
 
2) P2 R/K P1 
 
Where P1 or P2 is Gly. Thrombin can cleave between R/K and P1. 
 
 
 
These are marked in the GST-CeTK1 sequence below. 
 
Linker sequence between GST and CeTK1: LVPRGSPG (The grey box marks the thrombin 
cleavage site) 
 
Full sequence of GST-CeTK1 linked by thrombin cleavage site (56.2 kDa) 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLT
QSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKM
FEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKY
IAWPLQGWQATFGGGDHPPKSDLVPRGSPGMDIEAAKNEMTCCSSNSSLSDFNTLPRCPNRVGSI
TVILGPMFSGKTTELLRLHDRQIIAKRTCVLVKYAGDTRYDADLVATHSKMTGQGRTVKAHRLSEV
QSQIFNDEVQVVSIDEGQFFEDLAETCEELAQRGKVVCVAALNGTFERKPFPQISLLLPYANEIKQ
VTAVCVECGSQANFSFRSTLDKKVEVIGGSDTYTALCRECYVQKSEEKDAEEQMKTGCDKNENDIT
GIFLAKKEQRSDGSVSPPRKKIGLSKSMALEATART 
 
C-term    24.8    54.8        30.0  ~14.7          35.5               19.7 
N-term    31.4    1.4         26.2  ~41.5        20.7               36.5 
 
The numbers below the sequence are the molecular masses in kDa of the N- and C-
terminal fragments that will result from cleavage in the different thrombin cleavage sites. 
 
The amino acids, M42, L143 and S182, which are mutated in this work, are underlined in 
the sequence. 
 
CeTK1-M42I and -L143A: Appeared on the electropherograms from automated 
electrophoresis as approx. 35 kDa subunits. Thrombin cleavage at AFPKLV in the GST 
protein results in a 35.5 kDa protein consisting of a full length CeTK1 attached to a 
fraction of GST in the N-terminal. 
 
CeTK1-S182T and -S182A: Appeared on the electropherograms from automated 
electrophoresis as approx. 41 kDa subunits. Thrombin cleavage at RGK inside the CeTK1 
protein results in a 41.5 kDa protein consisting of a full length GST protein attached to a 
fraction of CeTK1 in the N-terminal. This is unlikely to be a functional enzyme. 
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Appendix D - Alternative stop codons  
 
 
Below is shown a segment of the pGEX-2T vector harbouring the CeTK1 gene. The first 
part is the GST-coding region which is followed by the CeTK1 gene (shown with capital 
letters). After the CeTK1 gene are the deoxynucleotides in and after the multi-cloning site 
in pGEX-2T. Nucleotide numbering is from the pGEX-2T vector [Ncbi nr. U13850]. 
 
 
     ...tagtttg ttttaaaaaa cgtattgaag ctatcccaca aattgataag tacttgaaat 
 841 ccagcaagta tatagcatgg cctttgcagg gctggcaagc cacgtttggt ggtggcgacc 
 901 atcctccaaa atcggatctg gttccgcgtg gatccccggg cATGGACATT GAAGCGGCCA  
     AGAATGAGAT GACTTGCTGC TCGTCCAATT CATCTCTATC AGATTTCAAC ACTTTGCCCA  
     GATGCCCGAA TCGTGTTGGC TCTATCACTG TTATTCTGGG GCCAATGTTC AGTGGCAAAA 
     CCACCGAACT TCTTCGTCTT CATGATCGTC AGATAATTGC AAAAAGAACA TGTGTTCTTG 
     TCAAGTATGC AGGAGACACT CGTTACGATG CCGATCTCGT GGCTACTCAT AGCAAGATGA 
     CTGGCCAGGG ACGGACTGTC AAGGCTCATC GTCTCTCTGA AGTTCAATCT CAGATCTTCA 
     ACGATGAGGT TCAAGTCGTT TCGATTGACG AGGGACAGTT CTTTGAAGAT CTCGCCGAAA 
     CTTGCGAAGA ACTTGCTCAA AGAGGGAAAG TTGTTTGTGT CGCTGCACTC AATGGAACAT 
     TCGAGAGAAA GCCGTTCCCA CAAATTTCTT TGCTACTTCC GTACGCGAAT GAAATCAAGC 
     AAGTTACCGC TGTATGTGTC GAATGCGGAT CGCAAGCAAA CTTCTCATTC CGCAGCACAT 
     TGGACAAAAA GGTTGAGGTG ATCGGAGGTT CGGACACTTA TACAGCTCTC TGCAGAGAAT 
     GTTATGTTCA AAAGAGCGAA GAAAAAGATG CTGAAGAACA GATGAAAACT GGTTGTGATA 
     AGAACGAAAA CGATATTACT GGGATTTTCT TGGCGAAAAA AGAGCAAAGA TCTGATGGAT 
     CCGTGTCTCC TCCACGAAAG AAAATCGGAT TGAGCAAGTC AATGGCTCTG GAGGCCACAG 
     CTCGGACTTA Agaattcatc gtgactgact ga 
 961 cgatctgcct cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg 
1021 agacggtcac agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt 
1081 cagcgggtgt tggcgggtgt cggggcgcag ccatgaccca gtcacgtagc gatagcggag 
1141 tgtataattc ttgaagacga aagggcctcg tgatacgcct atttttatag gttaatgtca 
1201 tgataataat ggtttcttag acgtcaggtg gcacttttcg gggaaatgtg cgcggaaccc 
1261 ctatttgttt atttttctaa atacattcaa atatgtatcc ... 
 
 
EcoRI restriction site = gaattc 
XmaI restriction site = cccggg 
STOP = taa / tga /tag 
 
The sequence above is translated to the corresponding amino acid sequence beginning 
from deoxynucleotide 931 which is corresponding to the site where the the GST-CeTK1 
fusion protein is cleaved by thrombin. 
 
 
G S P G Met D I E A A K N E Met T C C S S N S S L S D F N T L P R C P N R V G S I T V I L G P Met F 
S G K T T E L L R L H D R Q I I A K R T C V L V K Y A G D T R Y D A D L V A T H S K Met T G Q G 
R T V K A H R L S E V Q S Q I F N D E V Q V V S I D E G Q F F E D L A E T C E E L A Q R G K V V C 
V A A L N G T F E R K P F P Q I S L L L P Y A N E I K Q V T A V C V E C G S Q A N F S F R S T L D 
K K V E V I G G S D T Y T A L C R E C Y V Q K S E E K D A E E Q Met K T G C D K N E N D I T G I 
F L A K K E Q R S D G S V S P P R K K I G L S K S Met A L E A T A R T Stop E F I V T D Stop R S A 
S R V S V Met T V K T S D T C S S R R R S Q L V C K R Met P G A D K P V R A R Q R V L A G V G A 
Q P Stop P S H V A I A E C I I L E D E R A S Stop Y A Y F Y R L Met S Stop Stop Stop W F L R R Q V 
A L F G E Met C A E P L F V Y F S K Y I Q I C I  
The normal stop codon is marked with a framed grey box and all following stop codons 
are marked with unframed gray boxes. The numbers above the sequence denote the 
molecular masses of the protein resulting from termination at the different stop codons.  
~38.5 kDa ~31 kDa ~36.5 kDa ~40 kDa 30 kDa
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Appendix E – Overview of kinetic parameters 
 
 
 
Activity parameters with substrate dThd – Table 9.3 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
 
 
CeTK1-WT -ATP (n=2) 2.29 ± 0.24 12700 ± 256 6.30 ± 0.13 2.75×106 
CeTK1-WT +ATP (n=3) 2.45 ± 0.23 22600 ± 472 11.2 ± 0.23 4.56×106 
CeTK1-C∆57 -ATP (n=2) 7.41 ± 0.80 4580 ± 166 1.80 ± 0.07 2.43×105 
CeTK1-C∆57 +ATP (n=2) 6.17 ± 0.84 15800 ± 698 6.21 ± 0.27 1.00×106 
HuTK1-WT -ATP * 16 ± 3.4  6.3 ± 0.9 0.4×106 
HuTK1-WT +ATP * 0.7 ± 0.2  6.9 ± 0.2 9.9×106 
HuTK1-C∆41 -ATP * 1.4 ± 0.6  9.5 ± 1.1 6.8×106 
HuTK1-C∆41 +ATP * 0.6 ± 0.1  9.7 ± 0.2 1.6×10 7 
 
 
 
Activity parameters with substrate dThd  - Table 9.5 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
 
 
CeTK1-WT (n=2) 2.29 ± 0.24 12700 ± 256 6.30 ± 0.13 2.75×106 
    S182T (n=2) 1.04 ± 0.19 2080 ± 63.5 1.03 ± 0.03 9.90×105 
    S182A (n=2) 73.7 ± 12.6 1470 ± 111 0.73 ± 0.05 9.87×103 
    L143A (n=1) 252 ± 63 13200 ± 1260 6.53 ± 0.62 2.59×104 
    M42I (n=2) 565 ± 94 5590 ± 410 2.77 ± 0.20 4.90×103 
 
 
HuTK1-WT * 16 ± 3.4  6.3 ± 0.9 3.9×105 
 
 
HuTK1-C∆41 * 1.4 ± 0.6  9.5 ± 1.1 6.8×106 
    C∆41-T163S (n=2) 58.6 ± 13.4 7690 ± 653 2.70 ± 0.23 4.61×104 
    C∆41-L124A (n=2) 36.2 ± 3.6 5210 ± 175 1.83 ± 0.06 5.06×104 
    C∆41-M28I (n=3) 349 ± 29 4180 ± 155 1.47 ± 0.05 4.21×103 
    C∆41-M28A (n=2) 354 ± 25 12100 ± 337 4.26 ± 0.12 1.20×104 
 
 
 
Activity parameters with substrate AZT  - Table 9.6 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
 
Hill kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
 
 
CeTK1-WT -ATP (n=1) 15.5 ± 1.6 13100 ± 407 - 6.48 ± 0.20 4.18×105 
CeTK1-WT +ATP (n=1) 12.7 ± 1.2 15100 ± 558 - 7.47 ± 0.28 5.89×105 
    C∆57 (n=2) 71.5 ± 7.8 5520 ± 202 - 2.17 ± 0.08 3.03×104 
    S182T (n=1) 29.1 ± 3.9 2830 ± 117 - 1.40 ± 0.06 4.81×104 
    S182A (n=1) 406 ± 51 1160 ± 49 - 0.57 ± 0.02 1.41×103 
    L143A (n=2) 4760 ± 1200 4830 ± 884 - 2.39 ± 0.44 5.02×102 
    M42I (n=3) 984 ± 220 1010 ± 135 - 0.50 ± 0.07 5.08×102 
 
 
HuTK1-WT ** 1.7  ~4000 - ~1.7 ~1×106 
    C∆41-T163S (n=2) 0.58 ± 0.05 5140 ± 214 1.26±0.10 1.81 ± 0.04 3.12×106 
    C∆41-L124A (n=1) 48.6 ± 5.5 4960 ± 208 - 1.74 ± 0.07 3.59×104 
    C∆41-M28I (n=2) 449 ± 35 179 ± 5 - 0.063 ± 0.00 1.40×102 
    C∆41-M28A (n=2) 444 ± 36 3380 ± 97 - 1.19 ± 0.03 2.68×103 
 
 
 
Activity parameters with substrate dCyd  - Table 9.7 
 
 
 
Km 
(µM) 
Vmax 
(nmol min-1 mg-1) 
kcat 
(sec-1) 
kcat/Km 
(sec-1 M-1) 
CeTK1-L143A (n=1) 5.41 ± 0.59 1.06 ± 0.04 5.23×10-4 ± 2.0×10-5 97 
CeTK1-M42I (n=2) 3.57 ± 0.78 0.34 ± 0.02 1.70×10-4 ± 8.2×10-6 48 
 
Kinetic parameters for CeTK1 and HuTK1 enzymes with different substrates determined by non-
linear regression to the Michaelis-Menten or Hill equation. The molecular masses applied to 
calculate kcat are 30.0 kDa for CeTK1 enzymes with the exception of CeTK1-C∆57, for which it is 
23.9, and 21.1 kDa for HuTK1-C∆41 enzymes. The parameters are presented with standard error 
on the curve fitting, and n denotes the number of separate experiments from which the data are 
determined. * Values from Zhu et al., in press. ** Values from Munch-Petersen et al., 1995b. 
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Appendix F - Deoxynucleosides and nucleoside 
analogs 
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